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General Introduction 
Since the 1980's, emerging and re-emerging infectious diseases 
have made an enormous impact on public and animal health, food supply, 
economies, and the environment. An estimated 75% of emerging infectious 
diseases in humans are zoonotic (pathogens of non-human vertebrate animals 
that may be transmitted to humans under natural conditions), mainly of viral 
origin and often vector-borne 1• Since 1980, more than 35 new infectious 
agents have emerged in humans 2, including Severe Acquired Respiratory 
Syndrome (SARS coronavirus) 3•4 , West Nile Virus (WNV) 5 , Ebola virus 6 and 
Avian Influenza A Virus (AIV) 7·8 . Although the recognition of emerging or re-
emerging infectious diseases can in part be attributed to increased interest or 
attention and to improved diagnostic methods, the foremost cause should be 
sought in human behaviour: (1) demographic changes: exponential growth 
of the human population, world-wide urbanisation, encroachment on wildlife 
habitat; (2) generalised social changes: globalisation of trade, increased and 
accelerated legal and illegal transport of animals, wildlife trade (live animal and 
bushmeat markets); (3) ecosystem disturbance: deforestation, eutrophication 
of waterways; and (4) climatic changes: global warming 9•12• Livestock has 
been severely affected by direct mortality and depopulation policies, for 
example: to date, highly pathogenic avian influenza (H5N1) has resulted in 
culling of at least 220 million birds in 41 countries. The impact of emerging 
infections is of special concern for endangered wild animal populations, which 
can be pushed to the brink of extinction by such events 13-15• 
Early detection of outbreaks, by improved surveillance in animals 
for (zoonotic) pathogens is critical for managing these infections 16 . Linking 
comprehensive pathogen surveillance of wild and domestic animals with 
public health surveillance will make an important contribution to the detection 
and control of emerging zoonotic infections 10·11 . Current technological 
capabilities facilitate a rapid response to emerging infectious diseases in 
terms of rapid identification and diagnostic techniques and, to a lesser degree, 
the development and use of vaccines and therapeutic agents. 
Vaccination is one of the tools that can be used to combat infections 
in individual animals, or large scale outbreaks. Vaccination is only one of the 
factors (e.g., nutrition, parasite control, hygiene) associated with preventive 
medicine, and vaccines can never be absolutely guaranteed to provide 
adequate protection against emerging diseases. 
The principal objective of vaccination is to induce a protective 
immune response that mimics protection acquired after natural infection. The 
ideal vaccine would: (1) induce a strong virus neutralising serum antibody 
response with high titres, of long duration, and broadly reactive; (2) induce T-
cell mediated immunity, with a strong T-helper cell response and induction of 
cytotoxic T-cell responses; (3) induce mucosal immunity; (4) induce a robust 
protection; (5) be needle free; and (6) be safe. Obviously, no vaccine used 
today fulfils all these criteria. This is certainly true for vaccines used in non-
domestic species. 
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Historically there have always been two major types of viral vaccines 
for non-domestic animals classified according to the nature of the antigens 
used. (1) Modified live virus (MLV) vaccines use attenuated pathogens 
which replicate in the vaccinated animal, thereby closely mimicking a natural 
infection, and eliciting an immunologic response without causing severe clinical 
disease signs (a "controlled" infection); (2) vaccines based on antigens that 
are non-living or inactivated - often termed killed vaccines (KV), for which the 
immunologic response they illicit is directed towards the inactivated antigen. 
Vaccines are generally not approved for non-domestic species and thus their 
use is always extra-label 17, and there is always a potential liability to such 
use18. 
(1) MLV vaccines infect host cells, cause viral replication, and the 
infected cells will process endogenous antigen. In this way immune responses 
of both T-cells (CDS+ and CD4+) and B-cells are triggered. MLV vaccines have 
been designed to be minimally virulent, while retaining maximal immunogenicity 
in the domestic species for which they have been developed. When used in 
other species or delivered by another route, residual virulence may cause 
clinical disease or death 19 which has occurred in numerous non-domestic 
species after vaccination with MLV vaccines registered for domestic animals 
(Table 1 ). Several viruses induce a suppression of the immune system, and it 
is known that some attenuated virus strains may still be able to cause immuno-
suppression, like MLV canine distemper virus (CDV) and canine parvo virus 
(CPV) vaccines 20• Sometimes the individual vaccine strains are not detectably 
immunosuppressive, but when used in a combination vaccine they may 
induce e.g. suppression of blood lymphocyte counts 21 . Immune-suppression 
caused by combination vaccines that contain live canine adenovirus type 1 
(CAV-1) and canine corona virus (CCoV) may lead to clinical disease signs 
attributed to the attenuated CDV component of the vaccine, and may lead to 
COY-encephalitis 22-24 . 
(2) Inactivated vaccines are preferred in case of safety concerns of 
the MLV vaccines, as they do not contain infectious virus and are therefore 
incapable of causing an infection. However, inactivated vaccines act as 
exogenous antigens, triggering an immune response dominated by CD4+ 
and often Th2 cells, which may not always be the most effective response to 
the pathogen vaccinated against. Additionally, the process of inactivation may 
dramatically reduce immunogenicity, usually resulting in an immune response 
that is shorter in duration, narrower in antigenic spectrum, weaker in cell-
mediated and mucosal immune responses, and less effective in preventing 
viral replication 25 . 
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Species Latin name 
Domestic dog Canis lupus familiaris 
Maned wolf Chrysocyon brachyurus 
African wild dog Lycaon pictus 
Black-footed ferret Mustela nigripes 
Bush dog Speothos venaticus 
Domestic ferret Mustela putorius furo 
European mink Mustela Jutreola 
Fennecfox Fennecus zerda 
Gray fox Urocyon cinereoargentus 
Kinkajou Potos flavus 
Maned wolf Chrysocyon brachyurus 
Red panda Ailurus fulgens 
Domestic cat Felis catus 
Domestic dog Canis lupus familiaris 
Striped skunk Mephitis mephitis 
Cheetah Acinonyx jubatus 
Domestic cat Felis catus familiaris 
Pallas's cat Felis manu/ 
Cheetah Acinonyx jubatus 
Table 1. Examples of vaccine-induced disease. 
Reference 
201 
127 
65,202,203 
121,125 
123 
143 
126 
128 
58 
122 
127 
120,204 
205 
206 
207 
52 
208 
209 
210 
To maximise the efficacy of vaccines, especially inactivated vaccines, 
adjuvants are usually added. These adjuvants can greatly enhance specific 
immunological responses to vaccination by several mechanisms, including: 
protecting the antigen from degradation, promoting efficient delivery of antigens 
to antigen presenting cells, and enhancing cytokine production. However, the 
use of adjuvants can also cause severe inflammation and systemic toxicity, 
have an impact on growth of the animal or reproductive rate, and repeated 
or high doses of antigen can induce hypersensitivity reactions 26 . In both 
domestic and non-domestic species, it is not unusual to observe side-effects 
such as elevated temperature, swelling, and irritation at the site of injection, 
or anaphylactic reactions like hyperaemia, hyper-salivation, or vomiting 27 and 
these side-effects may in some cases be severe 28• Anaphylactic reactions 
may occur after the use of any vaccine, but are particularly thought to occur 
following the use of multivalent, adjuvanted vaccines containing large amounts 
of foreign proteins 29 . Adjuvanted inactivated vaccines are used more widely in 
domestic cats than in dogs, as several MLV vaccines have shown a significant 
association with upper respiratory tract infections in cats. However, a significant 
association between the use of these usually aluminium adjuvanted vaccines 
and local reactions (granulomas and sarcomas) has also been found 30 • This 
has led to recommendations such as alternating predisposed vaccination 
sites, avoiding aluminium adjuvanted and polyvalent vaccines, and avoiding 
over-vaccination 31 -33• 
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Recent advances in immunology, molecular biology and biochemistry 
have allowed the construction of subunit vaccines based on recombinant 
viruses and bacteria, peptides, or bacterial and viral vectors, which may lead 
to safer, and more efficacious vaccines that can also be used in non-domestic 
species. 
Effective vaccination should not only trigger cell-mediated responses, 
but also elicit a high titre of neutral ising antibodies (humoral immune response) 
of the appropriate class: Immunoglobulin M (lgM), immunoglobulin G (lgG) 
and/or immunoglobulin A (lgA), directed against the relevant epitopes on the 
virion. The immunity induced by vaccination has mainly been evaluated and 
quantified in domestic animals by measuring the levels of serum antibodies. 
For certain infections (e.g. CDV, CAV, CPV, feline panleukopenia virus (FPV) 
or Borrelia burghdorfen) the level of the humoral response, although not the 
only mechanism involved, tends to correlate with level of protection from 
clinical disease, and therefore is a useful indicator of the immune status. 
Other agents (e.g. CCoV, feline enteric coronavirus (FCoV), canine para-
influenza virus (CPIV), Bordetella bronchiseptica, and Chlamydophila psittac1) 
all replicate and cause damage on mucosal surfaces, and might require a 
mucosal immune response for protection. As a consequence, serum antibody 
titres do not necessarily correlate with (adequate) protection against these 
pathogens. 
Effective vaccination induces not only a humoral and a cell-mediated 
response but also memory T and B cells, which will remain for years after the 
effector mechanisms have declined. These memory cells rapidly differentiate 
during a subsequent infection into effector cells that can eliminate an infection 
before clinical signs appear 34• Additionally, "memory effector B-cells" can 
produce antibodies for years without overt antigenic stimulation 35•36. In order 
to obtain a complete view of the immunologic status of an animal one therefore 
needs to look (ideally) at the humoral, cell-mediated, and local (mucosal) 
responses. One can only know if the measured level of immunity is protective 
by challenging the vaccinated animal with the pathogen. However, for non-
domestic endangered or otherwise irreplaceable species (I UCN Red list, http:/ I 
www.iucnredlist.org), challenge infection studies should not be conducted from 
a conservation point of view, and humoral and/or cellular immune responses 
have to be used as correlates of protection. 
The recent debate concerning vaccine safety, efficacy and duration 
of immunity in domestic cats (Felis catus familiaris) and dogs (Canis lupus 
familiaris) 3745 resulted in the need for more objective and scientific data. 
Vaccinated domestic dogs and cats have shown a range of protective antibody 
titres after challenge infections with the viruses used in standard vaccines. 
Additionally, these protective antibody titres may vary per virus due to the variety 
of techniques and standards used in different laboratories. There is little or no 
standardisation of serological assay methods, and this non-standardisation of 
serologic tests can make comparisons between laboratories of questionable 
use 46 . 
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Currently, several long-term vaccination/infection studies have shown 
that protective immunity against certain viruses upon vaccination may last 
for several years, and annual re-vaccination of domestic dogs and cats may 
not always be required 36• Recommendations based on these recent studies 
are currently different for "core" vaccines (which are considered essential: 
CDV, CPV, CAV, rabies virus (RV), FPV, FCV, FHV), and "non-core" vaccines 
(all other vaccines, which should be given in high risk situations, but are not 
considered essential). The vaccination schedule for carnivores should start 
at the age of 6-8 weeks, with 3 week intervals so that the last dose is given 
at the age of 12-14 weeks, then revaccination at 1 year, and then every 3 
years for "core" vaccines. Antibodies induced against "non-core" vaccines 
are detectable for a shorter period of time after vaccination, and should be 
repeated yearly or more frequently 36 . 
In non-domestic animals controlled vaccination studies are limited, 
and their evaluation is largely restricted to evaluation of humoral responses 
extrapolated to known challenge infection data from domestic animals 47•73 • 
However, analytical tests are not standardised or validated for the different 
non-domestic species, thereby hindering evaluation and comparison of 
vaccine-induced immunity in the many different non-domestic species. 
Recommendations for use in non-domestic mammals are generally 
based on tradition, anecdotal/personal experiences or taken from more 
precise, published data. This has led to a plethora of differing opinions and 
therefore the use of many different vaccination protocols (Table 2 for CDV 
vaccination). However, there are some general rules for using extra-label 
vaccines in non-domestic animals. Monovalent inactivated viral or bacterial 
vaccines are preferred, and the use of polyvalent vaccines containing 
unnecessary antigen should be avoided whenever possible. Animals with 
active clinical illness should preferably not be vaccinated. In the event of a 
viral disease outbreak in an animal collection, all susceptible species should 
ideally be vaccinated immediately and boostered 10-14 days later, regardless 
of age and last time of immunisation 74 . The use of some drugs, such as 
tetracycline, chloramphenicol, dapsone, clindamycin, griseofulvin, nalidixic 
acid and sulphamethoxypyradizine have been associated with an inadequate 
response to vaccination 40 • Vaccination should also be avoided in animals 
undergoing glucocorticoid therapy, although challenge studies have been 
performed which show that "immuno-suppressive" doses given at the time 
of vaccination do not significantly affect the level of post-vaccinal immunity to 
CDV or RV 75 . When using remote delivery systems one must be sure that a 
full dose is delivered, as syringe darts may rebound quickly on impact and 
fail to deliver the dose required to elicit a satisfactory immune response 76 • 
The type, serial number, and source of product should be recorded in the 
veterinary records 77 . Any vaccination programme should also take the current 
local infection risk by the pathogen into account, upon which the decision can 
be made if vaccination is warranted. 
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Species 
All susceptible 
Mustelidae 
All susceptible 
Mustelidae 
Procyonidae 
All susceptible 
Procyonidae 
All susceptible 
All susceptible 
All susceptible 
All susceptible 
Vaccine 
MLV § 
MLV § 
KVor MLV* 
KVfor 
black-footed 
ferret & initial, 
then MLV 
KV 
KV 
(unavailable) 
MLV* 
KV preferred 
(unavailable) 
thus MLV 
(avian origin)* 
MLV 
(avian origin)* 
ISCOM 
Canarypox-
vectored 
recombinant 
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Regime 
Initial at 3-6 weeks, at 9 weeks 
combination vaccine. Single 
vaccination after 12 weeks 
10 weeks 
Initial at 5-6 weeks repeat every 
2 weeks until 15 weeks 
Initial at 8 weeks, repeat after 2-3 
weeks 
Booster 
Semii-
annually 
Annually 
Initial at 6-8 weeks, repeat every Annually 
2-3 weeks unti114 weeks 
Initial distemper/measles at Annually 
6-8 weeks, at 12-14 weeks 
combination vaccine. 
Initial at 8 weeks, repeat at 12 
and 16 or 18 weeks of age 
Single dose after weaning im, 
monthly booster up to 4 months 
Annually 
Reference 
133 
133 
209 
209 
209 
116 
66 
76 
Initial at 6-8 weeks, repeat Annually 74.211 
every 2-3 weeks with a total of 
3 vaccinations, in special cases 
(ie early weaning, ill juveniles, 
high probability of exposure to 
disease) extended to 4 or 5. 
8, 11, 14 weeks of age Annually Rotterdam 
Zoo 
3 doses with 3 weeks interval Annually AAZV 
Table 2. CDV vaccination regimes recommended for use in non-domestic species. 
Vaccination with modified live virus (MLV) vaccines were recommended (§) until 
the beginning of the 1980s, when a growing number of species were reported 
with vaccine-induced CDV infections. Hereafter, inactivated (or 'killed') virus (KV) 
were recommended, or MLV vaccines of avian origin - usually due to KV being 
unavailable (:j:). Currently, the use of MLV vaccines in non-domestic carnivores is 
not recommended, although safe and effective CDV vaccines for non-domestic 
species are not commercially available or legal to use in many countries. 
Vaccination of non-domestic species is especially useful in captive 
collections, where the population density may be higher than in wild 
populations, with an increased infection risk. Infection/exposure risks can 
16 
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be minimised by strict hygiene and quarantine protocols, proper fencing to 
reduce contact with unvaccinated domestic and non-domestic species, and 
vaccination. Vaccination of endangered species in conservation projects 
can contribute to the survival of these species. African wild dog 13 and black-
footed ferret 15 conservation projects have been severely affected by CDV 
outbreaks, and a safe and effective vaccine is much needed 65 . Following the 
phocine distemper virus (PDV) epidemic of 1988 78-80 in harbour seals (Phoca 
vitulina) and the development of an experimental CDV-ISCOM vaccine 8\ all 
rehabilitated seals from the Seal Rehabilitation and Research Centre (SRRC) 
in Pieterburen, the Netherlands, are vaccinated upon arrival. The duration 
of protective immunity following this vaccination in seals is unknown, but is 
intended to last for at least the duration of stay in the rehabilitation centre. 
The question is often raised whether free-ranging non-domestic 
animals should be vaccinated. It is an interference with natural selection, and 
therefore a topic under discussion. Re-introduced or translocated animals 
may not have been challenged under natural conditions with the local 
pathogens when young (and maternal immunity is still present), but can be 
vaccinated while in captivity (prior to release) to obtain a level of immunity 
against these pathogens. The World Conservation Union (IUCN) guidelines 
for the reintroduction of captive animals into the wild include the description of 
preventive vaccination strategies 82• A problem faced is the difficulty to boost 
under field conditions, so that the level of immunity may not be sufficient 
for prolonged periods of time. The vaccination regime should therefore be 
completed before release when possible, to allow sufficient time to develop 
the required immunity and detect possible adverse effects before release of 
the animals. 
Vaccination of a wild population of Mediterranean monk seals 
(Monachus monachus) was considered during a morbillivirus epizootic on 
the west coast of Africa in 1992 83 , and this discussion flared up during the 
recent PDV epidemic in North European harbour seals in 2002, but it was 
generally not considered a viable option 84·85• Vaccination of seals with a MLV 
vaccine should be considered contraindicated 86 , as for all non-domestic 
animals. When vaccinating free-ranging wildlife it is of utmost importance to 
consider the fact that MLV vaccines may not be sufficiently attenuated for 
exotic species, and that vaccine induced disease or shedding of virus may 
occur, potentially infecting free-living populations. 
The only examples of effective vaccination campaigns of free-ranging 
carnivores are those against rabies. The zoonotic and economic aspects of 
RV infection have resulted in prophylactic vaccination of free-ranging vector 
species, which are much more difficult to vaccinate than captive specimens. 
The development of oral MLV vaccines 87 proved its value when an advancing 
epidemic was stopped by the vaccination zone 88 . This vaccine has since been 
replaced by a poxvirus based recombinant vaccine, which has proven to be 
efficacious and safe for the target species (the European fox, Vu/pes vu/pes), 
as well as for numerous non-target species 89-91 . 
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This thesis focuses on the vaccination of non-domestic species 
against two groups of viruses which have recently caused large outbreaks 
with high mortality: morbilliviruses and avian influenza viruses. 
MORBILLIVIRUSES 
Morbilliviruses are relatively large ( 150-600 nm) negative sense 
single stranded RNA viruses which belong to the family of Paramyxoviridae. 
The viral RNA is associated with the nucleoprotein (NP), forming a helical 
nucleocapsid. The matrix (M) protein forms a linkage between the glycoproteins 
in the membrane and the nucleocapsid, thus stabilising the virus structure. 
Two membrane proteins, the haemagglutinin (H) and fusion (F) proteins 
form projections on the viral membrane, and are involved in attachment of 
the virion to receptors on target cells (H), and fusion of viral and target cell 
membranes or between host cells (F). Both the H and F proteins are the major 
immunogens for the induction of antibodies that play an important role in the 
prevention of and the recovery from infection. 
All families of the taxonomic order Carnivora are in principle 
susceptible to CDV infection, which is among the most significant infections 
of domestic dogs and many non-domestic species in terms of mortality. 
Infections with CDV and the closely related PDV have caused major outbreaks 
in naive populations of terrestrial carnivores and marine mammals 13·15•80•92-99 . 
Transmission is mainly via droplet infection or direct and indirect contacts, and 
the highly contagious virus may be excreted for up to 90 days by domestic 
dogs. Morbidity and mortality varies per species, but case-fatality rates can be 
as high as 1 00% in naive animals. 
Pathogenesis of CDV infection has been best described in domestic 
dogs, in which the clinical signs are dependent on the virus strain, environmental 
conditions, host susceptibility and immune status. Acute infection is clinically 
predominantly associated with catarrhal and respiratory infection (conjunctivitis, 
pneumonia, diarrhoea, anorexia, and dehydration). Neurologic manifestation 
of CDV infection often follows 1-3 weeks after recovery from acute generalised 
infection, and is most commonly seen in dogs with a poor immune response. 
Neurologic signs may manifest themselves as a chronic progressive disease, 
even if the infected dog has not shown systemic signs previously. In non-
domestic species, clinical signs may vary between species, but respiratory, 
gastro-intestinal (GI) tract, integumentary and central nervous (CN) systems 
are most commonly affected. 
Vaccination of susceptible species in zoos has been recommended 
since 1963 100. In general, CDV vaccination has always been recommended in 
all members of the taxonomic families Canidae, Procyonidae and Mustelidae. 
Vaccination of large cats is recommended in high risk situations 76·82•101-103 , after 
several outbreaks occurred among captive and free-ranging large felids93·99,1°4-
18 
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106
. Although clinical disease as a result of CDV infection is rare in ursids, 
serologic surveys have shown the presence of CDV specific antibodies107• 
111
• Clinical disease and presence of CDV specific antibodies have been 
documented in spotted hyaenas (Crocuta crocuta) 112-114 and a palm civet 
(Paguma larvata) 115, therefore vaccination is recommended in these species 
by some authors 74•82•101 •116•118 However, the susceptibility, and therefore need 
for vaccination of members of the Ursidae, Hyaenidae and Viverridae to CDV 
is disputed by some 76•103•119 . 
All members of the taxonomic order Carnivora are potentially 
susceptible, and vaccination of non-domestic carnivores with a safe and 
efficacious vaccine is therefore recommended if local exposure is high, and 
contact with infected animals can not be prevented. 
A problem faced in the prophylaxis of CDV in non-domestic 
carnivores is the variation between and within species in their reaction to MLV 
vaccines, and many species have been documented with vaccine-induced 
canine distemper with possible lethal consequences 58 ·120·127• Currently the 
majority of commercially available morbillivirus vaccines are MLV vaccines. 
Between the different commercially available MLV vaccines there is a clear 
difference in vaccine efficacy 128•130 and adverse effects. Chicken embryo-
attenuated MLV CDV vaccines specifically attenuated for domestic ferrets 
(Mustela putorius furo)131 appear to be safe and efficacious in maned wolves 
(Chrysocyon brachyurus), bush dogs (Speothos venaticus) and fennec foxes 
(Vu/pes zerda) 65 , but have caused disease in several species of minks, 
ferrets, grey foxes (Urocyon cinereoargenteus) and red pandas (Ailurus 
fu/gens) 121 ·124•126•132. Vaccine virus attenuated by passages in canine kidney 
cells has been responsible for vaccine-induced distemper in a much larger 
number of species (Table 1 ). Until 1983 the use of MLV was mentioned 
without warning of the adverse effects 133 . After 1985 inactivated virus 
vaccines were recommended for use in non-domestic species 76·117·119•134,135 
even though the efficacy of inactivated vaccines against CDV infection has 
been questioned 136·137• Currently there are no monovalent inactivated CDV 
vaccines commercially available, due to their limited efficacy in domestic dogs 
compared to MLV vaccines, and the absence of a commercially interesting 
market for non-domestic animals 138 . 
The large range of (highly susceptible) host species in zoos for which 
vaccination is recommended underpins the need for the production of a safe 
and efficacious vaccine for use in non-domestic carnivore species. Several 
alternatives to MLV vaccines have been tried in non-domestic species. 
(1) Non-domestic canine pups have previously (early 1980's) been 
vaccinated with a MLV measles vaccine 133•139 . Measles virus and CDV are 
antigenically closely related, but the measles virus is not neutralised by the 
maternal antibodies in 6-week-old puppies of domestic dogs 136, therefore a 
level of immunity is induced. However, the induced protection is not complete 
136
, and vaccination requires a booster vaccination with a modified live CDV 
vaccine, and is currently not recommended anymore. 
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(2) An experimental saponin-adjuvanted inactivated CDV vaccine 
has been used in red pandas and giant pandas (Ailuropoda me/ano/euca) in 
several zoos. The vaccine appeared to be safe and efficacious, but produced 
low titres with inadequate durability, requiring booster vaccinations two to 
three times annually 124. This vaccine is no longer produced. In Germany a 
small amount of aluminium hydroxide adjuvanted inactivated vaccine was 
previously produced for use in zoos (K. Frolich, pers. comm), although no 
published data exists of its efficacy in different non-domestic species. 
(3) An experimental subunit vaccine incorporating the F and H 
surface proteins of CDV into immuno stimulating complexes (ISCOM) has 
been developed and tested in domestic dogs and harbour seals, producing 
humoral and cellular immunity 81 •140. ISCOMS are stable complexes containing 
cholesterol, phospholipids, saponin, and antigen, and can be used as an 
adjuvant Micelles can be constructed using protein antigens and a matrix 
of a saponin mixture called Qui! A They are highly effective in targeting 
antigens to the antigen processing cells, while the saponin activates these 
cells, promoting cytokine production and the expression of co-stimulatory 
molecules. Depending on the antigen and adjuvant composition, Th1 or Th2 
responses can be stimulated. Although the immunity achieved is not sterile 
(infection of the upper respiratory tract occurs), CDV-ISCOM vaccinated seals 
were protected from a potentially lethal challenge with the closely related 
PDV81 • The ISCOM vaccine has since been used experimentally in several 
European zoos (W. Schaftenaar, pers. comm), although no data on its efficacy 
in different non-domestic species have been published. 
(4) In 1997 a recombinant canarypox-vectored vaccine expressing 
the H and F surface antigens of CDV was introduced141 and tested in domestic 
dogs for its safety and efficacy 142. Recently a similar monovalent canarypox-
vectored vaccine has become commercially available in the US (Purevax®, 
Merial, Duluth, Minnesota, USA). It is registered for use in domestic ferrets 
in which its efficacy and safety have been demonstrated143• In black-footed 
ferrets (Mustela nigripes) x Siberian polecat (Mustela eversmanm) hybrids the 
use of this vaccine has produced a good immune response144, and it has since 
been used and evaluated in a large number of exotic species (R Montali, pers. 
comm.). Its extra-label use in all susceptible species in zoos is recommended 
by the American Association for Zoo Veterinarians (AAZV) and the IUCN82 , 
although only limited published data on its efficacy in these non-domestic 
species exist 145• In the EU its use is not permitted, as it is a non-registered 
genetically modified organism (although currently several other recombinant 
vaccines have been registered for domestic species146). 
The main advantage of recombinant canarypox-vectored vaccines 
is their safety in mammals. Members of the Avipox genus (e.g. fowlpox and 
canarypox) are non-pathogenic and replication-deficient in mammals due to 
their natural host range restriction to avian species. However, they still have 
the ability to enter mammalian cells, reach an early stage of morphogenesis, 
and (importantly) express exogenous genes 147•148. Protective cellular and 
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humoral immunity is induced in the absence of the complete virus, therefore 
eliminating the possibility of infection with CDV. Canarypox virus generally 
appears to be superior to fowl pox virus in the induction of immune responses 
in mammals 149. Because the vector is replication deficient in mammalian cells, 
the potential for dissemination of the vector within the vaccinate is eliminated 
and therefore there is no spread of the vector to non-vaccinated contacts or 
the environment 150. Currently there is no safe, commercially available CDV 
vaccine that can be used in non-domestic carnivores in the EU. 
AVIAN INFLUENZA VIRUSES 
Avian influenza viruses (AIV) are type A influenza viruses and belong 
to the Orthomyxoviridae family, which also contains the influenza virus B 
and C types. The influenza A virion is a particle of approximately 120 nm in 
diameter, and its genome consists of eight segments of negative sense single 
stranded RNA. It can be classified according to the antigenicity of its surface 
proteins haemagglutinin (H) and neuraminidase (N). Currently 16 H (H1-16) 
and 9 N (N1-9) subtypes have been described in avian species 151 . Individual 
subtypes can theoretically be composed of any combination of one of the H 
and one of the N proteins. Furthermore the subtypes can be classified on the 
basis of their pathogenicity in chickens after intravenous inoculation. 
Highly pathogenic avian influenza (HPAI, formerly termed fowl plague), 
an acute generalised disease in which mortality in chickens may be as high 
as 100%, is restricted to subtypes H5 and H7, although most viruses of these 
subtypes have low pathogenicity, and do not cause HPAI. All other AIV strains 
are low pathogenic avian influenza (LPAI) virus strains which cause more 
variable morbidity and mortality (ranging from sub-clinical to fatal) but are 
generally associated in poultry with mild, primarily respiratory disease with 
loss of egg production 152 , or mild enteric disease in wild birds. In certain cases 
(in poultry flocks) the LPAI virus phenotype (of subtype H5 or H7) may mutate 
into the HPAI virus phenotype by the introduction of basic amino acid residues 
(arginine or lysine) at the cleavage site of the precursor haemagglutinin 
(HA0)153, which facilitates systemic virus replication. H5 and H7 subtypes with 
an amino acid sequence at the HAO cleavage site comparable to those that 
have been observed in virulent AI viruses are considered HPAI viruses, even 
when mortality in chickens is low 154• However, the two forms of avian influenza 
(HPAI and LPAI) are distinctly different and should be regarded as such. 
Avian influenza viruses have a worldwide distribution and are in 
principle infectious to all avian species (domestic and wild), with variable 
morbidity per virus isolate and species. Aquatic avian species, mainly those 
of the taxonomic orders Anseriformes (Anatidae: ducks, geese and swans; 
Anhimidae: screamers; andAnseranatidae: magpie goose) and Charadriiformes 
(Scolopaci: snipe-like waders; Thinocori: aberrant charadriforms; Larii: gulls 
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and allies; Turnici: buttonquails; Chionidi: thick-knees and allies; Charadrii: 
plover-like waders) are considered the main natural reservoir of all avian 
influenza viruses, including the LPAI ancestral viruses of HPAI strains 155·156. 
Replication of LPAI viruses occurs mainly in the intestinal tract, with excretion 
of high virus loads for up to 45 days 157 and AI virus remains infectious in 
faeces for 30 to 35 days 158 . In lake water AI virus remains infectious for 4 days 
at 22°C to more than 30 days at oac 159 , and the relatively high prevalence 
of AIV infection in birds living in aquatic environments may be due in part 
to efficient transmission via the faecal-oral route via surface waters 159•160• 
Migrating waterfowl are thought to carry LPAI viruses over long distances, and 
can initiate outbreaks of HPAI by the introduction into poultry flocks of these 
LPAI viruses, which subsequently can change into HPAI viruses 160 . Recent 
HPAI H5N1 viruses have been predominantly associated with oropharyngeal 
shedding 161 •162: the impact of this on environmental contamination, persistence 
and transmission is yet unknown. 
Terrestrial poultry species (e.g., chickens, turkeys, quail and ostriches) 
are generally highly susceptible to infection with HPAI virus, but waterfowl were 
considered resistant until 2002. However, in 2002 an outbreak of HPAI H5N1 
virus occurred in wild migratory avian species and resident waterfowl, and the 
high pathogenicity in ducks was confirmed in laboratory infections 163 • Since 
2002, this particular HPAI virus subtype has made an unprecedented spread 
from South East Asia throughout Asia and into the Middle East, Europe and 
Africa, with morbidity and mortality not only in poultry, but in a large number of 
other avian species. To date HPAI virus infection with the H5N1 subtype has 
been confirmed in at least 1 05 species ( spp.) from 14 orders: Anseriformes (33 
spp.), Charadriiformes (5), Ciconiiformes (6), Columbiformes (3), Falconiformes 
(11), Galliformes (10), Gruiformes (4), Passeriformes (22), Pelecaniformes (2), 
Phoenicopteriformes (1 ), Strigiformes (4 ), Struthioniformes (1 ), Psittaciformes 
(1 ), and Podicipediformes (2) 164• Outbreaks along the recognised flyways 
from South East Asia into Europe have suggested that this HPAI virus subtype 
may be distributed directly by migrating waterfowl, and HPAI virus infections 
have been detected in several migratory species 165•169• However, domestic 
waterfowl 162•170·171 , specific farming practices, agro-ecological environments, 
and transportation of domestic avian species or their products with trade at 
local markets may all have played a key role in the amplification and spread 
of HPAI H5N1 virus in Asia 167,172. 
Several mammalian species (including ferrets, horses, pigs 170 , seals 
and humans 7·173) had been reported with infections with the H5 and H7 
subtypes of AIV up to 1997. The recent HPAI H5N1 virus subtype has caused 
mortality in a large number of mammalian species (Table 3), and has caused 
313 human cases with 191 deaths to date (301h of June 2007) 174• Noteworthy 
are the fatal HPAI H5N1 virus infections with severe pneumonia of domestic 
cats, tigers and leopards that fed on infected poultry carcasses, as felids had 
previously been considered to be resistant to disease upon AIV infection 175• 
Horizontal spread of infection was suspected 176, and has been demonstrated 
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experimentally in domestic cats 177, with excretion from both the respiratory 
and intestinal tracts 178 • 
Taxonomic Common name Latin name Reference family 
Canidae Domestic dog Canis lupus familiaris 212 
Felidae Domestic cat Felis catus 177,178,213,214 
Felidae Clouded leopard Neofelis nebulosa 215 
Felidae Tiger Panthera tigris 176,216 
Felidae Leopard Panthera pard us 216 
Mustelidae American mink Mustela vison 164 
Mustelidae Stone marten Martes foina 164 
Viverridae Owston's banded palm Chrotogale owstoni 218 
civet 
Table 3. Mammalian species documented with natural infections with highly 
pathogenic avian influenza virus (H5N1 ). 
Documented outbreaks of Asian lineage H5N1 HPAI virus in zoo birds 
have been limited to 5 cases: Penfold Park, Hong Kong, (People's Republic 
of China, 2002) and Kowloon Park, Hong Kong (People's Republic of China, 
2002), Ragunan Zoo, Jakarta (Indonesia, 2005), Dresden Zoo (Germany, 2006) 
and Islamabad Zoo (Pakistan, 2007). Large felids with H5N1 infection have 
been reported in Suphanburi Zoo (Thailand, 2003), and Sri Racha Tiger Zoo 
(Thailand, 2004). To curtail these outbreaks, a combination of increased bio-
security measures (isolation and quarantine of infected animals, disinfection 
of the area), feeding of cooked poultry only, treatment of infected animals in 
quarantine areas, selective culling, extensive surveillance of migratory and 
captive birds and vaccination were used. 
Vaccination is a useful means of reducing the horizontal spread of 
AIV in poultry 179•180 • An inactivated vaccine (Nobilis Influenza H5, lntervet 
International, Boxmeer, the Netherlands), using an H5N2 strain (A/Chicken/ 
Mexico/232-CPA/94) proved efficacious in chickens in Hong Kong under field 
conditions and after high dose laboratory challenge with HPAI H5N1 viruses 
181
• Furthermore, other inactivated vaccines, H5N1 reverse genetics based 
vaccines, and fowl pox recombinant vaccines with H5 inserts have been shown 
to be protective in chickens 182•183 , domestic ducks 184•185, and domestic geese 
186 against diverse HPAI H5N1 virus strains. Vaccination protects against 
disease and mortality, but does not always prevent infection and virus spread. 
However, the dose required for infection is much higher, and vaccinated birds 
shed far less field virus after infection than unvaccinated birds 187·188• 
Protective antibodies produced in response to infection or vaccination 
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are directed against the H and N surface proteins. Vaccine-induced protection 
is species-, dose-, and vaccine strain-dependent. The degree of homology 
of the H protein will largely affect the level of cross-protection and therefore 
efficacy of the vaccine 189 . A so-called Differentiation of Infected from Vaccinated 
Animal (DIVA) strategy, with a heterologous vaccine (using the same H 
subtype as the field virus, but a different N subtype), is recommended to 
differentiate between vaccinated and field-virus infected animals 190. However, 
in housing systems where birds are not housed permanently indoors (e.g., in 
zoos), contact with free-ranging birds can result in LPAI virus infections that 
go by unnoticed, but which may interfere with the DIVA principle. 
Antibody responses upon AIV vaccination may vary between avian 
species, being higher in chickens than in other poultry species 191 • Published 
minimum serum antibody titres measured by HI test in vaccinated chickens 
that correlate with protection after challenge with HPAI are 1:10 183 or 1 :16181 •186. 
However, domestic ducks with very low or undetectable antibody titres post 
vaccination have been shown to be protected from HPAI virus challenge 184•185 . 
Duration of protection from HPAI virus challenge may vary between species: 
chickens for up to 40 weeks after one dose of vaccine, domestic ducks for 
more than 52 weeks after 2 doses, while domestic geese which received 3 
doses were protected for 34 weeks 186 . 
In the EU there is currently a non-vaccination policy with regard to 
routine vaccination of poultry against AIV due to interference with stamping-
out policies and international trade agreements. Instead, eradication measures 
during an outbreak in poultry include (long-term) confinement, large-scale 
culling and safe disposal of carcasses of all poultry on the infected farm, and -
depending on the poultry density in the area and the epidemiological situation 
- pre-emptive culling of poultry on neighbouring farms (since 2003, more 
than 220 million birds have been culled world-wide to eradicate H5N1 avian 
influenza outbreaks), and emergency vaccinations (Directive 92/94/EEC). 
The standard eradication measures used to prevent and eradicate 
HPAI virus outbreaks in poultry would be detrimental to the welfare and 
breeding programmes of avian species in zoos. Large scale culling in zoological 
collections that include endangered species would be highly undesirable from 
a conservation point of view. Directive 2005/94/EC foresees a derogation from 
killing of birds provided the birds can be brought inside and are subjected to 
virus detection tests that give negative results (after the last death/positive 
finding, 2 tests at an interval of 21 days have to be performed according to 
the diagnostic manual Decision 2006/437/EC). However, most zoos will not 
have the facilities to suitably confine their entire bird collections for prolonged 
periods oftime, and many species will not be able to adjust to confinement and 
increased stress with subsequent welfare problems and increased exposure 
to pathogens resulting in disease (e.g. aspergillosis, bumblefoot) 192-194• 
Vaccination of zoo birds as an additional preventive measure against 
HPAI virus infection (while reducing confinement measures) in Belgian, Dutch 
and German zoos was first allowed during an outbreak of HPAI H7N7 virus 
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in poultry in 2003 (Decision 2003/291/EC). In 2005, Decision 2005/744/ 
EC allowed vaccination in European zoos against the encroaching H5N1 
subtype. Targeted preventive vaccination campaigns in poultry have since 
been authorized in the Netherlands: voluntary vaccination of hobby poultry 
and free-range laying hens as an alternative to the requirement that these 
birds be kept indoors (Decision 2006/147/EC), and France: domestic ducks 
and geese which cannot easily be kept indoors and be separated from wild 
birds (Decision 2006/148/EC). These campaigns were subject to rigorous 
surveillance and control requirements. 
Surveillance of wild birds can provide early warning signs for the 
introduction of HPAI virus 156•195 • Several countries have initiated surveillance 
campaigns of free-ranging wild birds. Wild bird populations that experience 
high mortality rates should be submitted to national or regional reference 
laboratories for testing (for a European listing see the EAZWV handbook of 
infectious diseases 196). Birds showing clinical signs can be captured, isolated 
and selectively culled when testing is positive to HPAI virus. There is no 
scientific basis for large scale culling of free-ranging wild bird populations to 
control outbreaks or their spread, and it would be highly undesirable from a 
conservation perspective 197. Instead, measures should be taken to prevent 
contact between non-vaccinated captive and wild bird populations. 
Increased bio-security remains the first line of defence during 
outbreaks of HPAI, and can be complemented by vaccination. Accreditation of 
zoos (e.g., by AZA, EAZA or other (inter-)national organisations) has resulted 
in standardised high levels of bio-security, decreasing the risk of introduction 
and increasing the likelihood of containment of infectious diseases. However, 
in the face of an outbreak of HPAI, levels of bio-security should always be 
raised immediately with hygienic measures implemented accordingly to 
prevent entrance or spread of the virus. Attention should be paid to both 
exclusion (identification and elimination of possible routes of entrance [e.g., 
by live birds, cages, equipment, clothing]), and containment (reduction of the 
risk of infection for neighbouring cages) of the virus, as described in guidelines 
for zoos 198•199. Derogations to bio-security measures (such as an alleviation 
of confinement measures) can be made in zoos, when birds are vaccinated 
(Decision 2005/94/EC), provided that such derogations do not interfere with 
disease control. 
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OUTLINE OF THIS THESIS 
The last 20 years a growing number of (re-) emerging infectious 
diseases have had an enormous impact on public and animal health. Early 
detection of outbreaks, by improved surveillance in animals for pathogens is 
critical for managing these infections. Preventive vaccination can be used in 
individual animals to prevent morbidity and mortality from infectious agents, 
but it is also one of the tools that may be used to combat outbreaks of emerging 
infections in captive populations of non-domestic species. 
The first part of this thesis (chapter 2) focuses on morbillivirus infections 
of non-domestic carnivores and marine mammals. Morbilliviruses have caused 
several large outbreaks in these animals, with high morbidity and mortality. 
Clinical signs observed in juvenile harbour seals during an outbreak of PDV 
are documented in chapter 2.1. To evaluate the prevalence of morbilliviruses 
and other viral pathogens in free-ranging terrestrial carnivores and marine 
mammals, hundreds of serum samples from Canada and France were tested 
for antibodies to these pathogens (chapters 2.2.1 and 2.2.2), providing 
important management implications for re-introduction of certain species like 
the European mink. To protect susceptible species from CDV infection, they 
can be vaccinated. However, commercial vaccines against CDV have caused 
fatal infections in numerous non-domestic carnivore species, and currently 
there is no safe, commercially available vaccine for use in non-domestic 
species in the EU. An experimental CDV-ISCOM vaccine developed for seals 
during a PDV epidemic was evaluated and compared to a canarypox-based 
recombinant vaccine (which is authorised for use in ferrets in the USA) in 
conservation projects of highly endangered European mink and African wild 
dogs (chapter 2.3.1 and 2.3.2). 
The second part of this thesis focuses on avian influenza A viruses 
(chapter 3). In the past decade, HPAI outbreaks have occurred frequently, 
and the current outbreaks of the HPAI H5N1 subtype are unprecedented in 
their duration and spread. Standard eradication measures used in poultry 
in the EU (e.g., long-term confinement and large scale culling) would be 
detrimental to the welfare and conservation of the often endangered species 
kept in zoological collections. Two separate EC Decisions allowed vaccination 
in zoological collections to alleviate confinement measures and prevent large 
scale culling. However, detailed information about the safety and efficacy of 
vaccines for poultry against HPAI viruses in the large variety of bird species 
in zoos was not available at the time of vaccination. During an outbreak of 
HPAI H7N7 virus in poultry in the Netherlands, and due to the encroaching 
threat of HPAI H5N1 virus, birds in zoos were vaccinated and the safety and 
efficacy of these vaccination campaigns were evaluated (chapter 3.1 and 
3.2). The longevity of serum antibodies after vaccination, and the effect of 
one vaccination one year after the initial two vaccinations are discussed in 
chapter 3.3. The susceptibility of pigeons and other species in the taxonomic 
order Columbiformes to HPAI virus and the efficacy of vaccination has been 
26 
General Introduction 
questioned Therefore the effect of vaccination towards challenge with two 
strains of HPAI H5N1 virus from different antigenic clades in pigeons was 
studied (chapter 3.4.). 
The findings presented in chapters 2 and 3 are evaluated and 
discussed in chapter 4 in the light of additional data on CDV vaccination in 
Rotterdam Zoo, and additional data on AI vaccination in other European zoos. 
The latter was presented in a recent EFSA report 200 . 
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Clinical signs of natural PDV infection 
The Northern European harbour seal (Phoca vitulina) population 
experienced a phocine distempervirus {PDV) epidemic with high mortality 
{22.000) during the summer of 2002. Clinical signs were recorded for 
20 harbour seal pups that were admitted to the Seal Rehabilitation and 
Research Centre {SRRC) with clinical disease and were diagnosed 
PDV infection positive by RT-PCR at necropsy, confirming that indeed 
they had died from PDV infection. The most prominent clinical signs 
were respiratory signs of varying extent in 100%, conjunctivitis in 70%, 
and neurological signs developed in 50% of the infected seals. Severe 
neurological signs were one of the euthanasia criteria during the 
epidemic, and a large number of juvenile seals that were euthanised on 
humane grounds and not admitted to the SRRC are not included in this 
study, due to lack of complete data sets. Consequently, neurological 
signs were among the most prevalent signs of fatal PDV infection in 
harbour seal pups. Reported lymphoid depletion in dead seals collected 
during the epidemic was not reflected in the total mononuclear leukocyte 
count of seals upon admittance. Haematological tests further showed 
absolute granulocytosis, thrombocytosis, anaemia, and an increase in 
total white blood cell count. At time of admittance, 55 % had a positive 
serum immunoglobulin G {lgG) titre, and lgM titres were positive in 20%. 
High levels of PDV-specific lgG serum antibodies at admittance were not 
correlated to absence of clinical signs or to longer survival. 
INTRODUCTION 
Phocine distemper virus (PDV), a single stranded RNA virus belonging 
to the genus Morbillivirus, is a highly contagious pathogen that has caused two 
rapidly progressing epidemics with high mortality in naive seal populations. 
The Northern European harbour seal (Phoca vitulina) population was struck 
by a PDV epidemic in 1988 97, resulting in the death of 18 000 seals. During 
the summer of 2002 this population was struck by another PDV epidemic, and 
22 000 seals died 219 . A nucleotide sequence analysis of this virus showed a 
close match (>97% homology) to the virus from 1988 94. Canine distemper 
virus (CDV), the closest relative of PDV 220 , has a wide host range including 
all terrestrial carnivores, and has also caused epidemics among pinnipeds: 
Baikal seals (Phoca sibirica) 221 ·222 and Caspian seals (Phoca caspica) 95·223 . 
Clinical signs of PDV infected seals are usually compared to those seen 
in dogs with CDV infection, focussing on the respiratory (coughing, dyspnoea) 
and catarrhal aspects (oculo-nasal mucopurulent discharge, conjunctivitis), 
but also fever, diarrhoea, abortion and with a small number of infected seals 
exhibiting neurological signs 78•224. CNS involvement in CDV infected dogs 
is dependent on the host's immune response 128• Lymphocytic depletion has 
been reported in PDV infected seals, and the subsequent immune suppression 
increases the susceptibility to secondary infections 225•226 • These secondary 
infections (viral, bacterial and parasitic) contributed in part to the large variety 
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of clinical signs seen in 1988. Main necropsy findings in PDV infected seals in 
1988 were pulmonary congestion and emphysema, atrophy of lymphoid tissue 
resulting in secondary bacterial infection, and degenerative changes in the 
mucosa of the airways, while only 1/29 seals showed evidence of encephalitis 
227
. Clinical signs of CDV infected seals have included debilitation, ocular and 
nasal exudation, muscle spasms and tremors; and main necropsy findings 
were severe pneumonia, lymphoid depletion, and microscopic lesions of non-
suppurative demyelinating encephalitis 95,228• 
The clinical signs alone are not sufficiently characteristic to make 
the diagnosis of PDV or CDV infection of marine mammals, and therefore 
laboratory examinations are essential 86 • Paired sera demonstrating a rise in 
PDV-specific immunoglobulin G (lgG) titre, or a single high immunoglobulin M 
(lgM) titre are used to diagnose infeCtion 224. Seals are routinely vaccinated 
against morbilliviruses upon admittance to the SRRC 81 , therefore testing 
of paired sera cannot be used for diagnostic purposes in this setting. A fast 
diagnosis of PDV infection is essential in seal rehabilitation centres to ensure 
that the necessary precautions are taken to minimise the dramatic effect of 
this highly contagious pathogen. 
The objective of this study was to obtain an improved picture of clinical 
signs of harbour seals with natural PDV infection, and to assess diagnostic 
methods which may assist in future diagnosis of PDV infected seals admitted 
to rehabilitation centres. 
MATERIALS AND METHODS 
We used data collected from 20 juvenile harbour seals that were 
admitted with clinical disease signs suggestive for morbillivirus infection to 
the Seal Rehabilitation and Research Centre (SRRC) in Pieterburen, the 
Netherlands during the PDV epidemic in 2002, and later diagnosed with fatal 
PDVinfection by RT-PCR analysis of tissues collected at necropsy. Importantly, 
we did not include seals that were euthanised on humane grounds outside the 
rehabilitation centre. Severe neurological signs were one of the euthanasia 
criteria used during the outbreak, and a large majority of these euthanised 
seals had severe respiratory and neurological signs. However, no detailed 
descriptions of clinical signs or haematology and serum biochemistry data of 
these animals were available. 
On arrival at the SRRC, a clinical examination was performed, 
and clinical signs were monitored daily, together with body temperature 
measurements twice daily. The seals were manually restrained, and blood 
was collected from the epidural vertebral vein using a 20 gauge x 38mm 
needle and vacutainer, into ethylene diamine tetra-acetic acid (EDTA) tubes 
and serum separator tubes. 
Haematological parameters (platelet count, total leukocyte count, 
granulocyte count (neutrophils, eosinophils and basophils ), mononuclear 
leukocyte count (lymphocytes and monocytes), percentage granulocytes, 
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and percentage mononuclear leukocytes) were determined in duplicate using 
a Quantative Buffy Coat analyser (QBC®, Becton Dickinson, USA), then 
averaged. No further differentiation was done. The haematocrit (HCT) was 
determined by centrifugation of blood in a microhaematocrit tube. A Reflotron® 
(Hoffmann- La Roche, Switzerland) was used to analyse serum chemistry: 
serum glutamate pyruvate transaminase I alanine aminotransferase (SGPT or 
ALT), serum glutamic oxaloacetic transaminase I aspartate aminotransferase 
(SGOT or AST), glucose, creatinin and urea levels were determined. 
Two-sample t-tests were used to compare mean blood values of the 
confirmed PDV infected seals with those of juvenile harbour seals which had 
all tested negative to PDV infection when admitted to the SRRC during the 
same time of year in 2001. A significance level of Ps;0.05 was used for all 
statistical tests. 
An indirect enzyme-linked immunosorbent assay (ELISA) was used 
to determine lgG titres, and lgM titres were determined using an antibody 
capture ELISA, as previously described 223 • These tests were done on serum 
taken at admittance only, as CDV-ISCOM vaccination would interfere with 
further diagnostic tests for PDV. 
Necropsies were performed following a standard protocol, and tissues 
(brain, lung, kidney and urinary bladder) were collected for detection of nucleic 
acid by reverse transcriptase-polymerase chain reaction (RT-PCR) 223 , with a 
set of universal morbillivirus primers, P1 (5'-ATGTTTATGATCACAGCGGT-3') 
and P2 (5'-ATTGGGTTGCACCACTTGTC-3'), that are based on conserved 
sequences in the phosphoprotein gene, for viral antigen by means of 
immunohistochemistry (IHC) with rabbit-a-Measles as primary antibodies 228 , 
and bacteriologic testing. 
Treatment 
All seal pups (bodyweight 8-10kg) were tube-fed 300-400 ml oral 
re-hydrating solution (ORS) before transport to the SRRC. On arrival, the 
seal pups were vaccinated with a CDV-ISCOM vaccine 81 , given ORS, and 
housed in single quarantine units. All seals were treated with a bronchodilator, 
Clenbuterol (Ventipulmin® syrup, Boehringer lngelhiem Vetmedica Inc.), a 
mucolytic, N- Acetyl cysteine (Fiuimicil®, Zambon Group), and broad-spectrum 
antibiotics ( enrofloxacin [Baytril®, Bayer] and/or amoxicillin-clavulanic acid 
[Synulox®, Pfizer]). Seizures were controlled symptomatically with diazepam 
(0, 1-0,2 mg/kg i.m.) or phenobarbitone (0,03-0,04 mg/kg i.m.). Anti-parasitic 
medication was given following standard protocols, and additional fluid therapy 
was given as needed. 
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RESULTS 
Respiratory signs of varying severity were seen and heard in 1 00% 
(20/20) ofthe pups examined, conjunctivitis in 70% (14/20), and a combination 
of neurological signs in 50% (1 0/20) of the pups. Further specifications of 
the clinical signs are given in table 1. Occasional peaks in body temperature 
above 38°C were seen in 35% (7/20), and in general the animals became 
hypothermic a few days prior to death (to as low as 33.4°C). Eighty percent 
(16/20) of the seal pups died or had to be euthanised on humane grounds 
within 14 days after admittance to the SRRC. On the day of admittance to the 
SRRC, 45% (9/20) had detectable lgG antibody titres, while 20% (4/20) had 
lgM antibody titres. 
Clinical signs 
Conjunctivitis 
Myoclonus (flipper or facial muscles) 
Productive cough 
Depression 
Nasal mucopurulent discharge 
Laboured breathing 
Dyspnoea 
Oculo-nasal mucopurulent discharge 
Cranial nerve deficits: uni- or bilateral blindness 
Head tremors 
Seizures 
Tachypnoea 
Palpable subcutaneous emphysema 
Nystagmus 
Paresis and ataxia 
Skin lesions 
Auscultation 
Ron chi 
Wheezing 
Crackling 
Increased respiratory sounds 
Decreased respiratory sounds 
n 
14 
10 
8 
8 
7 
7 
6 
6 
6 
5 
5 
5 
3 
2 
10 
10 
7 
5 
2 
% 
70 
50 
40 
40 
35 
35 
30 
30 
30 
25 
25 
25 
15 
10 
5 
5 
50 
45 
35 
25 
10 
Table 1. Clinical signs recorded in 20 PDV infected juvenile harbour seals during 
their stay at the SRRC. 
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Haematology and serum chemistry 
Of the haematological parameters, total granulocyte count, percentage 
granulocytes, and thrombocyte count were statistically higher than mean 
values of PDV-negative pups admitted the previous year (Table 2.). The total 
WBC was higher compared to wild pups, but not statistically higher than that 
of PDV-negative pups from the previous year. Serum chemistry values were 
statistically lower for AST/GOT and ALT/GPT compared to PDV-negative pups 
from the previous year. 
Bacteriology 
Bordetella bronchiseptica was cultured from the lungs of 35% (7/20) 
of the seals at necropsy. Escherichia coli was cultured from the lungs of 25% 
(5/20) at necropsy. 
Parasitology 
Otostrongylus circumlitis infections were found in 25% (5/20) of the 
lungs at necropsy. Sporadic infections with Parafilaroides gymnurus (5% -
1/20) and Dipetalonema spirocauda (5%- 1/20) were also seen. 
RT-PCR and IHC 
All animals were positive in at least one organ tested by means of 
RT-PCR, and 80% (16/20) by means of IHC. Lung tissue was positive in 50% 
(10/20) and 55% (11/20) of seals with respiratory signs by RT-PCR and IHC 
respectively. Brain tissue was positive in 40% (8/20) and 10% (2/20) of animals 
with-, but also 40% (8/20) and 20% (4/20) of animals without neurological 
signs by RT-PCR and IHC respectively. 
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Admit pups, PDV Admit pups, PDV negative, Wild pups, PDV 
infected, 2002 2001 negative 
Mean Mean Mean 
Range n Range n p Range 
±SD ±SD ±SD 
47.4 ± 22.8- 51.5 ± 31.4- 61.0 ± 42.4-
HCT(%) 20 80 0.066 
11.8 69.8 7.9 70.85 6.7§ 78.8 § 
Thrombocyte 445.1± 284.5- 368.3 44- 373-
20 80 0.012 ND 
count (1 09/1) 10.8 631 ±136.2 805 1164 t 
18.7 ± 3- 14.2 ± 5.4- 8.7 ± 4.6-
WBC (109/1) 20 80 0.055 
9.1 34.5 7.9 43.8 3.2§ 20.8 § 
Granulocytes 15.2 ± 2.15- 10.3 ± 3.4-
20 80 0.022 NO NO 
(1 09/l) 8.2 28.2 7.4 41.2 
Mononuclear 3.8± 0.85- 4.0 ± 0.8-
20 80 0.682 NO ND 
leukocytes (1 09/1) 2.3 11.1 1.7 11.5 
76.9 ± 50.5- 68.6 ± 44.5-
% Granulocytes 20 80 0.006 ND NO 
11.1 95.5 12.0 95.5 
%Mononuclear 24.4 ± 4.5- 31.9 ± 4.5-
20 80 0.072 ND ND 
leukocytes 14.1 64 12.1 55.5 
AST/GOT 96.8± 56.4- 139.0 13.8- 133 ± 70-
19 80 0.034 
(U/1) 29.2 164 ± 83.7 471 45 t 241 ' 
ALT/GPT 32.4 ± 13.6- 91.3 ± 13.4- 21.6 ± 12.0-
19 80 0.000 
(U/1) 11.3 61.3 76.7 421 7.7 § 43.0 § 
5.55 ± 
Glucose 7.9 ± 3- 7.8 ± 0.78- 2.28-
16 78 0.538 10.23 
(mmol/1) 2.6 13.6 3.25 26.6 9.02 t 
Urea 13.2± 5.6- 11.4 ± 3.3- 15.5 ± 8.7-
19 78 0.232 
(!Jmol/1) 5.7 28 4.9 28.5 3.4 § 22.7 § 
Creatinin 52.9 ± 44.3- 50.4 ± 26.6- 61.6 ± 35.2-
7 31 0.598 
(mmol/1) 7.8 67.3 7.1 66.1 17.6 t 123.2 t 
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Table 2 (left). Mean and standard deviation (SD), range, and sample size (n) for 
juvenile harbour seal pups on day of admittance to the SRRC (Admit), in 2002: 
with PDV infection, and at the same in 2001, without PDV infection. In bold are 
given significant differences between the groups (P< 0.05). In the last column, 
published values for wild harbour seals are given (§ = 257; :t: = 26o). 
Figure 1. Dorso-ventral thoracic radiograph of a juvenile harbour seal (Phoca 
vitulina) exhibiting diffuse interstitial pneumonia (X), and mediastinal, pericardia! 
(black arrows) and subcutaneous emphysema (white arrows). 
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DISCUSSION 
In the present paper we have shown that although there are many 
similarities, there are certain differences in the clinical signs observed during 
the PDV epidemic of 2002 compared to those previously described for the 
1988 outbreak. The respiratory signs (1 00% of the seals: 20/20) and catarrhal 
aspects (conjunctivitis in 14/20 or 70%, and mucopurulent oculonasal 
discharge in 7/20 or 35%) were prominent as in 1988. Pulmonary emphysema 
was heard as crackles on auscultation in 7 animals (35%), and in severe cases 
(3/20) it tracked via the mediastinum to subcutaneous cervical and thoracic 
regions (figure1.), where it could be palpated, causing a crackling sensation. 
Subcutaneous emphysema can have patho-physiological consequences 
for seals by affecting their diving ability, and it is thought to be extremely 
uncomfortable for the animal (in analogy with humans), therefore attempts 
were made to remove air with a large gauge needle, but a relapse was seen 
soon afterwards. A more effective method in humans is by subcutaneous 
catheter 229, and this may be useful in seals. Seals with laboured breathing 
had an abnormal posture - with an arched back, and front-flippers stretched 
out at right angles to facilitate breathing. The prominent respiratory signs are 
in accordance with necropsy findings during the epidemic of 2002, where 
approximately 80% of stranded seals in the Netherlands had pulmonary 
consolidation 219 • 
An important secondary infection after CDV infection in dogs 230 and 
seals 95•231 is Bordetella bronchiseptica, an opportunistic pathogen commonly 
carried in the upper respiratory tract of dogs, but which may cause suppurative 
pneumonia 232 . B.bronchiseptica was isolated from the lungs of 35% (7/20) of 
the seals in this study during necropsy. In another study B.bronchiseptica was 
isolated from 60% of dead seals in the Netherlands during the 2002 PDV 
epidemic (Wagenaar, pers.comm), making it the most common secondary 
bacterial infection, as in 1988 233 . It should be noted that the seals used in this 
study were treated with antibiotics, to which B. bronchiseptica strains previously 
isolated had proven to be sensitive, although most of these seals died before 
the therapy could be completed. Other pathogens that will have contributed to 
the respiratory signs seen are Escherichia coli and Otostrongylus circumlitus, 
which were both found in 25% of these seals at necropsy. 
Lethargy/depression was seen in 40% ofthe seals, possibly as a result 
of exhaustion and malnourishment, or with a neurological cause. Neurological 
signs were observed in 50% ( 1 0/20) of the pups, more often than was expected 
from publications and experiences from the 1988 outbreak, where "a small 
number of seals exhibited nervous signs" 78 . The percentage of pups with 
neurological signs reported in the current study would have been higher if 
animals that were euthanised outside the rehabilitation centre were included, 
but no exact data of these animals were available. Morbilliviruses are known 
to be highly neurotropic and capable of causing chronic persistent infections 
of the CNS 234 , and experimental PDV and CDV infections of harbour seals 
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have shown neurological signs in 212 and 119 seals respectively 235•236 . 
Neurological signs we observed in PDV infected seals correlate with 
those seen in dogs with acute CDV encephalitis (myoclonus, seizures, ataxia) 
and chronic I multifocal CDV encephalitis (uni- or bi-lateral menace deficits, 
head tilt, head tremors, nystagmus, weakness I paralysis of pelvic limbs). A 
myoclonus, or muscle spasm of the flippers or facial muscles was seen in 50% 
(10120) of seal pups, and is also the most common sign of acute distemper 
encephalitis in dogs 237• Grand mal seizures were recorded for 24% of the 
seals. As in dogs with CDV infection 237 , neurological signs of PDV-infected 
seals became more frequent and severe over time. 
Neurological signs were varied and suggest a spread of the virus 
throughout the CNS. PDV could be detected by RT-PCR in the brains of 
only 40% (8120) of animals with neurological signs, but also in 40% (8120) of 
animals without neurological signs. Although IHC is recognised as a sensitive 
and specific method, PDV was detected in the brain by IHC in only 10% 
(2120) of animals with, and 20% (4120) of animals without neurological signs. 
Although the neurological signs should reflect the distribution of the virus and 
lesions in the central nervous system, a clinico-pathological correlation is 
often lacking in dogs with CDV infection 238 , and variation with virus strains 
in the extent of encephalomyelitis, and therefore the clinical signs has been 
shown 239 • Also, IHC was only performed on one section of cerebrum and one 
section of cerebellum, therefore PDV antigen expression in a large part of the 
CNS was not detected. Whereas PDV infected seals exhibited a combination 
of neurological and catarrhal signs, in dogs with CDV infection neurological 
signs typically follow catarrhal signs after about 2-3 weeks. 
Differentially, neurological signs in pinnipeds have been associated 
with electrolyte imbalances associated with renal disease and I or nutritional 
deficiencies 240 and domoic acid intoxication 241 . Encephalitis has been 
attributed to infections with herpes viruses 242 , West Nile virus 243 , bacteria 
(Enterococcus spp., Escherichia coli, Klebsiella spp., Pseudomonasspp., and 
Salmonella spp. 244), fungi 245 , and protozoa (Toxoplasma gondii 246 Sarcocystis 
neurona 247 and Eimeria phocae 248 . 
Haematological parameters showed an absolute granulocytosis, 
anaemia, thrombocytosis compared to PDV-negative seals from the previous 
year, and increased total WBC count (compared to healthy wild seals, not 
significant with pups at admittance the previous year). Granulocytosis or 
neutrophilia (the most abundant granulocytes) is most commonly associated 
with bacterial infection. In the later stages of canine distemper with secondary 
bacterial infection, the total WBC count may be normal or increased with 
neutrophilia, lymphopenia, and sometimes increased band neutrophils 249 . 
Physiological neutrophilia may occur with epinephrine and corticosteroid 
release during exercise, excitement, or stressful situations 250 , but levels 
were significantly higher than those of seal pups undergoing similar stressful 
situations without PDV infection. A decrease of the haematocrit was seen 
instead of the expected haemoconcentration, although a possible effect of 
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ORS administered prior to transport to the SRRC can not be excluded. Virus-
induced immune mediated haemolytic I haemophagocytic anaemia (resulting 
in a neutrophilia, anaemia and thrombocytopenia) has been described for CDV-
infected dogs, and measles infected humans 251 -254 . The thrombocytopenia 
is thought to reflect megakaryocytic damage by the virus, or be the result 
of immunologic components on the thrombocytes (eg phagocytosis and 
peripheral depletion). However, thrombocyte count of PDV infected seals was 
significantly higher than PDV-negative seals in the previous year. Physiologic 
mobilisation from splenic and non-splenic platelet pools occurs following 
epinephrine release, but this stress-related thrombocytosis is expected 
be found in the control seals from 2001 as well, and the thrombocytosis is 
therefore more likely to have been secondary to virus-induced endothelial or 
inflammatory changes 255 . 
Extended periods of lymphopenia and haemoconcentration were 
previously reported in harbour seals with phocine or canine distemper 97·235•256). 
The described lymphopenia (::;; 1 09/1) after experimental CDV infection of seals 
starts 5 days post-infection (dpi), and lasts for about 3 weeks 235 • Marked 
lymphoid depletion was found in dead PDV-infected seals during the 2002 
epidemic in Germany 226 • However, this previously described lymphopenia 
was not reflected in the total mononuclear leukocyte counts of PDV-infected 
seals in 2002. 
ALT/GPT and AST/GOT levels were significantly lower than in PDV-
negative pups admitted the previous year, and comparable (in the case of ALT/ 
GPT) to values of healthy wild pups. The serum levels of these liver enzymes 
have been documented to be significantly lower in wild pups compared to 
pups admitted for rehabilitation 257• 
A PDV-specific lgG titre~ 30 was found in 55% (11/20) of the seals 
on the day of admittance. In a naive population, as the northern European 
harbour seals had been for at least 1 0 years 94 a single lgG titre can be of 
diagnostic value, although these may be of maternal origin in juvenile seals. 
There was no correlation between lgG titre and severity of clinical signs, or 
duration of survival. In (experimentally) infected seals neutralising antibodies 
appear 10-20 dpi. However, Duignan et al reported the absence of lgG titres 
in harbour seals with natural morbillivirus infection, especially in those with 
respiratory infection 258 . Dogs that succumb to infection between 2-4 weeks 
post infection have little or no circulating antibodies and the antibody response 
is inversely correlated with the severity of disease 259 . 
lgM titres have proven to be more useful for diagnosis in the past, 
as these are produced sooner after infection (7 dpi) (Harder 1992) but false 
negative results may also occur in this assay. In the present study on the day 
of admittance, only 20% of the seals in this study had a positive lgM antibody 
titre, making it a less useful method of detection of PDV infection in juvenile 
harbour seals admitted to a rehabilitation centre than lgG titre. Caspian seals 
with CDV infection had a lower percentage lgM positive animals at necropsy 
(61 %), compared to lgG antibody titres (92%) 223 • 
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Pyrexia was occasionally recorded in only 33% of the pups during 
their stay at the SRRC. Although the time of infection and duration of clinical 
disease of the seals before admittance to the SRRC is unknown, the onset 
of clinical signs usually coincides with the second peak of pyrexia (for CDV 
infection of harbour seals 7-9 dpi 235 , suggesting that 66% of the seals had 
been infected more than 7 days prior to being taken to the SRRC. 
In conclusion, it can be said thatthe clinical signs observed were similar 
to those seen in 1988, however with some striking differences. In 2002 the 
virus caused clinical signs of respiratory and catarrhal infection in the majority 
of seals, with a higher prevalence of neurological signs than in 1988. Fifty-five 
percent (11/20) of the seals had serologic responses on admittance to the 
SRRC, and the percentage of seals with a positive lgG titre was higher than 
for lgM. No correlation between level of lgG titres and presentation of clinical 
signs were seen. The most prominent changes in haematological parameters 
were total granulocytosis, anaemia, thrombocytosis and an increase of total 
WBC count. Previously described lymphocytic depletion was not reflected in 
total mononuclear leukocyte counts. 
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We determined antibody titres to selected pathogens [canine 
adenovirus (CAV-2), feline herpesvirus (FHV), phocine herpesvirus (PHV-
1), canine distemper virus (CDV), dolphin morbillivirus (DMV), phocine 
distemper virus (PDV), canine para-influenzavirus (CPIV), rabiesvirus 
(RV), dolphin rhabdovirus (DRV), canine coronavirus (CCoV), feline 
coronavirus (FeCoV), feline leukaemiavirus (FelV), Borrelia burghdorferi, 
and Toxoplasma gondii] in whole blood or serum samples collected 
from selected free-ranging terrestrial carnivores and marine mammals, 
including cougars (Felis concolor), lynxes (Felis lynx), American badgers 
(Taxidea taxus), fishers (Martes pennant1), wolverines (Gulo gulo), 
wolves (Canis lupus), black bears ( Ursus american us), grizzly bears 
( Ursus arctos), polar bears ( Ursus maritimus), walruses ( Odobenus 
rosmarus), and belugas (Delphinapterus leucas). These samples had 
been collected at several locations in Canada between 1984 and 2000. 
The results show, among other findings, the presence of antibodies 
against a number of viruses in species in which these infections have 
not been reported before, e.g. antibodies to CAV-2 in walruses, to PDV 
in black bears, grizzly bears, polar bears, lynxes, and wolves, to DMV in 
grizzly bears, polar bears, walruses and wolves, to CPIV in black bears 
and fishers, and to DRV in belugas and walruses. 
INTRODUCTION 
Mass mortalities due to virus infections may occur in previously 
unaffected, and therefore susceptible populations of free-ranging terrestrial 
and aquatic carnivores. Epizootics resulting in mass mortalities caused by 
infections with morbilliviruses 80·99·105, herpes viruses 242 and influenza viruses 
261 have raised considerable public interest. Besides such high-profile epizootic 
infections, several other pathogens may influence population dynamics with 
less dramatic effects or infect species that act as intermediate reservoirs, 
e.g. infections with canine adenovirus 108 , canine coronavirus 262 , dolphin 
rhabdovirus 263 , Borrelia burghdorferi 264 and Toxoplasma gondii 265 . 
Introduction of "new" pathogens in populations may result from 
ecological changes in relation to the host, pathogen or both. A shrinking or 
fragmented wildlife habitat has changed population numbers and in some 
areas has caused increased population densities. These population changes 
can result in increased inter- and intra-species contacts, and exposure to 
new pathogens. The ability of a pathogen to infect multiple hosts, including 
hosts in other taxonomic orders, poses a direct threat of the "spill-over" of 
infectious agents from reservoir animal populations. By means of reverse 
spill-over, or "spill-back", these pathogens may represent a threat to sympatric 
populations of domestic animals. Domestic carnivores like dogs and cats may 
be maintenance hosts and sources of virulent pathogens to free-ranging 
carnivores 266 . The risk of interspecies transmission is likely to depend on both 
the intensity of inter-species contact rates and the possible modes of pathogen 
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transmission. The translocation of wildlife for conservation, agriculture, or 
hunting brings an additional inherent risk of exposure of wildlife species to 
exotic infectious agents. This form of emergence is of particular concern to 
conservation programmes that bring allopatric species into close proximity 
or that alter host-infectious agent variables such as population density 267 . 
Examples of this are certain rehabilitation centres where the risk of spill-
over and spill-back of infections includes transmission of possible zoonotic 
infections present in wildlife populations. 
This study aims to determine the prevalence of antibodies to selected 
pathogens, and to estimate the possible biological importance of intra- and 
interspecies transmission of infections (including zoonotic infections) on 
population dynamics and health status in different species of free-ranging 
Canadian carnivores and marine mammals. 
MATERIALS AND METHODS 
Samples 
The survey was conducted on serum and whole blood samples 
collected at several locations where they were banked in -20°C freezers. The 
terrestrial carnivore blood and/or serum samples were taken from animals 
that had been involved in biological research projects during which they were 
caught and manually restrained, or were chemically immobilised prior to blood 
collection, after which they were released. Between 1994 and 2001, 23 black 
bears (Ursus americanus), 11 grizzly bears (Ursus arctos), 8 wolves (Canis 
lupus) and 8 cougars (Felis concolor) were sampled in Banff National Park, 
Alberta. Between 1996 and 2001, 15 badgers (Taxidea taxus), 15 black bears, 
25 grizzly bears, 15 cougars, 28 fishers (Martes pennanti), 1 wolf and 20 
wolverines (Gulo gulo) were sampled in various locations in British Columbia. 
In 1997, 60 polar bears (Ursus maritimus) were sampled in Resolute Bay, 
Nunavut. The 5 lynxes (Felis lynx) were hospitalised at the veterinary faculty 
on Prince Edward Island after they were taken from Cape Breton Island and 
Nova Scotia mainland in 2000. 
The marine mammal samples: 54 belugas (Delphinapterus leucas) 
and 102 walruses (Odobenus rosmarus), were obtained from hunter-killed 
animals from Nunavut and the Northwest Territory between 1986 and 1993. 
None of the animals had a known history of vaccination. 
Serology 
Serum samples were centrifuged for 5 minutes at 10 000 x G, heat 
inactivated at 56°C for 30 minutes and screened for antibodies against 
selected viral and protozoan pathogens using an indirect enzyme-linked 
immunosorbent assay (ELISA), as previously described 268. In short, anti-dog 
immunoglobulins were used for species belonging to the Canidae, anti-cat 
immunoglobulins were used for the species belonging to the Felidae, and 
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horseradish-peroxidase conjugated Protein A was used for all other species 
to detect the pathogen-specific immunoglobulins bound to the antigen coated 
wells (European Veterinary Laboratory, Woerden, the Netherlands). After the 
addition of a tetramethylbenzidine solution and the development of the colour 
reaction, the reaction was stopped by the addition of a sulphuric acid solution 
(2M), and the resulting optical density was read at 450 nm. Dilutions of whole 
blood or serum (1 :50 and 1:1 00) were made using a buffer consisting of 
phosphate buffered saline solution + 0.2% bovine serum albumin + 0.1% milk 
powder+ 5% NaCI. Control sera of known positive and negative animals were 
included in the test. An optical density of three times the background optical 
density in both dilutions was considered positive. 
A confirmatory screening was done by a virus neutralisation (VN) 
test using a serum dilution of 1:40, and 50-100 TCID50 of the respective 
viruses, essentially as previously described 269 • Specific cell lines were used 
for the different viruses: Vera cells for the dolphin rhabdovirus (DRV, 263) 
and morbilliviruses [canine distemper virus (CDV Brussel strain), dolphin 
morbillivirus (DMV-16a, 270), phocine distemper virus (PDV-1 /88/NL)], Madin-
Darby canine kidney cells (MOCK, ATCC CCL-34) for canine adenovirus (CAV-
2 Manhattan strain), and Crandell feline kidney cells for the herpesviruses 
(feline herpesvirus (FHV): F1134, phocine herpesvirus (PhHV-1): PB-84). The 
serum antibody titres of samples considered positive (equal to or larger than 
40) were subsequently determined by means of a VN test using 2-log dilution 
series of the pre-diluted samples (1:10-1:1280). The end point titre of each 
serum was expressed as the reciprocal of the highest dilution that completely 
inhibited cytopathic effect (CPE) after 5 days incubation. The VN assay proved 
unsuitable for the whole blood samples due to cytotoxicity of the samples. 
Serum samples of animals belonging to the Canidae, Mustelidae, or 
U rsidae families were analysed for antibodies against CAV-2, canine coronavirus 
(CCoV), morbilliviruses (CDV, DMV and PDV), canine parainfluenza virus type 
3 (CPIV), rabiesvirus (RV) and Toxoplasma gondii. 
Serum samples of members of the Felidae family were analysed for 
antibodies against Borrelia burghdorferi, morbilliviruses, feline coronavirus 
(FCoV), FHV, feline leukemiavirus (FeLV), and T. gondii. 
Serum samples of the waluses and belugas were analysed for 
antibodies against CAV-2, morbilliviruses, PhHV-1, CPIV and DRV. 
RESULTS 
Canine adenovirus 
The total prevalence of CAV-2 specific antibodies in certain species is 
comprised of the prevalences found in different areas: 8% in black bears (9% 
from Banff National Park, 7% from British Columbia), 17% in walruses (15% 
from lgloolik, 2% from Hall Beach) and 89% in wolves (88% from Banff, 1/1 
from BC). Six of the polar bears with antibodies to CAV-2 also had antibodies 
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to at least one of the respective morbilliviruses. One of the black bears also 
had antibodies to CPIV. 
Herpes viruses 
In cougars, the prevalence of antibodies to FHV ranged from 38% in 
BC to 57% in Banff, making the total prevalence 47%. 
B. 
n CAV CCoV FeCoV CDV DMV PDV FHV PhHV FeLV CPIV RV DRV 
burgh 
badger 15 X 0 0 X 7 0 0 X X X 0 0 X 
beluga 54 X 0 X X 0 0 0 X 2 X 0 X 7 
black bear 38 X 8 0 X 3 0 3 X X X 5 0 X 
cougar 15 0 X X 0 0 0 0 47 X 0 X X X 
fisher 28 X 4 4 X 0 0 0 X X X 4 4 X 
grizzly bear 36 X 0 0 X 28 33 47 X X X 0 0 X 
lynx 5 0 X X 0 20 0 20 60 X 0 X X X 
polar bear 60 X 17 0 X 39 13 35 X X X 0 0 2 
walrus 102 X 17 X X 14 13 6 X 0 X 0 X 15 
wolf 9 X 89 0 X 67 22 33 X X X 0 0 X 
wolverine 20 X 0 0 X 0 0 0 X X X 0 0 X 
Table 1. Overall prevalences of antibodies to the different pathogens tested for, 
samples taken from one species from several locations are depicted as one 
total percentage. For the percentages per location see text. X: Not tested. 0: All 
samples negative 
Morbilliviruses 
T. 
gondii 
0 
X 
13 
11 
18 
0 
20 
0 
X 
0 
0 
The total prevalence of antibodies to at least one of the three 
morbilliviruses tested for were comprised of the prevalences found in different 
areas: 3% of the black bears (Banff 0%, BC 13%), 64% of the grizzly bears 
(Banff 55%, BC 68%), 53% of the polar bears, 18% of the walruses (18% 
lgloolik; 15% Hall Beach), and 77% ofthewolves (Banff75%, BC 1/1). 
Para-influenza virus 
None of the black bears from BC, compared to 9% of the black bears 
from Banff, showed antibodies to CPIV, making the total prevalence 2%. One 
of the black bears also had a positive titre to CAV. 
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Figure 1 and 2. Antibody titres to the different morbilliviruses in polar bear (figure 
1, left hand panels) and walruses (figure 2, right hand panels). The sizes of the 
bubbles are related to the number of samples. Only samples which tested positive 
to at least one of the three morbilliviruses tested for are plotted on the graphs, 
samples depicted in a graph as having titres of <1 0 on both axes are therefore 
positive to the third morbillivirus tested for. 
Toxoplasma gondii 
None of the samples taken from Banff showed antibodies to T. gondii. 
In BC 33% of the black bears tested were positive (including one Kermodie 
bear, Ursus americanus kermodie). The only cougar with antibodies to T. 
gondii was 1 of 8 cougars (13%) tested in BC, making the total prevalence 
7%. One of the 2 T. gondii positive lynx samples (40%) came from the Nova 
Scotia mainland, the other from Cape Breton Island. 
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Figures 3 and 4. Serum antibody titres to the different morbilliviruses in grizzly 
bears (3, left hand panels) and wolves (4, right hand panels). The sizes of the 
bubbles are related to the number of samples. Only samples which tested positive 
to at least one of the three morbilliviruses tested for are plotted on the graphs, 
samples depicted in a graph as having titres of <1 0 on both axes are therefore 
positive to the third morbillivirus tested for. 
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DISCUSSION 
In the present paper we have shown, among other findings, the 
presence of antibodies against a number of viruses in species in which the 
infections have not been reported before. This includes the presence of 
antibodies to CAV-2 in walruses; antibodies to DMV in grizzly bears, polar 
bears, walruses and wolves; antibodies to PDV in black bears, grizzly bears, 
lynxes, polar bears and wolves; antibodies to CPIV in black bears and fishers, 
and antibodies to DRV in belugas and walruses. These infections, or infections 
with closely antigenically related viruses, may either be endemic in these 
species or result from interspecies transmission. 
The humoral immune response to virus infections (e.g. CDV, CAV, 
FPV), although not the only mechanism involved, tends to correlate with the 
level of protection from disease and sometimes infection. it may be an indicator 
of immune status: a high concentration of virus neutralising antibodies usually 
implies that an animal is protected from infection or disease, but protective 
antibody titres may differ between viruses and animal species, and cannot 
generally be extrapolated from those known to correlate with these parameters 
in domestic animal species. 
Antibodies to morbillivirus were found in sera from all locations, 
suggesting a wide-spread presence among Canadian free-ranging carnivores. 
There have been no mass-mortalities related to CDV infection in free-ranging 
animals in Canada. CDV specific antibodies have been documented in 
wolves271 and lynxes 272 , and clinical infections of river otters, raccoons, and 
coyotes 273 have been reported. The only two animals in this survey reported 
with clinical symptoms correlating with a distemper infection (emaciation, 
neurological signs and abnormally tame) were the two lynxes with a positive 
morbillivirus titre (Daoust pers. comm.). 
In several species the antibody response was directed at more than 
one of the morbilliviruses tested for. Figure 1 suggest that production of 
antibodies in polar bears is probably caused by two different viruses: CDV 
and PDV. Figure 2 suggest that the antibody response in walruses is caused 
mainly by infection with CDV and DMV. In grizzly bears (Figure 3) titres to 
CDV are generally higher, with incomplete cross-reactivity to DMV and PDV. 
Most of the positive samples had a titre to PDV, often in combination with 
a titre to DMV. Antibody titres suggest that morbillivirus infection in wolves 
is mainly by CDV with cross reactivity to PDV. One of the wolves only had 
antibodies to DMV. The only positive badger had a much higher titre to CDV 
than to the other morbilliviruses. The antibody reaction in black bears was to 
CDV in one bear, and PDV in the other. In the lynx samples there was a high 
level of cross-reactivity between CDV and PDV. The presence of antibodies to 
PDV and DMV in terrestrial species may be explained as a result of infection 
by a closely antigenically related virus, or interspecies transmission. 
A possible explanation for the presence of antibodies to PDV and 
DMV in polar bears, and to PDV in walruses may be predation, which provides 
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a means of direct contact with subsequent production of antibodies. Polar 
bears are the top predator in the Arctic marine ecosystem and rely largely on 
seal blubber as their main energy source. They are also known to predate 
on larger cetaceans at breathing holes when food is scarce. Walruses feed 
almost entirely on bottom dwelling, or benthic shellfish, supplemented by an 
assortment of other invertebrate species. On rare occasions certain adult males 
display a shift in food preference and start feeding on pinnipeds. They feed 
mainly on carrion, but have reportedly attacked and killed young pinnipeds 274• 
However, these antibodies were also found in species in which contact with 
phocids and cetaceans is unlikely or virtually impossible (black bear, grizzly 
bear, lynx and wolf). All the morbilliviruses cross-react serologically, but titres 
are highest against the homologous virus 269 , therefore suggesting infection by 
a closely antigenically related (PDV- or DMV- like) virus, as well as CDV. 
The results for morbillivirus specific antibodies in walruses, which 
suggest infection mainly by CDV, but also DMV, are not consistent with those 
reported in walruses in arctic Canada over the time period 1984-1993 275, 
where 50% had PDV neutralizing antibodies, versus 16% CDV. In their study, 
however, a titre of 16 was considered positive, and specific antibodies to DMV 
were not tested. 
The low prevalence of CAV-2 specific antibodies found in black bears 
is in agreement with those found in black bears in Florida 108. Previously 
reported serological surveys in grizzly bears in Alaska showed a prevalence of 
12% 276 and 14% 277 , but grizzly bear sera collected from both British Columbia 
and Alberta in this survey did not have CAV-2 specific antibodies. Previous 
surveys among wolves from Canada have shown a prevalence of less than 
40% 271 • More recent studies conducted in the USA have shown prevalences 
of 81% 278 and 94.7% 279 , which are more in agreement with those found in 
our survey. 
One adult black bear from Banff National Park tested positive to both 
CAV-2 and CPIV, a combination that causes infectious tracheo-bronchitis 
(kennel cough) in domestic dogs. The only other species that tested positive 
to CPIV was the fisher. The fisher was also the only species to have antibodies 
to CCoV, indicating its susceptibility to a large number of virus infections found 
in domestic carnivores. 
The prevalence of antibodies to FHV in cougars (46%) and lynxes 
(60%) is high~r than those from previous studies, which have shown 19% 
prevalence among free-ranging cougars in California 280 , and 0,5% among 
free-ranging lynxes in Canada 272 . Our results show that FHV is widely present 
in the free-ranging Canadian feline species, on the east and west coast. 
The polar bear with an antibody titre against DRV did not have a titre 
above the threshold for RV neutralizing antibodies, suggesting that the polar 
bear has been exposed to a rhabdovirus that is antigenically distinct from 
RV. These titres might result from an interspecies infection with DRV, or an 
infection by a virus that is closely antigenically related to the DRV. There has 
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been one documented case of RV infection in polar bears 281 , but arctic foxes, 
a species which shares the polar bear's habitat and relies on food left over by 
polar bears, are the primary reservoir species in the Arctic 282. The walrus and 
beluga samples were not tested for rabies specific antibodies. 
The results obtained from this survey show that T. gondii infections 
occur among free-ranging felids in the Western and Eastern regions of Canada. 
None of the samples collected in Banff had T. gondii specific antibody titres. 
The infection is being sustained in BC, as it is seen in its primary host (felidae), 
as well as various secondary hosts. A previous survey conducted by Aramini 
and others 283 on Vancouver Island, BC, showed a much higher prevalence 
(92%) among cougars than this survey (13%). The cougar population density 
on Vancouver island is much higher than that of the BC mainland, a possible 
explanation for the higher prevalence. In the United States studies have 
shown prevalences ranging from 9-58% 280•284 . A previous study among lynxes 
in Alaska showed a prevalence of 15% 285 . In our survey all grizzly bears were 
negative, and only 13% of the black bears from BC had antibodies to T. gondii. 
Previous serosurveys of antibodies to T. gondii among bears in the United 
States have shown titres ranging from 8-84% in black bears 277•286-288 , and 
between 9-37% in grizzly bears 277•289• The only other species with an antibody 
titre was the fisher, with a prevalence of 18%. 
Regional differences in the prevalences of the different pathogens 
may be related to differences in population densities, and the distribution 
of other species (including domestic species) that may act as sources of 
infection. For example, wolverines were sampled in very remote areas, where 
a lower exposure to sources of infection may be a possible explanation for the 
absence of antibodies to any of the pathogens tested for. 
In conclusion, our data provide information on the prevalence of a 
number of infectious diseases among different species of free-ranging wildlife 
throughout Canada. The morbidity or mortality of these infections is often not 
known in these species. Therefore serologic surveys such as these may be 
useful in directing further studies on the impact of infectious diseases on free-
ranging populations. 
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In order to investigate the possible role of selected pathogens in 
the decline of-, and the threat posed to the survival of the endangered 
European mink (Muste/a Jutreo/a), a serologic survey was conducted 
using serum samples collected from March 1996 to March 2003 in 
eight departments of south-western France. In total, 481 free-ranging 
individuals of five mustelid species (including the European mink} were 
tested, as sympatric mustelids can serve as 'sentinels' to determine the 
presence of antibodies to viruses in the study area and could potentially 
be a source of infection. Antibodies to canine distemper virus (CDV) 
were detected in all species, Le., in 9% of 127 European mink, 20% of210 
polecats (Mustela putorius), 5% of 112 American mink (Mustela vison), 
33% of 21 stone marten (Martes foina) and 5% of 20 pine marten (Martes 
martes). Seroprevalence was significantly higher in stone marten and 
polecats, possibly because their ranges overlap more closely with that 
of domestic species than that of the other species tested. Antibodies to 
canine adenovirus were detected in all species but the pine marten, with 
seroprevalence ranging from 2 to 10%. Seroprevalence of canine para-
influenza virus was 1% in European mink, 1% in American mink and 
5% in polecats, and was not detected in Martes species. Antibodies to 
rabies virus (RV) detected in three animals may be due to inter-species 
transmission of bat lyssaviruses as the sampling area is considered to 
be free of RV, or to a lack of specificity of the test, as titres measured 
were borderline. Higher prevalence of the potentially lethal CDV than that 
of the other viruses suggests that this pathogen could have significant 
effects on the free-ranging populations, and has implications for the 
conservation efforts for the endangered European mink. 
INTRODUCTION 
The European mink (Muste/a /utreo!a), a small semi-aquatic mustelid, has 
retracted dramatically from its former territory during the last century 290-293 
and is currently listed as endangered (i.e., facing a very high risk of extinction 
in the wild in the near future) by the International Union for the Conservation 
of Nature and Natural Resources 294• Presently, the remaining population is 
spread out over two distinct areas: a relatively large Eastern population (in 
the Russia, Belarus, Kazakhstan, and Romania) and a very small Western 
population located in south-western France and northern Spain 294• In France, 
there are probably no more than a few hundred individuals, and population 
density seems to be low. Possible reasons for the decline include excessive 
trapping, change or loss of habitat and competition with the larger introduced 
American mink (Muste!a vison), and infectious diseases 290·295• Recent studies 
in the western population of European mink have shown the presence of 
Aleutian disease virus (ADV), that could contribute to the decline because 
of its persistent nature and its potential negative effects 296•297• So far, the 
incidence of other infectious diseases has not been investigated in free-ranging 
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European mink. A number of other viruses have been reported in captive or 
free-ranging mustelids, which could potentially damage free-ranging European 
mink populations: canine distemper virus (CDV) 15•128•298-300, rabies virus (RV) 
301
, canine adenovirus (CAV) 110•302-304, canine parainfluenza virus (CPIV) 110•305· 
307
, parvoviruses, including feline panleukopenia, mink enteritis and canine 
parvoviruses 308•309 , corona virus associated epizootic catarrhal enteritis 310 , 
SARS corona virus 311 , feline leukaemia virus, rotavirus, Powassan virus, and 
herpes viruses including Aujeszky's disease virus, and a alpha herpes virus 
(herpes necrotizing encephalitis) 312. 
In order to investigate the potential threat of viruses to the western range 
of European mink, a serologic survey was conducted in several mustelid 
species, including European mink, feral American mink, polecat (Muste/a 
putorius), stone marten (Martes foina) and pine marten (Martes martes). All 
of these mustelids have much larger ranges than the European mink, and co-
inhabit certain habitats with European mink, therefore providing opportunities 
for interspecies transmission of infections. American mink were introduced 
in Europe for the fur trade, but subsequent escapes from fur farms and 
successful colonisation of habitats have led to the establishment of populations 
in large parts of Europe 313 . Polecats are found throughout most of Europe, 
pine martens are found throughout central/northern Europe and as far East 
as Siberia, while stone martens are found throughout central and southern 
Europe 314. There are no current studies on population sizes and densities of 
these four mustelid species in the sample area. 
Serological surveys can be used to determine prevalence of antibodies 
to different pathogens, and to gain knowledge on whether these pathogens 
are endemic in the region tested, if repeated infections occur from an external 
source, or if an epidemic has occurred. Differences in prevalences should 
furthermore be attributed to differences in population density, or differences in 
host-virus interaction. However, prevalence of antibodies should be interpreted 
with caution, as it does not necessary equate to the prevalence of exposure. 
Exposed animals that died from the infection, that have not yet seroconverted, 
or that no longer have detectable antibody titres will not be detected in such 
ad hoc surveys. Furthermore, serum antibody tests are usually produced for 
use in domestic species, and have not been validated for use in non-domestic 
species. 
To our knowledge, free-ranging mustelids in Europe have previously 
only been tested for the presence of antibodies to RV 315 , ADV 296•316•317 and 
CDV 299•300•318-320. Apart from recent data on prevalence of ADV 296 , there is no 
knowledge of the infection status of the mustelid populations in south-western 
France. 
We tested for antibodies against four viruses which are common in domestic 
animals (CDV, CAV, CPIV, and RV) and for which serological tests are readily 
available. Although ADV is seen as a potential threat to the European mink, 
this virus was not included in this survey, as the data on ADV prevalence in 
this population have been published recently 296 • 
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Mustelids are known to be very susceptible to CDV infection 321 ·322 . In the 
highly endangered black-footed ferret (Mustela nigripes) of Wyoming, CDV 
has contributed to the decline of free-ranging and captive populations 15 • 
Effects of CDV on European mink is poorly documented, but fatal vaccine-
induced distemper has been published 126•323 . The endangered European 
mink is therefore expected to be very susceptible to infection with virulent 
CDV. Members of the Canidae, Ursidae and Mustelidae (including striped 
skunks (Mephitis mephitis), American mink, and ferrets) are susceptible to 
CAV-1 infection, and transmission among domestic and wildlife species is 
well documented 324 , but reports of clinical disease in free-ranging species 
associated with natural infection are limited 304 . Experimental intranasal 
infections with CPIV in ferrets usually cause mild respiratory symptoms 306 , but 
its prevalence and significance in free-ranging mustelids is largely unknown. 
The zoonotic potential of RV has initiated effective vaccination programmes 
of domestic dogs and free-ranging vector species, which have eradicated it in 
many areas, including our study area. 
The objectives of this study were (1) to determine the prevalence of 
antibodies to CDV, CAV, CPIV and RV in free-ranging European mink from 
south-western France as a measure of exposure to these major pathogens; 
and (2) to determine antibodies in sympatric mustelids which co-inhabit home 
ranges of the European mink and which can serve as sentinels to determine 
the presence of these four viruses in the study area or could potentially pass 
virus to them. 
MATERIALS AND METHODS 
Serum samples were collected from 127 European mink, 112 American 
mink, 201 polecats, 20 pine martens and 21 stone martens trapped during 
several studies 296 in eight departments of south-western France (42°47 to 
46°22'N and 0°54' to 4 ?W) between March 1996 and March 2003 (Figure 
1 ). Most animals (n=327) were caught in live traps, between September and 
April to avoid birth and nursing periods. Some animals (n=154) were also 
accidentally captured in live traps during pest control campaigns. Individuals 
were sometimes caught several times. 
Animals were anaesthetised with an intramuscular injection of 150 IJg/ 
kg medetomidine (Domitor® 1 mg/ml, Pfizer Sante Ani male, Paris, France) and 
7.5 mg/kg ketamine (Ketamine UVA 500® 50 mg/ml, Laboratories UVA, lvry-
sur-Seine, France) and a detailed clinical exam was performed 296 . All animals 
were marked by a cut on the ear and received a subcutaneous transponder 
(Injectable Trovan®, Eid Aalten B.V., Aalten, The Netherlands) between the 
shoulders. Blood was taken from the jugular vein using a disposable syringe 
with a 0.6 x 25mm disposable needle (Terumo®, Terumo Europe N.V., Leuven, 
Belgium), and transferred into a plain silicone coated glass tube (Venoject, 
Terumo). When the procedures were completed, anaesthesia was reversed 
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with 750 IJg/kg Atipamezole (Antisedan®, 1 mg/ml, Pfizer Sante Ani male), and 
the animal was placed back in the trap to recover, and released at the capture 
site 2-3 hr after recovery. Blood was centrifuged at 3000 g for 5 minutes on the 
same or the next day and serum was stored at -20°C. 
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Figure 1 : Geographic distribution of 480 free-ranging mustelids tested for 
antibodies to canine distemper virus, canine adenovirus, parainfluenza A virus 
and rabies virus in southwestern France. 
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Serum was centrifuged for 5 minutes at 10 000 g, heat-inactivated at 
56°C for 30 minutes, and screened for antibodies against CDV, CAV, CPIV 
and RV using an indirect ELISA, as described 268 . In short, horseradish-
peroxidase conjugated protein A was used to detect the pathogen-specific 
immunoglobulins bound to the antigen coated wells (European Veterinary 
Laboratory, Woerden, the Netherlands).An optical density (OD) read at450nm 
of three times the background OD was considered positive. Dilutions of serum 
were made in a buffer consisting of phosphate buffered saline solution, 0.2% 
bovine serum albumin, 0.1% milk powder and 5% sodium chloride. Positive 
and negative control sera were included in the tests. Positive samples in the 
screening dilution of 1:50 were then retested using 2-log dilution series (1 :10 
-1:1280) to determine the titre. CAV-1 and CAV-2 are closely related viruses 
(CAV-2 causes milder, predominantly respiratory disease in domestic species) 
and antibodies against these viruses can not be distinguished with the 
methodology used. Results are therefore given for CAV (without specification 
of the subtype). 
The CDV-specific serum antibody titres of samples considered positive 
by ELISA were subsequently determined by means of a virus neutralisation 
(VN) test as previously described 269 using 2-log dilution series of the pre-diluted 
samples (1: 10-1: 1280). The end point titre of each serum was expressed as 
the reciprocal of the highest dilution that completely inhibited cytopathic effect 
(CPE) in Vera cells after 5 days incubation. 
Twenty European mink, four polecats and two American mink were 
sampled repeatedly, two to four times (one European mink three times and 
one four times), with a mean interval of 48 weeks (6 to 123 weeks). For 
determination of antibody prevalence and for all statistical tests, re-sampled 
animals were represented once (the first sample that tested positive). Cytotoxic 
sera in the VN test (n=11) were excluded from calculations of prevalence. 
For each virus, we used the chi-square test to compare the prevalence 
of antibodies between sex within species, or a Fisher exact test when the 
contingency table contained an expected frequency of less than 1.0 in any 
cell 325. For CDV, the same tests were used to compare, within species, the 
difference between prevalences measured by ELISA and VN test. Difference 
of prevalence of antibodies between species was tested using a Chi-square 
test followed by a multiple comparisons test 325·326 . For all statistical tests .E::;:; 
0.05 was considered significant. 
RESULTS 
Clinical Examination 
None of the animals sampled showed clinical signs of disease upon 
capture and sampling. 
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Canine distemper virus 
Antibody titres to CDV were detected in all species (Table 1 and 
Figure 2), without significant differences in prevalence between sexes, tested 
per species. For each species, the difference of prevalence between the 
ELISA and the VN test was not significant. Prevalence tested by ELISA was 
significantly different between species (~=26.8, p<0.005) and the multiple 
comparison test (with a'= 0,0051) revealed that for both polecat and stone 
marten, prevalence was significantly higher than in European mink (~=8.0 
and ~=10.3, respectively), and than in American mink (~=14.6, and ~=17.9, 
respectively). Prevalence tested by VN was also significantly different between 
species (x"=18.8, p<0.005) and multiple comparisons test only revealed 
significantly higher prevalence for both polecat and stone marten versus 
American mink (~=1 0.2 and ~=12.1, respectively). 
CDV by ELISA CDV by Virus neutralisation 
Positive Prevalence Positive Prevalence 
/tested (95% confidence /tested (95% confidence interval) interval) 
Mustela lutreola 11/127 8.7% (3.4-14.0) 8/126 6.3% (1.7-11.0) a, b f, g 
Mustela putorius 41/201 20.4% (14.6-26.2) 30/192 15.6% (1 0.2-21.0) a, c f, h 
Mustela vison 5/112 4.5% (0.2-8.8) 4/111 3.6% (0.0-7.5) c, d h, i 
Martes foina 7/21 33.3% (14.6-57.0) 5/20 25.0% (8.7-49.1) b, d, e 9. i 
Martes martes 1/20 5.0% (0.1-24.9) 1/20 5.0% (0.1-24.9) 
Table 1: Antibody prevalence to canine distemper virus (CDV) in free-ranging 
small mustelids from south-western France using indirect ELISA and virus 
neutralisation tests. a, b, c, ct. •· 1• s. h,; : Mean values with the same superscript are 
significantly different between species (P::; 0.05). 
VN titres ranged from 40 to 640 in European mink and polecat, 20 to 
160 in American mink, 80 to 160 in stone martens and was 320 in the positive 
pine marten. 
No seroconversion was observed in 21 negative re-sampled 
individuals. One European mink had an increased titre when recaptured 48 
weeks later (320- 640). One other, positive in ELISA test only, was negative 
in both tests 13 months later. Three polecats with an antibody titre of 80 were 
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negative(::;; 20) 12, 42 and 44 weeks later, respectively. 
CAV (ELISA) CPIV (ELISA) RV (ELISA) 
Positive Prevalence Positive Prevalence Positive Prevalence 
/tested (95% Cl) /tested (95% Cl) /tested (95% Cl) 
Mustela 3/126 2.4% (0.0- 1/126 0.8% (0.0- 1/126 0.8% (0.0-lutreola 5.5) 2.7) 2.7) 
Mustela 5/201 2.5% (0.1- 9/201 4.5% (1.4- 2/201 1.0% (0.0-putorius 4.9) 7.6) 2.6) 
Mustela 6/112 5.4% (0.7- 1/112 0.9% (0.0- 0/112 0.0% (0.0-
vi son 10.0) 3.1) 0.4) 
Martes 2/21 9.5% (1.2- 0/21 0.0% (0.0- 0/21 0.0% (0.0-foina 30.4) 16.1) 16.1) 
Martes 0/20 0.0% (0.0- 0/20 0.0% (0.0- 0/20 0.0% (0.0-
martes 16.8) 16.8) 16.8) 
Table 2: Antibody prevalence to canine adenovirus (CAV), parainfluenza virus 
(CPIV) and rabies virus (RV) in free-ranging small mustelids from southwestern 
France using an indirect ELISA test. 
Canine adenovirus 
Antibody titres to CAV were detected in all species except pine marten 
(Table 2 and Figure 2), without any significant difference in prevalence between 
sexes. No significant difference was observed between species ()(=5.4). All 
re-sampled individuals were negative without any serologic conversion. 
Canine parainfluenza virus 
Antibody titres to CPIV were only detected in one European mink, 9 
polecats and two American mink, without any significant difference between 
these three species (i"=5.9) (Table 2 and Figure 2). One negative polecat was 
positive 12 weeks later. All other re-sampled animals were negative without 
any serologic conversion. 
Rabies virus 
Low "borderline" antibody titres to RV (s; 50) were only detected in one 
European mink, and two polecats (Table 2). All re-sampled individuals were 
negative without any serologic conversion. 
Multiple exposures 
One stone marten and two polecats were positive to both CDV and CAV, 
three polecats were positive to both CDV and CPIV, and one European mink 
was positive to both CDV and with a low, possibly non-specific titre to RV. 
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DISCUSSION 
In the present study we showed the presence of antibodies to COY in all 
species investigated, to CAY in all species but the pine marten, and to CPIY 
and possibly RY in all Mustela sp. Serological evidence of exposure to COY 
occurred in all five mustelid species tested and throughout the sample area. 
The significantly higher prevalence observed in polecats and stone martens 
(33% and 20%, respectively, versus 9 and 5% in European mink and American 
mink, respectively) correlates with previous prevalence found in stone martens 
from Germany 259·299 . The high prevalence of COY is possibly related to the 
natural habitat of these species. They live in close proximity to humans 327·328 , 
making it more likely that they have come into direct or indirect contact with 
COY-infected domestic dogs, which can act as an external source of virus for 
free-ranging populations. Studies have shown that COY strains in dogs and 
free-ranging carnivores in Germany are identical, suggesting transmission of 
the virus between these populations 259•299 . In the study area, hunting with 
hounds is widespread in rural regions, and COY infection probably occurs 
regularly in these hounds. Although European mink is strongly specialised 
in aquatic habitats, generally far from humans, they have very large home 
ranges 329, occasionally resting near rural human habitation 330• American 
mink are known to cause damage to hen houses and poultry farms. Therefore 
interspecies contact with domestic species is also likely to occur, but less 
frequently than the polecat or stone marten. High prevalence was observed in 
free-ranging polecats, while COY has a very high mortality rate in naive ferrets 
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• A COY epidemic could not be demonstrated, as the numbers of animals 
sampled were too small to perform statistical tests between years in the study 
period to determine a peak in prevalence. This therefore indicates that COY 
may be endemic in this species or these species collectively, or that repeated 
infections occur from an external source. Whatever the source of infection of 
polecats, this species is known to have close contact with European mink, as 
hybrids have been found in the wild 331 , and the high prevalence in this species 
suggests that COY poses a serious threat to the European mink. 
Although specific data on longevity of antibody titres are unknown for 
these species, three polecats which were COY-positive at the time of their first 
capture, were negative when recaptured, illustrating that serologic studies like 
this document the prevalence at particular points in time. The neutralisation 
titres of 20 to 640 are higher than those previously reported 299 , although 
differences in methodology impedes direct comparisons. 
Antibodies to CAY were detected in all species, except pine marten, and 
throughout the sample area. In our study, prevalence ranged from 2 to 10%. 
Previous serological surveys of Canadian mustelids have shown prevalences 
of 4% in 28 fischers (Martes pennanti), and 0% in 15 American badgers 
(Taxidea taxus) 110, but 62% prevalence was observed in striped skunks, and 
two cases of fatal disease have been described in this species 302 . Disease 
caused by CAY infection is generally not severe in carnivores and our results 
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probably reflect a relatively low exposure to the virus. 
Antibodies to CPIVwere found mainly in polecats (5% of201 individuals). 
Of all other species, only one positive American mink and one positive 
European mink were detected. Our results probably reflect a low exposure 
to the virus, particularly in minks, and suggest that CPIV infection is a lesser 
threat for free-ranging mustelids. 
The detection of antibodies against RV is surprising, as the sampling 
areas are considered rabies-free. There are two possible explanations. First, 
it may be attributed to a lack of specificity of the test method used, as the titres 
detected were low (~ 50). Usually a higher cut-off (=1 00) is used for positivity 
in this ELISA. Second, the antibodies detected may be directed against 
European bat-lyssa virus type-2 (EBLV-2), since there is a high level of cross-
reaction between the closely related rabies and bat-lyssa viruses, and it is 
difficult to distinguish the antibodies to either of these viruses by the serologic 
method used. Spill-over of bat-origin lyssa virus type-1 has been documented 
in stone martens in Germany 332, although these spill-over infections do not 
occur frequently, are supposed to be fatal, and mustelids are dead-end hosts, 
so the infection is self-limiting 333. It is interesting to note that experimental 
infection of ferrets with EBLV-2 has induced high neutralising titres, and all 
ferrets survived 334, although no natural infections have been documented. 
A VN test could confirm the specificity of the borderline titre against RV. 
However, insufficient volumes of serum of these animals would not allow this 
confirmation. 
We have shown that free-ranging mustelids of South-western France 
are exposed to all the viruses investigated (possibly except RV). The high 
prevalence of antibodies against the potentially lethal CDV suggests that 
this pathogen could have significant effects on the free-ranging populations 
and its contribution to the decline of the weakened population of endangered 
European mink cannot be excluded. This has several implications for the 
conservation of the species. Strict sanitary protocols should be implemented 
during (pest-) trapping programs- European mink are occasionally accidentally 
captured in live-traps used for pest control -, to exclude live-traps as sources 
of infection. Recently a breeding program has been set up in Spain, with the 
intention to eventually release European mink, and a similar program may 
also be set up soon in France. Virus burdens in the release areas may be 
reduced by vaccination campaigns of domestic dogs in the region, as is done 
to protect endangered free-ranging carnivores in Africa 335·336 , or by restrictive 
dog-hunting measures. Vaccination of immunologically naive European mink 
(especially against CDV) before release into endemic or epidemic areas is 
recommended (and the vaccine should be administered early enough to allow 
for the development of protective immunity prior to release) in order for these 
programmes to be maximally successful. Vaccines against the viruses reported 
in this study are commercially available for domestic dogs, but unfortunately 
contain a modified-live CDV component, among other modified-live viruses. 
Only inactivated vaccines (or other vaccines that have proven to be safe and 
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effective in the targeted species) should be used in non-domestic animals, as 
fatal vaccine-induced diseases have occurred in several non-domestic species, 
including vaccine-induced CDV infections in European mink. Currently there 
is no safe and effective CDV vaccine commercially available for non-domestic 
species in the European Union, and the safety and efficacy of (the extra-
label use of) vaccines against other pathogens have not been described in 
European mink. 
In conclusion, this study has shown that free-ranging mustelids in south-
western France have been exposed to CDV, CAV and CPIV. Future studies 
should focus on isolation and identification of these viruses in order to improve 
our understanding of their epidemiology and impact in these species, and on 
the development and evaluation of preventive measures like vaccination with 
safe and effective vaccines. 
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CDV vaccination of European mink 
The endangered European mink (Muste/a lutreola) is highly 
susceptible to infection with canine distemper virus (CDV), and live 
vaccine-induced CDV infections have been reported in this species. 
Currently there is no safe and efficacious commercially available CDV 
vaccine for use in highly susceptible non-domestic species like the 
European mink. We evaluated the safety and efficacy of an experimental 
CDV immune-stimulating complex (ISCOM) and a canarypox-vectored 
recombinant vaccine which is commercially available in the USA, but 
which is not authorised for use within the European Union. Both vaccines 
were inoculated in six European mink each, and proved to be safe and 
induced antibodies to CDV. However, compared to the recombinant 
group, CDV-specific antibody titres in the ISCOM group appeared sooner 
after first vaccination, peaked at higher levels, and remained higher one 
year after the third vaccination. These results indicate that while both 
CDV vaccines are effective, using virus neutralising serum antibody 
titres as correlate of induced protection, the CDV-ISCOM vaccine is more 
immunogenic than the recombinant vaccine in European mink. 
INTRODUCTION 
All families of the order Carnivora are susceptible to infection with 
canine distemper virus (CDV), a ubiquitous and potentially fatal pathogen 
which has caused outbreaks in several species. Mustelids (black-footed ferret 
[Mustela nigripes], Siberian polecat [Mustela eversmanm], and the domestic 
ferret [Mustela putorius furo]) are extremely susceptible and exhibit almost 
100% morbidity and mortality after experimental and natural infections. 
Domestic dogs and domestic ferrets can be protected against canine 
distemper by vaccination with a modified live virus (MLV) vaccine. However, 
other carnivores show a large variation (between and within species) in reaction 
to MLV vaccines. Vaccines approved for domestic ferrets and dogs which use 
MLV attenuated via passage in avian- or primate cell lines, are generally safer 
for use than those of canine kidney cell origin 337. However, MLV vaccine-
induced disease and mortality have been reported in several non-domestic 
carnivore species, including highly endangered mustelid species like the 
European mink (Mustela /utreola) 126•323 and black-footed ferret 121 •125• 
Safer alternatives are inactivated virus vaccines, subunit vaccines, or 
recombinant vaccines. Monovalent inactivated virus vaccines do not induce 
disease after vaccination, although the process of inactivation may affect 
their immunogenicity, usually resulting in an immune response that is shorter 
in duration, narrower in antigenic spectrum, weaker in cell-mediated and 
mucosal immune responses 25• Recombinant poxvirus-based CDV vaccines 
have proven to be safe and efficacious in Siberian polecats, a species closely 
related to the European mink, and in other carnivore species 73. In the USA, 
a canarypox-vectored recombinant CDV vaccine is commercially available 
for use in domestic ferrets (Purevax™, Merial, Duluth, GA, USA), and is 
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recommended for use in exotic species by the American Association of Zoo 
Veterinarians (AAZV). However, the use of this recombinant CDV vaccine 
is currently forbidden in the European Union, and monovalent inactivated 
vaccines are no longer commercially available. An experimental CDV 
immune-stimulating complex (ISCOM) vaccine was developed and tested 
in harbour seals (Phoca vitulina) during an outbreak of the closely related 
phocine distemper virus 338• This vaccine protects seals and domestic dogs 
against challenge infection 140·236 , and has since then been used in several 
non-domestic carnivore species in zoos, although little published data exist 
of its use in these species. Currently there are no safe and effective CDV 
vaccines registered and available for use in highly susceptible non-domestic 
species within the EU. 
The European mink, a small semi-aquatic mustelid, has withdrawn 
dramatically from its former territory during the last century 290-293 and is 
currently listed as endangered by the International Union for the Conservation 
of Nature and Natural Resources (IUCN, 2006). Presently, the population is 
spread out over two distinct areas: a relatively large eastern population (in 
Russia, Belarus, Romania, Kazakhstan and the Ukraine) and a very small 
western population located in South-western France and northern Spain. 
Reasons implicated for the decline include excessive trapping, change or loss 
of habitat and interspecies competition by the larger American mink (Muste/a 
vison), but the role of diseases has been also suggested 290•295 . An EU LIFE 
project (2001-2004) was set up together with Foundation Lutreola in Estonia 
for the recovery of the species and the preservation of biological diversity, 
both in situ and ex situ. The ex situ project includes a breeding facility at 
the Tallinn zoo with a capacity of 1 00 animals as the core of the European 
endangered species breeding programme (EEP) and to serve as a source 
of animals to eventually re-establish a population on two Estonian islands. A 
similar breeding programme has recently been started in Spain. 
The impact of CDV infections in captive breeding and re-introduction 
programmes has been devastating for endangered species like the black-
footed ferret 15 and African wild dogs 13. A safe and effective vaccination 
campaign is therefore essential for the protection (and therefore survival) of 
valuable and endangered susceptible species in breeding centres and re-
introduction projects. The endangered status of the European mink precludes 
challenge infections, but serum antibodytitres measured by virus neutralisation 
(VN) test, which is regarded as the gold standard method for determination of 
immunity to morbilliviruses 339 can be used as correlate of protection. Survival 
rates after challenge infection with CDV increases with vaccine-induced VN 
titre 73 in polecats - closely related mustelids, which may be regarded as 
sympatric sister species of the European mink 340• The goal of the present 
study was to evaluate and compare the humoral immunogenicity and safety 
of a commercial recombinant CDV vaccine and an experimental CDV-ISCOM 
vaccine in European mink. 
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MATERIALS AND METHODS 
Previously unvaccinated captive European mink housed in a breeding 
centre in Tallinn Zoo, Estonia were used for this study, which was conducted 
in the summer of 2003. Six mink were vaccinated with one ml of a commercial 
canarypox-vectored recombinant CDV vaccine (Purevax®, Merial, Duluth, GA, 
USA) and six mink were vaccinated with one ml of an experimental immune-
stimulating complex (CDV-ISCOM, Erasmus MC, Rotterdam, the Netherlands) 
with an antigen content of 10 j..Jg/ml, produced as previously described 140. As 
a negative control group, five mink were injected with a phosphate buffered 
saline solution. The mink were vaccinated three times intramuscularly at three 
week intervals, monitored daily for the development of adverse reactions or 
CDV-Iike disease, and clinically examined at times of vaccination. 
Blood was collected from the jugular vein prior to each vaccination, 
and at 3 weeks and 1 year after the third vaccination. To collect blood, the 
European mink were manually restrained in a cloth bag, and anaesthetised 
with an intramuscular injection of 150 j..Jg/kg medetomidine (Domitor® 1 mg/ 
ml, Pfizer Animal Health, Capelle a/d ljssel, the Netherlands) and 7.5 mg/kg 
ketamine (Ketamine 10%, Alfasan, Woerden, the Netherlands). Anaesthesia 
was reversed using 750 j..Jg/kg atipamezole (Antisedan®, 1 mg/ml, Pfizer Animal 
Health, Capelle a/d ljssel). Initial dosage was based on estimated weight, and 
subsequently on weight measured during previous anaesthesia. 
Study design 
The VN test is regarded as the gold standard test for determination 
of immunity against morbilliviruses. The enzyme-linked immunosorbent assay 
(ELISA), is easy and rapid to perform, conducted in most veterinary diagnostic 
labs, and commercially available as kits. Future evaluation of vaccine-induced 
antibody titres would be more practical if the ELISA test can be used. Therefore 
serum antibody titres were determined by both methods and compared. 
Blood was centrifuged for five minutes at 10 000 g, serum was 
separated and stored at -20°C. Serum was then heat-inactivated at 56°C for 
30 minutes and tested for CDV-specific antibodies by means of a VN test using 
2-log dilution series (1: 10 to 1 :1280), and 100 median tissue culture-infectious 
doses (TCID50 ) of CDV in Vero cell culture, essentially as previously described 
269
. The end-point titre of each serum was expressed as the reciprocal of the 
highest dilution that completely inhibited a cytopathic effect after five days 
incubation. We considered a high serum antibody titre (;:>: 80) protective, 
based on published protective antibody titres to CDV infection in polecats 
which varied between ;::: 3 and ;::: 152, and showed higher survival rates with 
increasing VN serum antibody titres 73 . 
Serum antibody titres were then determined by an indirect ELISA 268 , 
using 2-log. dilution series. An optical density of three times the background 
optical density in both dilutions, read at 450 nm was considered positive. 
An ELISA using uninfected Vero cell lysate was used as a negative control 
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antigen for each sample tested, providing the background optical density 
using 2-log dilution series, and control sera from known positive and negative 
animals were included in the tests. Undetectable titres were regarded as 5 for 
calculation of geometric mean titres (GMT). 
For comparison, three Asiatic small-clawed otters (Aonyx cinerea) 
and two European otters (Lutra lutra) that had been vaccinated three times 
with three week intervals with the same batch of CDV-ISCOM in Rotterdam 
Zoo were also tested for the development of VN serum antibody titres. 
RESULTS 
None of the vaccinated animals showed clinical signs of CDV 
infection, and no local or systemic side effects that could be attributed to 
vaccination were noticed. Control animals did not produce serum antibody 
titres throughout the study. 
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Figure 1. Antibody titres induced in European mink by CDV-ISCOM and a 
canarypox-vectored recombinant CDV vaccine, measured by ELISA and virus 
neutralisation. Mink were vaccinated three times with three weeks interval, 
and blood was collected on days of vaccination, three weeks after the third 
vaccination, and one year later. White circles depict CDV-ISCOM vaccinated 
animals, black circles depict canarypox-vectored vaccinated animals. Dotted 
line connects geometric mean titres of CDV-ISCOM vaccinated animals (n=6), 
black line connects GMT of canarypox-vectored recombinant vaccinated animals 
(n=6). Arrows depict time of vaccination. 
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CDV-ISCOM vaccinated animals 
Low GMTs (by VN and ELISA test) were induced by one dose of the 
ISCOM vaccine (figure 1 ). Virus neutralising serum antibody titres were high 
(;?: 80) in 33% of vaccinated animals after one vaccination (67% measured by 
ELISA). After 2 doses, high GMTs were induced by the ISCOM vaccine, and 
100% had high serum antibody titres (measured by both VN and ELISA). A 
third dose boosted antibody titres, with VN titres ;::: 640 in all animals, and VN 
GMT 1140. The GMTs measured by ELISA followed the same trend, but were 
higher (Figure 1 ). One year after the last vaccination, VN titres had declined 
(GMT: 160) but 100% had high (;::: 80) serum antibody titres (measured by both 
VN and ELISA). 
In comparison, two other mustelid species: Asiatic small-clawed otters 
(Aonyx cinerea) and European otters (Lutra lutra) that had been vaccinated 
three times at three week intervals with the same batch of CDV-ISCOM in 
Rotterdam Zoo showed high VN GMT after 2 vaccinations. The GMT in these 
species remained high one year after the first three vaccinations, and one 
booster-vaccination at this time resulted in high GMT one year later in the 
Asiatic small-clawed otters (Figure 2) 
Recombinant vaccine vaccinated animals 
After 2 doses low GMTs were induced in the European mink by the 
recombinant vaccine (Figure 1 ), and 0% had high (;::: 80) VN serum antibody 
titres (33% measured by ELISA). A third dose boosted antibody titres, and 
33% had high VN serum antibody titres (50% measured by ELISA). GMT 
declined but remained for at least one year. In all animals, both VN and ELISA 
serum antibodies were induced after three vaccinations, with titres ;::: 40 in all 
animals, and VN GMT 50. The GMTs measured by ELISA followed the same 
trend, but were higher (Figure 1 ). One year after the initial three vaccinations, 
VN titres had declined, but were still detectable (GMT: 22) although only 33% 
had high VN and ELISA titres, and 33% did not have a detectable titre (by both 
VN and ELISA) at that time 
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Figure 2. Virus neutralising antibody titres in two other mustelid species: European 
otter (n=2) and Asiatic small-clawed otter (n=3) induced by the same batch of 
CDV-ISCOM as used in the European mink. The otters were vaccinated three 
times with three weeks interval, and blood was collected on days of vaccination, 
three weeks after the third vaccination, and one year later. One year after the 
initial three vaccinations, the Asiatic small-clawed otters were re-vaccinated 
with one vaccine dose, and blood was collected one year later. Triangles depict 
Asiatic small-clawed otters, squares depict European otters, dotted line connect 
geometric mean titres (GMT) of Asiatic small-clawed otters, black line connects 
GMT of European otters 
DISCUSSION 
In the present study we have shown that the CDV-ISCOM and 
canarypox-based recombinant CDV vaccines do not cause adverse effects or 
canine distemper-like clinical signs and induce humoral immune responses in 
European mink as determined by VN and ELISA tests. Using CDV neutralising 
serum antibody titres as correlate of protection, these results indicate that 
the CDV-ISCOM vaccine is more efficacious in European mink, whilst both 
seem to be safe. Furthermore, vaccination with this CDV-ISCOM proved 
also efficacious in terms of VN serum antibody titres in two other mustelid 
species. 
Serum antibody titres measured by ELISA followed a similar trend 
as those measured by VN test, but were generally higher. The ELISA, which 
is based on Vero cell culture-grown detergent-treated virus antigens, detects 
antibodies directed at a large range of epitopes on the haemagglutinin (H) 
and fusion (F) surface proteins of CDV, but it also detects antibodies against 
the nucleoprotein (NP) antigen and cell components. The VN antibodies 
are exclusively directed to the H and F surface proteins of the virus, and 
mostly recognise conformational epitopes 341 • The ISCOM vaccine uses virus 
grown on Vera cells as used in the ELISA. It is produced in a manner that 
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incorporates the H and F proteins into the ISCOMs, and then purified, leaving 
little or no NP or cell components in the vaccine. However, the presence of 
small amounts of NP or cell components in the vaccine may induce additional 
antibodies against these additional epitopes, which are measured by ELISA. 
The inclusion of an ELISA coated with an uninfected Vero cell lysate used as a 
control for these sera excludes serum antibodies directed against the Vera cell 
epitopes. Antibodies induced by the ISCOM and recombinant vaccine are thus 
directed predominantly against the H and F surface proteins. Nevertheless, a 
difference in serum antibody titre is seen between the two test methods, which 
may be explained by the fact that the ELISA detects antibodies not exclusively 
against VN inducing epitopes on the H and F, like the VN test does. 
Vaccination with a canarypox-vectored recombinant CDV vaccine has 
induced protection in dogs without eliciting a pronounced serologic response, 
and it has been suggested that the vaccine-induced cell-mediated responses 
can result in adequate protection in the absence of high serum antibody 
titres 141 •142 . Efforts to document T-cell responses after vaccination of ferrets 
with canarypox-vectored CDV vaccines were not successful 342. Morbillivirus 
ISCOMs have been shown to effectively induce specific T-cell responses 
in macaques 343• Therefore it is likely that both the CDV-ISCOM and the 
recombinant vaccine used in this study will have induced virus specific T-
cell responses in this species, thus adding to the protective efficacy of both 
vaccines. 
For breeding and re-introduction programmes to be maximally effective, 
it is important to know the status of infectious agents in the designated area, 
so that animals can be vaccinated and thus obtain suitable levels of vaccine-
induced protection before release. Equally important is a screening of the 
animals before release to ensure that they do not introduce a new pathogen 
into the designated release area. 
In conclusion, these results suggest that while both vaccines induce 
a humoral response, the CDV-ISCOM vaccine may be expected to protect 
European mink better than the recombinant vaccine against CDV infection 
for at least one year after 3 vaccinations, based on the induction of higher 
virus neutralising antibody titres in this species. However, the contribution of 
vaccine-induced specific T-cell responses by each of the vaccines tested may 
contribute to the protective efficacy. Since no specific T-cell responses were 
measured, and no challenge infections can be carried out in this species, 
the relative protective efficacy between both vaccines for the European mink 
cannot be estimated. 
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CDV vaccination African wild dogs 
Modified live virus vaccines against canine distemper virus (CDV) 
for dogs have induced disease and mortality in several non-domestic 
carnivores, including the endangered African wild dog (Lycaon pictus). 
We evaluated safety and efficacy of alternative vaccines in African wild 
dogs: an experimental immunostimulating complex (ISCOM) vaccine 
and a commercially available canarypox-vectored recombinant vaccine. 
Two vaccine doses of both vaccines induced low virus neutralising 
(VN) antibody titres (GMT: 8 and 28 for the ISCOM and recombinant 
vaccinated groups respectively). One year after 3 vaccinations at three 
week intervals the VN GMT was 6 and 38 for the ISCOM and recombinant 
groups respectively. The percentage of animals with high VN serum 
antibody titres (~80) at this time was 39% in the recombinant vaccine 
group, whereas no high VN serum antibody titres were found in the 
IS COM group. Antibody titres measured by ELISA one year after the initial 
three vaccinations were higher than VN titres (GMTs: 84 and 80 for the 
ISCOM and recombinant vaccinated groups respectively, with 69% ~ 80 
for both vaccines). These results indicate that both vaccines were safe, 
but using vaccine-induced VN antibodies as a correlate of protection, 
neither vaccine proved to be adequately efficacious, for up to one year 
post-vaccination in this species. Interestingly, the same batch of CDV-
ISCOM vaccine induced adequate VN serum antibody titres in several 
other non-domestic carnivore species, using the same vaccination 
regimens. This shows that the African wild dog is a low responder to 
CDV vaccination with these vaccines. 
INTRODUCTION 
The African wild dog (Lycaon pictus) is one of the most endangered 
species of the taxonomic family Canidae. They once ranged widely throughout 
39 sub-Saharan African countries, but currently their population is estimated 
at 3 000 - 5 500 in 15 countries, and have been listed as endangered by the 
International Union for the Conservation of Nature and Natural Resources 
since 1990 (IUCN, 2006). Their dramatic decline is largely due to human 
persecution (snaring, shooting, and road accidents), habitat fragmentation, 
reduced prey availability, competition with other carnivores, and disease. A 
shrinking or fragmented wildlife habitat has changed population numbers and 
may have resulted in increased inter-species contacts and exposure to new 
pathogens. Outbreaks of canine distemper virus (CDV) infection 92·344 and 
rabies virus (RV) infection 345•346 have had a devastating impact on African 
wild dog populations, and have been associated with the close proximity to 
unvaccinated domestic dogs 92• 
Domestic dogs can be routinely vaccinated against CDV with 
modified-live virus (MLV) vaccines. A problem faced in the prophylaxis of CDV 
infection in exotic carnivores is the variation between and within species in 
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their reaction to vaccines. Vaccination with MLV CDV vaccines have resulted 
in clinical canine distemper (often resulting in death) in many non-domestic 
species, including the African wild dog 202•203•347. Inactivated virus vaccines are 
safer because they do not cause infection, but have decreased efficacy, and 
have largely failed to induce sufficient immunological responses in domestic 
136 and non-domestic carnivores, including the African wild dog 65·70 • There is 
one report in which an inactivated oil-adjuvanted vaccine has produced virus 
neutralising (VN) serum antibody titres > 20 in African wild dogs 348. However, 
currently there are no monovalent inactivated CDV vaccines commercially 
available, due to their lower efficacy in domestic dogs compared to MLV 
vaccines, and since the market for non-domestic animals is too small 138 • 
One safe alternative would be the use of an immune-stimulating 
complex (ISCOM) vaccine, which does not contain live virus. Such a vaccine 
has been developed and protects harbour seals (Phoca vitulina) and domestic 
dogs against phocine distemper virus infection 81 •338 , which is closely related to 
CDV. African wild dogs in a breeding programme in Mkomazi, Tanzania, were 
vaccinated with the CDV-ISCOM vaccine, which resulted in antibody titres to 
CDV in African wild dogs monitored at the beginning of this captive breeding 
program. However, despite recent vaccination there was a lack of VN antibody 
titres to CDV in sera of these African wild dogs just prior to an outbreak of CDV 
that subsequently killed 49 of the 52 animals 13• 
Another safe alternative is a recombinant canarypox-vectored 
vaccine which is registered for use in ferrets in the USA, and recommended 
for use in non-domestic carnivore species by the American Association of Zoo 
Veterinarians. However, its use in the European Union is not authorised. 
The endangered status of the African wild dog precludes challenge 
infections, but the presence of serum antibody titres measured by VN test, 
the gold standard method for determination of immunity to morbilliviruses 339 
can be used as a correlate of protection. Published vaccine induced serum 
antibody titres that protect domestic dogs against CDV infection range from 
20 349·350 to 100 65·351 •352• Survival rates after challenge infection with CDV 
correlates with the level of vaccine-induced VN serum antibody titres in dogs 
and polecats (Mustela eversmanm) 73·353• The objective of the present study 
was to evaluate safety and humoral immune responses to two different CDV 
vaccines - CDV-ISCOM and canarypox-vectored CDV vaccine - in previously 
unvaccinated African wild dogs. 
MATERIAL AND METHODS 
Previously unvaccinated and unexposed, young captive African wild 
dogs housed in a breeding centre in Mkomazi, Tanzania, or in Artis Amsterdam 
Zoo, The Netherlands, were used for this study. Thirteen African wild dogs in 
Mkomazi were vaccinated with one ml of a canarypox-vectored recombinant 
CDV vaccine (Purevax™, Merial, Duluth, GA, USA) and thirteen African 
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wild dogs in Artis were vaccinated with one ml of an experimental ISCOM 
vaccine, with an antigen concentration of 10 1-Jg/ml (CDV-ISCOM, Erasmus 
MC, Rotterdam, the Netherlands). The African wild dogs were vaccinated 
three times intramuscularly at three week intervals, monitored daily for the 
development of adverse reactions including CDV-Iike disease, and clinically 
examined by a veterinarian at the times of vaccination. 
Blood was collected from the jugular vein prior to each vaccination, 
and 1 year after the third vaccination. The number of serum samples available 
at time of second and third vaccination was 8 in the recombinant group, but 
one year post vaccination all 13 animals could be evaluated. In the ISCOM 
group blood was collected from all 13 animals prior to each vaccination. No 
blood was collected after the third vaccination to minimise the number of times 
the animals had to be anaesthetised. To collect blood, the African wild dogs 
were anaesthetised with an intramuscular injection by blowpipe of 0.05 mg/kg 
medetomidine (Domito~ 1 mg/ml, Pfizer Animal Health, Capelle a/d ljssel, the 
Netherlands) and 5 mg/kg ketamine (Ketamine 10%, Alfasan, Woerden, the 
Netherlands). Dosage was based on estimated weights. 
Study design 
The VN test is regarded as the gold standard test for determination 
of immunity against morbilliviruses. The enzyme-linked immunosorbent assay 
(ELISA), is easy and rapid to perform, conducted in most veterinary diagnostic 
labs, and commercially available as kits. Future evaluation of vaccine-induced 
antibody titres would be more practical if the ELISA test can be used. Therefore 
serum antibody titres were determined by both methods and compared. 
Blood was centrifuged for five minutes at 1 0 000 g, serum was 
separated and stored at -20°C. Serum was then heat-inactivated at 56°C for 
30 minutes and tested for CDV-specific antibodies by means of a VN test 
using 2-log dilution series (1:10 to 1:1280), and 100 median tissue culture-
infectious doses (TCID50) of CDV in Vera cell culture, essentially as previously 
described 269 . The end-point titre of each serum was expressed as the 
reciprocal of the highest dilution that completely inhibited a cytopathic effect 
after five days incubation. Serum antibody titres were then determined by an 
indirect ELISA 268 , using 2-log. dilution series of these sera. An optical density 
of three times the background optical density in both dilutions, read at 450 nm 
was considered positive. 
An ELISA using uninfected Vera cell lysate was used as a negative 
control antigen for each sample tested (providing the background optical 
density using 2-log dilution series), and control sera from known positive and 
negative animals were included in the tests. Undetectable titres were regarded 
as 5 for calculation of geometric mean titres (GMT). 
For comparison, five red pandas (Ailurus fulgens), two maned wolves 
(Chrysocyon brachyurus) and five Malay civets (Viverra tangalunga) that had 
been vaccinated in Rotterdam Zoo three times with three week intervals with 
the same batch of CDV-ISCOM, were also tested for VN serum antibody titres. 
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For 16 red pandas that had previously been vaccinated with another batch of 
CDV-ISCOM (with an antigen concentration of 5 IJg/ml), only serum antibody 
titres measured by ELISA were available. 
The African wild dog is an endangered carnivore species, therefore 
challenge infections using a highly virulent CDV virus would not be acceptable 
from a conservation point of view. We considered a high VN titre (~ 80) as a 
correlate of protection to measure vaccine efficacy, in analogy with published 
data in several other carnivore species, in which the protective titre ranges 
between 20 and 100 65,73,143,349,352,354,355_ 
RESULTS 
None of the vaccinated animals showed local or systemic clinical 
signs or side effects that could be attributed to vaccination. 
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Figure 1. Serum antibody titres measured by ELISA and virus neutralisation, at 
times of vaccination with an experimental CDV-ISCOM vaccine (white circles) and 
a commercially available canarypox-vectored recombinant CDV vaccine (black 
circles) in 13 African wild dogs (Lycaon pictus). Dotted lines depict geometric 
mean titres (GMT) after CDV-ISCOM vaccination, straight lines depict GMT after 
recombinant vaccination. Arrows depict times of vaccination. 
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CDV-ISCOM vaccinated animals 
On day zero, 31% (4/13) and 15% (2/13) of the animals had low 
CDV-specific antibody titres (20 - 40) by ELISA and VN respectively. After one 
vaccination four animals had low VN titres (20), and 11 animals had low ELISA 
titres (20-40). High VN serum antibody titres (~ 80) were first detected in 8% 
(1 /13) of the animals after 2 vaccinations (GMT: 8) (Figure 1 ). Serum antibody 
titres measured by ELISA after 2 vaccinations showed higher percentages of 
animals with high titres: 31% (4/13), and a GMT of 38 (Figure 1 ). 
One year after the initial three vaccinations none of the vaccinated 
90 
CDV vaccination African wild dogs 
animals had high VN serum antibody titres. Furthermore, antibodies were 
undetectable by VN in 92% (12/13) at this time. Percentages of animals with 
high serum antibody titres measured by ELISA were higher one year after the 
initial three vaccinations: 69% (9/13) (GMT: 84 ). 
In contrast, VN serum antibody titres in red pandas, maned wolves 
and Malay civets after CDV-ISCOM vaccination showed high GMT after 
two vaccinations, which had declined but remained adequate one year later 
(Figure 2). One yearly booster vaccination of Malay civets ensured that VN 
GMTs remained adequate. Vaccination of red pandas with the CDV-ISCOM 
vaccine with lower antigen concentration (51-Jg/ml) induced low serum antibody 
titres measured by ELISA. 
Recombinant vaccine vaccinated animals 
On day zero, 15% (2/13) animals had low CDV-specific antibody titres 
(20), only detectable by VN. One animal in the recombinant group had a titre 
of 80 on day zero. All animals were negative by both ELISA and VN after one 
vaccination. High VN serum antibody titres (~ 80) were first detected in 25% 
(2/8) of the animals after two vaccinations (GMT: 28) (Figure 1 ). Serum antibody 
titres measured by ELISA after 2 vaccinations showed higher percentages of 
animals with high titres: 38% (3/8), and a GMT of 26 (Figure 1 ). 
One year after the initial three vaccinations 39% (5/13) had high VN 
titres (GMT: 38). Antibodies were undetectable by VN in 16% (2/13) of the 
animals at this time. Percentages of animals with high serum antibody titres 
measured by ELISA were higher one year after the initial three vaccinations: 
69% (9/13) (GMT: 80). 
DISCUSSION 
In the present study we have shown that the canarypox-vectored 
recombinant CDV vaccine and CDV-ISCOM vaccine do not cause adverse 
effects, but induce poor immunity based on VN serum antibody titres in African 
wild dogs. For both vaccines 2 doses were required to induce low levels of 
VN serum antibodies, although this was only seen in a minority of the animals 
tested. One year post-vaccination the VN titres were low for the recombinant 
vaccine: GMT 38 and 39% ~ 80, and absent for the ISCOM vaccine. 
The VN test is regarded as the gold standard method for 
determination of immunity to morbilliviruses 339 because it measures functional 
neutralising antibodies. These VN antibodies are exclusively directed to the 
haemagglutinin (H) and fusion (F) surface proteins of the virus, and mostly 
recognise conformational epitopes 341 • The H-specific antibodies are the main 
correlate of vaccination-induced measles virus neutralisation 356• Antibodies 
to the nucleoprotein (NP) do not contribute directly to neutralisation and will 
therefore be missed in a VN test; however, antibodies against these structures 
are most abundantly produced in response to infection or vaccination with 
traditional vaccines 357 . 
91 
Chapter 2.3.2. 
10000 
·~ 1000 
.§ 
!~--------- .. ,...--- ----1 0 
------._ t t ~~ ------ ________ ; -----------------------------·r·----------------------------- .......... ----------------------! 
' . -· 
----:! 0 
10 ~ 
0 200 roo 8:)0 1000 1200 1400 
Figure 2. CDV-ISCOM induced virus neutralising antibody titres in 3 species of 
non-domestic carnivores. Black triangles depict red pandas vaccinated with 5urn/ 
rnl (measured by ELISA), black circles depict red pandas, white squares depict 
Malay civets, white circles depict maned wolves. Short dashed line connects 
geometric mean titres (GMTs) of red pands vaccinated with 5ul/ml; straight line 
connects GMTs of red pands vaccinated with 10 ug/ml; dotted line connects 
GMTs of Malay civet cats; long dashed line connects GMTs of maned wolves. 
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We have previously vaccinated other species of non-domestic animals 
e.g. the European mink (Muste/a lutreo/a) with the same vaccines (submitted), 
and the GMTs and percentages of African wild dogs with high titres after 
vaccination with the recombinant vaccine proved to be comparable to those 
seen in European mink. However, the vaccine-induced response of the African 
wild dog to CDV-ISCOM vaccination is much lower than the responses to the 
same batch of CDV-ISCOM in European mink, maned wolves, red pandas, 
and Malay civets (Figure 2). 
Interruption of the cold chain required for preservation of the CDV-
ISCOM vaccine as was previously suggested as one of the causes of CDV-
ISCOM vaccine failure in African wild dogs 13 could be excluded this time. 
In red pandas we have seen a major improvement in antibody response by 
increasing the antigen concentration of the ISCOM vaccine from 5 to 1 01-Jg/ 
ml (Figure 2). The increased dose may still not be sufficient to induce a 
humoral immune response in the African wild dogs. Alternatively, a loss of 
immunogenicity of the CDV antigen during ISCOM preparation, may have 
rendered it sub-optimal in terms of inducing a humoral response in the African 
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wild dog. Collectively, these data indicate that the reason for this relative 
vaccine failure should be sought in the intrinsic inability of the African wild dog 
to produce neutralising antibodies in response to CDV vaccination with these 
vaccines. It may e.g. be speculated that the population bottleneck created 
by the decimated and fragmented populations of African wild dogs may have 
resulted in a lack of genetic variability of this species, which subsequently can 
have had negative consequences for the immune system. 
Surprisingly, vaccination with both vaccines did induce satisfactory 
antibody titres detected by ELISA one year after the initial three vaccinations, 
suggesting that CDV-ISCOM vaccination does induce CDV specific antibodies 
in African wild dogs, although they do not neutralise virus in the VN test. The 
ELISA, which is based on Vera cell culture-grown and detergent-treated virus 
antigens, detects antibodies directed at the H and F surface proteins of the 
virus, but also against the NP and cell components. The ISCOM vaccine uses 
virus grown on Vera cells as used in the ELISA. It is produced in a manner 
that incorporates the H and F proteins into the ISCOMs, and then purified, 
leaving little or no NP or cell components in the vaccine. The presence of 
small amounts of NP or cell components in the vaccine may induce additional 
antibodies againstthese epitopes, which can be measured by ELISA. However, 
the inclusion of an ELISA coated with an uninfected Vera cell lysate used as 
a control for these sera excludes serum antibodies directed against the Vera 
cell components. 
Vaccine-induced antibodies tested in European mink were higher 
when tested by ELISA compared to VN (for both vaccines), but followed a 
similar trend, with a much smaller discrepancy than that observed in African 
wild dogs. Antibody titres measured by ELISA can be expected to be higher 
than by VN, because the ELISA detects antibodies against a large range of 
epitopes on the H and F, and not exclusively against virus neutralising epitopes 
which are conformational. This also explains the higher ELISA titres induced 
by the recombinant vaccine, which expresses only the H and F proteins. 
Challenge infections have not been performed in the endangered 
African wild dogs, therefore protective titres are not known. CDV-specific 
antibody titres tend to correlate with level of protection against distemper. 
Therefore the recombinant vaccine may be expected to protect populations of 
African wild dogs better against infection with CDV, than the ISCOM vaccine. 
However, GMTs and the percentages of animals with high antibody titres are 
low, therefore a large percentage of the vaccinated animals is not expected 
to be protected against CDV infection. Models indicate that for measles virus 
(a related morbillivirus), elimination is achieved by maintaining the fraction of 
fully immunized individuals with protective VN serum antibody titres above a 
threshold value (estimated to be 90-95%), to interrupt virus transmission 358. 
The presence of low antibody titres at day zero may be attributed to 
the presence of maternal antibodies, or alternatively to previous exposure 
to virulent CDV virus. This last scenario is unlikely for the African wild dogs 
housed in Artis Amsterdam zoo, but cannot be fully excluded for the animals 
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in Mkomazi game reserve. 
Effective vaccination induces not only a humoral, but also a cellular 
immune response. Vaccination with a canarypox-vectored recombinant 
CDV vaccine has induced protection in dogs without eliciting a pronounced 
serologic response 142• T-cell responses are likely to be of importance in 
providing immunity to infection with CDV, and it has been suggested that these 
vaccine-induced cell-mediated responses complement the humoral immunity, 
which can result in adequate protection in the absence of high serum antibody 
titres141 •142• Morbillivirus ISCOMs have been shown to effectively induce specific 
T-cell responses in macaques 343• Therefore it cannot be excluded that the 
CDV-ISCOM used in this study would have induced protective immunity in 
this species. 
In conclusion, the results indicate that both vaccines are safe, but 
neither vaccine proved to be efficacious, using vaccine-induced VN antibodies 
as correlate of protection. The recombinant vaccine proved to be more effective 
in inducing VN antibody responses. This study may aid in eventually providing 
the necessary adequate protection against infectious diseases through 
vaccination of this, and other endangered species in conservation projects. 
We recommend further research on the genetic variability and functioning of 
the immune system of the African wild dog, on specific T-cell responses and 
B-cell responses induced by vaccination, to understand the lower vaccine-
induced serum antibody responses compared to those seen in other species, 
and to study the reasons for the discrepancy between ELISA and VN tests. 
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H7N1 vaccination of zoo birds 
In 2003 an outbreak of highly pathogenic avian influenza virus 
(H7N7) struck poultry in the Netherlands. A European Commission 
directive made vaccination of valuable species in zoo collections 
possible under strict conditions. We determined pre- and post-
vaccination antibody titres in 211 birds by haemagglutination inhibition 
test as a measure of vaccine efficacy. After booster vaccination, 81.5% 
of vaccinated birds developed a titre of ~ 40, while overall geometric 
mean titre (GMT) was 190 (95% Cl: 144 to 251). Birds of the orders 
Anseriformes, Galliformes and Phoenicopteriformes showed higher 
GMT and larger percentages developed titres ~ 40 than those of the other 
orders. Antibody response decreased with increasing mean body weight 
in birds ~ 1.5 kg body weight. In the vicinity of the outbreak, H7N7 was 
detected by RT-PCR in wild species (mallards and mute swans) kept in 
captivity together with infected poultry, illustrating the potential threat of 
transmission from poultry into other avian species, and the importance 
of protecting valuable avian species by means of vaccination. 
INTRODUCTION 
Avian influenza A virus (AIV) is a member of the Orthomyxoviridae 
family and can be classified according to the antigenicity of its surface 
proteins haemagglutinin (H) and neuraminidase (N), and on the basis of its 
pathogenicity in chickens. Highly pathogenic avian influenza (HPAI), an acute 
generalised disease in which mortality may be as high as 100%, is restricted 
to subtypes H5 and H7, although not all viruses of these subtypes necessarily 
cause HPAI. All other AIV strains are low pathogenic avian influenza (LPAI) 
virus strains and cause a much milder, primarily respiratory disease with loss 
of egg production 152. 
The host range of AIV includes a large number of avian species 359· 
362
, with a worldwide distribution and variable morbidity per virus isolate and 
avian species 361-367. Free-ranging bird species of the order Anseriformes 
(ducks, geese, swans and screamers) and Charadriiformes (shorebirds), 
are considered natural reservoirs in which morbidity is low 361 •160•368• HPAI 
outbreaks have generally been restricted to poultry (turkeys and chickens), 
and farmed ostriches 369,370• Exceptions, where HPAI outbreaks have been 
reported in free-ranging birds, have been in terns in 1961 371 , several species 
of wild migratory birds as well as captive Phoenicopteriformes (flamingos) in 
2002 163•372, and in wild migratory birds in 2005 168• 
The Netherlands did not have an outbreak since 1927, but in March 
2003 the diagnosis HPAI virus (H7N7) infection was made by RT-PCR 7•373 • 
HPAI is categorised as an Office International des Epizooties (OlE) list A 
disease, for which the European Union (EU) has a non-vaccination policy. 
Eradication measures during an outbreak include confinement, stamping out 
of animals on the infected farm, pre-emptive culling of animals on neighbouring 
farms, and emergency vaccinations (EU Directive 92/40/EEC). The area 
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of the outbreak expanded 374 , and threatened to encroach on Dutch zoos. 
The Dutch Zoo Federation (Nederlandse vereniging van dierentuinen, NVD) 
proposed vaccination to avoid not only pre-emptive culling of the valuable and 
sometimes endangered species kept in zoo collections, but also confinement 
(of unknown duration) of birds, which they considered to be detrimental to 
welfare. Commission Decision 2003/291 /EC of 25 April 2003 replaced the 
implementation of pre-emptive culling and confinement in zoos with the 
preventive vaccination of zoo bird species listed as susceptible to avian 
influenza: Galliformes (fowl, quail, pheasants), Anseriformes, Struthioniformes 
(emus, nandus and ostriches) and rock doves (Columba Iivia) kept for 
consumption, provided that far-reaching requirements were met. 
Inactivated monovalent and polyvalent AIV water-in-oil emulsion 
vaccines have been demonstrated to be effective in reducing mortality and/or 
preventing morbidity, as well as reducing viral shedding 188 after HPAI virus 
challenge in chickens and turkeys 187 . The use of a heterologous vaccination 
(in which the N protein differs from the field strain) makes it possible to 
distinguish vaccinated birds from infected birds, while maintaining acceptable 
efficacy 190. 
The goals of this study were to determine whether transmission 
of HPAI H7N7 virus from poultry to free-ranging birds during an outbreak 
occurred, to evaluate the efficacy and safety of an inactivated H7 vaccine in 
a large number of exotic avian species, and whether vaccination would be 
a suitable alternative to pre-emptive culling and confinement during future 
outbreaks of H7 HPAI virus. 
MATERIALS AND METHODS 
Serology 
An inactivated H7N1 vaccine, strain A/CK/Italy/473/99, inducing 
at least 4 log2 haemagglutination inhibition (HI) units according to potency 
test, with liquid paraffin adjuvant, (Nobilis influenza®, lntervet International, 
Boxmeer, the Netherlands) was used. The vaccine strain had a homology 
of 97.4% to the field strain on the basis of nucleotide sequence (1174 base 
pairs, excluding basic cleavage site), and 98.7% on the basis of amino acids. 
The vaccine was produced and assayed according to the requirements made 
in the OlE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, 
chapter 2. 7.12 (further details may be obtained from the manufacturer). 
The birds were vaccinated twice with 6 weeks interval. Mode of vaccination 
[subcutaneous (s.c.) or intramuscular (i.m.)] differed according to zoo. Birds 
with a body weight smaller than 1.5 kg (n = 74) were given 0.25 ml, those with 
a body weight of 1.5 kg or more (n = 137) were given 0.5 mi. Bodyweights 
were not assessed individually, but published mean weights of the species 
were used 375·376• Blood was collected from 211 birds from 13 orders (Appendix 
1 ), approximately 1 0% of the total number vaccinated in 1 0 participating zoos 
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from the Netherlands. Blood was collected using manual restraint from the 
right jugular vein or the ulnar vein (left or right) on the day of vaccination and 
between 30 - 60 days following the last vaccination. Blood collection on the 
second vaccination date was not mandatory, and was only done in 3 of 1 0 
zoos. 
To evaluate humoral immunologic response to vaccination, H7N1 (A/ 
CK/Italy/473/99) specific antibody titres were determined by HI test, following 
standard procedures, using turkey erythrocytes 377•378• Undetectable titres (<1 0) 
were regarded as 5 for calculation of geometric mean titres (GMT). Vaccine-
induced HI titres of~ 40 were considered protective, as in humans 379. GMT 
and 95% confidence intervals (CI) were then calculated per order. For orders 
Chariidiformes, Ciconiiformes (storks, herons, egrets), Columbiformes (doves, 
pigeons), Coraciiformes (hornbills), Gruiformes (cranes), Pelicaniformes 
(pelicans, cormorants), Psittaciiformes (parrots, cockatoos), Sphenisciformes 
(penguins), and Strigiformes (owls), it was not meaningful to calculate 95% 
Cl of the GMT because of small numbers (<10). Birds in these orders were 
combined in two groups: "other orders <1.5 kg", and "other orders~ 1.5 kg". 
To evaluate vaccine-induced immunity against the HPAI H7N7 strain, 
a virus neutralisation (VN) assay was performed on post-vaccination serum 
from 48 randomly selected birds with different HI titres. VN assays were 
performed essentially as described previously 343 . Briefly, serial dilutions of the 
respective serum samples, which had been heat-inactivated for 30 min at 56°C, 
were incubated 1 h at 37°C with 100TCID50 of A/Chicken/Netherlands/1/03 (H7N7). The mixture was then transferred to MOCK monolayers in microtitre 
plates. After incubation for 1 h, the cells were washed with PBS and incubated 
in infection medium for 5 days. The supernatants of the cultures were then 
tested for HA activity. 
Virus detection 
A cloacal swab was taken from 1 08 birds from one zoo on the first 
day of vaccination, and stored in 1 ml transport medium (Hank's balanced salt 
solution containing 10% glycerol, 200 U/ml penicillin, 200 IJg/ml streptomycin, 
100 U/ml polymyxin B sulphate, 250 IJg/ml gentamycin (ICN, Zoetermeer, the 
Netherlands) to detect active shedding of H7 AIV. RNA was isolated from 200 
1-11 supernatant using the MagnaPure LC system (Roche Diagnostics, Almere, 
The Netherlands) and influenza A virus was detected by a Taqman assay, 
based on influenza A virus H7 gene sequences of A/Chicken/Netherlands/1/03, 
as described 7·380• 
Detection of AIV transmission from poultry to other species. 
Free-ranging domestic and wild birds (n=109, Appendix 2.), mainly 
road casualties but also birds found dead or euthanized, or shot, were collected 
either directly in the vicinity of depopulated HPAI virus infected poultry farms, 
or arbitrarily throughout the infected area. Species, sex and age category were 
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determined and the location and date found were recorded. Cloacal swabs 
were taken from all birds, with additional tracheal swabs from dead birds, and 
stored in transport medium. 
Full necropsies were performed on 4 mallards kept at a camping near 
an infected poultry farm, which had cloacal swabs positive for H7 AIV. Their 
carcasses were stored frozen prior to necropsy. Tissue samples of lung, brain, 
kidney, liver, spleen, duodenum, jejunum, ileum, caecum, colon, pancreas, 
heart, skin, and proventriculus were homogenized in 3 ml transport medium 
using a Polytron PT21 00 (Kinematica, Lucerne, Switzerland) and subsequently 
centrifuged (1590 x g). Virus detection was performed as described above, 
and a sequence analysis was performed on H7 AIV positive specimens. 
Sequence analysis. 
RT-PCR specific for the non-coding regions of H7 AIV was performed 
on the original material as described 381 . PCR products were run on a 1% 
agarose gel I 1 x TBE and purified by using the QIAquick gel extraction kit 
(Qiagen, Leusden, The Netherlands) and sequenced directly. The entire Hand 
N gene segments of the 7 H7 AIV positive birds were sequenced. Sequencing 
was performed using the Big Dye Terminator sequencing kit, version 3.1 
(Applied Biosystems, Nieuwekerk a/d ljssel, The Netherlands) and an ABI 
Prism 3100 genetic analyser (Applied Biosystems, Nieuwekerk a/d ljssel, 
The Netherlands). Primer sequences are available on request. Nucleotide 
sequences were aligned using BIOEDIT 5.0.9. 
RESULTS 
Serology 
For 116 birds, GMT after first and second (booster) vaccination could 
be assessed. Overall, GMT after second vaccination [166 (95% Cl: 117- 237)] 
and percentage of birds with titre;::: 40 (80.2%) were much higher than after 
first vaccination [20 (95% Cl: 14- 30) and 36.2%], demonstrating the need for 
booster vaccination. All but three birds (a domestic chicken, an emu and an 
Egyptian goose) had a pre-vaccination GMT< 10. In the following text, titres 
after one vaccination are ignored, and only titres after two vaccinations of all 
211 birds in this study are used. The post-vaccination GMT was 190 (95% Cl 
144- 251) and 81.5% of all tested birds produced an antibody titre;::: 40. GMT 
was significantly different between orders (Figure 1 ). No significant differences 
were found when Anseriformes, Galliformes, and Phoenicopteriformes were 
analysed for species differences within the orders. 
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Figure 1. Post-vaccination percentages titre ~ 40, and GMT versus mean body 
weight per order (lines: 95% Cl's). The humoral response of different avian 
orders to vaccination against avian influenza (H7) using an inactivated vaccine 
administered twice with 6 weeks interval. Titres shown were measured 30 to 60 
days following the second vaccination. The blue bars represent the percentage 
of birds with titre~ 40. The points represent the geometric mean titre (GMT) and 
mean body weight per order, with the 95% confidence intervals (CI) represented 
by vertical (GMT) and horizontal lines (mean body weight), respectively. 
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Figure 2. Post-vaccination natural logarithms of titres measured by virus 
neutralisation (In VN) and by haemagglutination inhibition (In HI). Natural 
logarithms of titres shown are 30 to 60 days following the second vaccination 
with an inactivated H7N1 vaccine in 48 birds chosen at random. Titres measured 
by haemagglutination inhibition are against the vaccine strain, those measured 
by virus neutralisation are against the highly pathogenic H7N7 strain. The red bar 
represents the regression line, the black bar represents the diagonal. 
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There was an inverse correlation between weight and antibody 
response (Figure 1) in birds ~ 1.5 kg (regression coefficient: -1.543, P < 
0.001 ), but not for those< 1.5 kg (regression coefficient: -0.076, P < 0.913). 
However, it should be noted that body weights used were published species 
averages, and not from the individual birds, therefore these results should be 
treated cautiously, and may not be regarded significant. 
Generally, i.m. administration (n = 1 09) resulted in both a higher GMT 
[214 (95% Cl: 149- 306) vs 168 (95% Cl110- 257)] and higher% of animals 
with a titre ~ 40 (84.4 vs 78.4) than sc administration (n = 1 02). However, 
a statistical comparison between s.c. and i.m. administration with regard to 
antibody response was not possible (no random administration). Mode of 
administration was nonetheless not regarded as a factor influencing antibody 
response in the statistical analysis of the results, as no large differences were 
observed. 
The degree of agreement (within a 4-fold margin) between the post-
vaccination results of HI and VN test against the HPAI virus strain was 79.2% 
(fig. 2). 
Necropsies of birds that died during this period did not reveal any 
HPAI virus- or vaccine-related cause of death. 
Virus Detection 
H7 AIV could not be detected by RT-PCR carried out on the cloacal 
swabs collected in the zoo. H7 AIV virus was detected by RT-PCR from 7 
captive birds (4 mallards and 3 mute swans, Cygnus o/or). All 7 H and N 
gene segments were identical to the NChicken/Netherlands/1 /03 H7N7 AIV 
(GenBank H AY338458, and N AY340077). All positive animals had been kept 
at a camp site situated about 100 metres from three of the first HPAI-positive 
poultry farms. These birds had been confined since the beginning of the HPAI 
outbreak, in the same shed as 8 domestic chickens (Gal/us gal/us), 1 emu 
(Dromaius novaehol/andiae), 1 guinea fowl (Numida meleagris), 2 greylag 
geese (Anser anser), 2 domestic turkeys (Meleagris gallopavo), 1 other 
mallard, and 1 other mute swan. The guinea fowl and one chicken died and 
tested serologically positive to H7 AIV (pers comm. Koch, 2005). The rest of 
the birds, which showed no clinical signs of AIV infection, were euthanized 
the next day. The turkeys, chickens and the emu tested serologically positive. 
From the remaining birds, tracheal and cloacal swabs were tested for the 
presence of H7 AIV, but were negative - except from the 4 mallards and 3 
mute swans described above. Free-ranging wild birds shot on the premises 
[1 greylag goose, 1 mallard and 1 pheasant (Phasianus co/chicus)] also 
tested negative for H7 AIV. 
Full necropsies on the 4 RT-PCR positive mallards showed the 
presence of H7N7 virus in the jejunum (3 birds), ileum (4 birds), caecum (3 
birds), colon (1 bird), lung (1 bird), spleen (2 birds) and heart (1 bird). 
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DISCUSSION 
In the present paper we have shown that H7 AIV vaccination of exotic 
birds with Nobilis influenza® is safe and is expected to be efficacious. We 
consider it to be useful and necessary in case of an outbreak, as transmission 
of H7N7 from poultry into non-poultry species did occur. Overall 81.5% of the 
birds tested developed to a titre 2: 40 30-60 days after the second vaccination 
(Figure 1 ). Antibodies produced against the surface protein H act as major 
determinants for protection against infection and disease in poultry 187·382·383 . 
Antibody titres to H7 were therefore used as a measure of immunogenicity, 
especially as efficacy could not be tested by challenge infections of these 
valuable or endangered species. Post-vaccination titres;::: 32 in chickens have 
prevented shedding after challenge infection with the vaccine strain384, and 
proven to be protective in chickens during an outbreak of HPAI virus (H5N1) 181 • 
On the basis of the antibody titres induced and the high degree of agreement 
(79.2%) between post-vaccination HI titres against the vaccine strain (H7N1) 
and VN titres against the HPAI virus strain (H7N7), vaccination may be 
expected to be efficacious during an outbreak. In analogy with vaccination of 
poultry, vaccination of exotic species may be expected to prevent morbidity 
and mortality, reduce environmental contamination with AI virus 179•182·385 , 
and thus reduce or prevent subsequent bird-to-bird transmission. However, 
because clinically healthy birds can shed HPAI virus, enhanced bio-security 
measures and regular virologic monitoring of vaccinated and non-vaccinated 
birds in the infected area will remain necessary 152. 
A booster vaccination was required to provide efficacy, using the 
criterion for efficacy as used by the Committee for Proprietary Medicinal 
Products (CPMP) for validation of human influenza vaccines (antibody titre 
;::: 40 in ;::: 70% of the vaccinated population 386); whether this criterion is valid 
for use in these avian species is unknown. In the present study only 36.2% 
of 116 birds developed a titre ;::: 40 after one vaccination, compared to a total 
percentage of 80.2% after the second vaccination. This booster effect has 
previously been shown in chickens and turkeys after AIV vaccination with 
two weeks interval 387, and is expected to be long-lasting 388•388. However, the 
necessity for a booster requires vaccination to occur soon after detection of an 
outbreak, as some time is required to build up immunity. 
The GMT after 2 vaccinations were significantly different between 
orders (Figure 1 ). Galliformes, the order for which the vaccine had been 
specifically produced, but also Phoenicopteriformes, reacted to vaccination 
with the highest GMT. Differences in neutralising antibody response to 
vaccination have been demonstrated between domestic avian species, with 
chickens producing highest titres 191 • More than 70% of birds from the orders 
Anseriformes, Galliformes, and Phoenicopteriformes developed titres ;::: 40 
in response to vaccination (Figure 1 ), and the vaccine may therefore be 
considered efficacious in these orders. 
The vaccine dose given to Struthioniformes, which are considered 
to be very susceptible to AIV infection 369 , and have significantly higher mean 
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weight than the other orders [Figure 1: 29.7 kg (95% Cl: 17,7- 41,6)], was 
likely too low. The humoral immune response to AIV infection in chickens is 
known to be associated with the virus doses administered 374•389 . Therefore, 
based on the low % seroprotection and low GMT, which is inversely correlated 
with published mean body weight (Figure 1 ), Struthioniformes are expected to 
respond better to a higher vaccine dose. 
Route of vaccine administration (s.c. or i.m.) had no large effect on 
antibody response, therefore mode of administration was not regarded as a 
factor influencing antibody response in the statistical analysis of the results. 
However, formal statistical comparison between s.c. and i.m. administration 
with regard to antibody response was not possible, as administration was not 
at random, but differed per zoo, and distribution of orders among zoos was 
not similar. 
The detection of HPAI H7N7 virus infection in mallards and swans kept 
in the same enclosure as infected chickens and guinea fowl demonstrates that 
this strain of HPAI H7N7 virus can be transmitted from poultry to other avian 
species. This illustrates the potential threat of transmission of HPAI H7N7 
from poultry to other avian species. 
In conclusion, vaccination is expected to be a useful and necessary 
tool for the protection of valuable exotic birds in zoos against HPAI H7 virus 
infection, and is a suitable alternative for confinement and pre-emptive culling 
when implemented together with virologic monitoring and strict bio-security 
measures at zoos within, or close to the infected area. The administration 
of twice 0.25 ml to birds < 1.5 kg, and twice 0.5 ml to birds <:: 1.5 kg, either 
by i.m. or s.c. route, is efficacious for Anseriformes, Galliformes, and 
Phoenicopteriformes, but possibly not for the other orders. Because of a 
negative correlation between antibody response and mean body weight, a 
higher dose may be required in Struthioniformes. A booster vaccination is 
essential for efficacy, therefore vaccination of zoo birds should commence 
soon after detection of an outbreak in poultry in the area. We recommend 
further research into the efficacy of vaccinating all orders of exotic birds 
against H7 and H5 AIV with a shorter interval before booster vaccination, and 
with higher doses for birds with high mean body weight 
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Appendix 1: Vaccinated species in zoos, geometric mean titres (GMT) 30 - 60 
days after 2 vaccinations with an inactivated H7N1 vaccine, and the percentage 
of birds from each species with a post-vaccination titre of;;:: 40 
Species 
Order % 
n GMT 
>40 Common name Scientific name 
Anseriformes 66 
3 773 100 Bahama pintail Anas bahamensis bahamensis 
320 100 bar-headed goose Anser indicus 
3 6873 100 black swan Cygnus atratus 
240 100 common goldeneye Bucephala c/angula 
2 560 100 common pochard Aythia ferina 
7 743 100 common shelduck Tadorna tadorna 
960 100 common shoveler Anas clypeata 
2 1600 100 domestic duck Anas platyrhynchos domesticus 
480 100 Egyptian goose Alopochen 
aegypticus 
4 900 100 emperor goose Anser canagicus 
3 400 100 Eurasian wigeon Anas Penelope 
3 106 33 European eider Somateria mol/issima 
mollissima 
3 100 100 European goosander Mergus merganser 
2 170 50 falcated duck Anas falcate 
5 392 100 fulvous whistling duck Dendrocygna bicolor 
1920 100 mallard Anas platyrhynchos 
6 467 66 Mandarin duck Aix galericu/ata 
80 100 maned duck Chenonetta jubata 
7 714 100 red-crested pochard Netta rufina 
5 636 100 smew Mergus a/be/Ius 
4 330 75 tufted duck Aythya fuligula 
20 0 white-winged wood Cairina scutulata . duck 
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Charadriiformes 4 
2 320 50 black-legged kittiwake Rissa tridactyla pof!icaris 
20 0 common puffin Fratercula arctica 
60 100 pied avocet Recurvirostra 
avosetta 
Ciconiiformes 7 
160 100 black stork Ciconia nigra 
3 773 100 black-headed ibis Threskiornis 
melanocephalus 
<20 0 glossy ibis Pfagadis fa/cine/Ius 
480 100 little egret Egretta garzetta 
<20 0 marabou stork Leptopifos 
crumeniferus, 
Columbiformes 6 
5 624 60 rock dove Columba Iivia 
80 100 Scheepmakers' Goura scheepmakeri 
crowned pigeon sclaterii 
Coraciiformes 2 
480 100 black and white Bycanistes 
casqued hornbill subcy/indricus 
960 100 blue-winged Dace/o /eachii kookaburra 
Strigiformes 2 
80 100 Eurasian eagle owl Bubo bubo bubo 
20 0 snowy owl Nyctea scandiaca 
Galliformes 56 
80 100 Andean guan Penelope montagnii 
montagnii 
640 100 Congo peacock Afropavo congensis 
40 100 crested woodpartridge Rollu/us roulrou/ 
41 1871 93 domestic chickenfred Gallus gallus junglefowl 
6 10 17 helmeted guineafowl Numida meleagris 
<20 0 koklass Pucrasia macrolopha 
80 100 Lady Amherst's Chrysofophus pheasant amherstiae 
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160 100 Palawan peacock Polyplectron pheasant emphanum 
1920 100 red-billed curassow Crax blumenbachi 
2 240 100 wild turkey Meleagris ga/lopavo 
Gruiformes 9 
4 1350 100 Demoiselle crane Anthropoides virgo 
2 <20 0 Manchurian crane Grus japonensis 
3 520 66 South African Balearica regu/orum 
crowned crane regu/orum 
Pelecaniformes 6 
2 60 50 dalmatian pelican Pe/ecanus crispus 
3 206 66 Eastern white pelican Pelecanus 
onocrotalus 
80 100 great cormorant Pha/acrocorax carbo 
Phoenicopteriformes 20 
6 236 100 Chilean flamingo Phoenicopterus 
chi/ensis Hyb 
4 350 100 greater flamingo Phoenicopterus ruber 
ruber 
10 3044 100 European flamingo Phoenicopterus 
rose us 
Psittaciformes 4 
160 100 blue-eyed cockatoo Cacatua aphtha/mica 
<20 0 long-billed corella Cacatua tenuiros tris tenuirostris 
160 100 Mexican military Ara militaris 
macaw mexicana 
320 100 Mitchell's cockatoo Cacatua leadbeateri 
Sphenisciformes 9 
5 76 80 Humboldt penguin Sphenicus humboldti 
4 90 100 jackass penguin Spheniscus demersus 
Struthioniformes 20 
2 640 50 Dromaius emu 
novaeho/landiae 
17 558 50 nandu/rhea Rhea Americana 
<20 0 ostrich Struthio came/us 
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Appendix 2: Free-ranging domestic and wild birds swabbed for avian influenza 
Order 
Species 
n Common name Scientific name 
Anseriformes 59 
black swan Cygnus atratus 
domestic goose Ansersp 
9 domestic duck Anas platyrhynchos domesticus 
duck Anassp 
4 greylag goose Anseranser 
31 mallard Anas platyrhynchos 
12 mute swan Cygnus o/or 
Charadriiformes 4 
4 black-headed gull Larus ridibundus 
3 common gull Larus canus 
Ciconiiformes 2 
2 grey heron Ardea cinerea 
Falconiformes 2 
2 sparrowhawk Accipter nisus 
Galliformes 10 
3 pheasant Phasianus co/chicus 
6 wood pigeon Columba palumbus 
quail Coturnix coturnix 
Gruiformes 6 
3 coot Fu/ica atra 
3 moorhen Ga!linula chloropus 
Passeriformes 20 
6 blackbird Turdus merula 
bohemian waxwing Bombyci!la garulus 
3 carrion crow Corvus corone 
1 fieldfare Turdus pilaris 
2 jackdaw Corvus monedula 
5 magpie Pica pica 
rook Corvus frugilegus 
song thrush Turd us phi/amelus 
Psittaciformes 4 
1 ring-necked parakeet Psitacu/la krameri mani!lensis 
Strigiformes 2 
little owl Athene noctua 
tawny owl Strix a/uco 
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Highly pathogenic avian influenza (HPAI) H5N1 virus infections 
have recently caused unprecedented morbidity and mortality in a wide 
range of avian species. European Commission directive 2005/744/EC 
allowed vaccination in zoos under strict conditions, while reducing 
confinement measures. Vaccination with a commercial H5N2 vaccine 
with vaccine doses adapted to mean body weight per species was safe, 
and proved immunogenic throughout the range of species tested, with 
some variations between and within taxonomic orders. After booster 
vaccination the overall homologous geometric mean titre (GMT) to the 
vaccine strain, measured in 334 birds, was 190 (95% Cl: 152-236), and 
80.5% of vaccinated birds developed a titre of;::: 40. Titres to the HPAI 
H5N1 virus followed a similar trend, but were lower (GMT: 61 (95% Cl: 
49-76); 61% ;::: 40). The breadth of the immune response was further 
demonstrated by measuring antibody titres against prototype strains 
of 4 antigenic clades of currently circulating H5N1 viruses. These data 
indicate that vaccination should be regarded as a beneficial component 
of the preventive measures (including increased bio-security and 
monitoring) that can be undertaken in zoos to prevent an outbreak of 
and decrease environmental contamination by HPAI H5N1 virus, while 
alleviating confinement measures. 
INTRODUCTION 
Avian influenza virus (AIV) is an Orthomyxovirus, which can be 
classified according to its pathogenicity and the antigenicity of its surface 
proteins haemagglutinin (H1-16) and neuraminidase (N1-9)151 . Viruses 
containing the subtypes H5 and H7 may become highly pathogenic after 
introduction in poultry and cause outbreaks of highly pathogenic avian 
influenza (HPAI), in which mortality may be as high as 100% 160 . The 
change from a low pathogenic avian influenza (LPAI) phenotype to the HPAI 
phenotype is achieved by the introduction of basic amino acid residues into the 
cleavage site of the precursor haemagglutinin 153• Aquatic wild avian species, 
in particular those belonging to the taxonomic orders Anseriformes (ducks, 
geese, swans) and Charadriiformes (shorebirds, gulls and terns) are generally 
considered to be the main natural reservoir of all LPAI viruses, including the 
LPAI ancestral viruses of HPAI strains 155·195• However, an outbreak of HPAI 
H5N1 virus in Hong Kong in 2002 caused mortality in wild migratory avian 
species and resident waterfowl 372• Isolates of this strain from 2002 caused 
systemic infections and severe neurological dysfunction in experimentally 
infected mallards (Anas platyrynchos) 163 confirming its high pathogenicity in 
ducks. Currently, the H5N1 subtype of HPAI virus has spread throughout Asia 
and into Europe and Africa, causing mortality in a wide range of avian species 
from different taxonomic orders: Anseriformes 165•168·170·372·390•392 , Galliformes 
(turkeys, pheasants, quail and grouse)391 ·392 , Charadriiformes 165•168•170•372·391 ·392 , 
Phoenicopteriformes (flamingos)372·393 , Ciconiiformes (storks and herons)372•394 , 
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Pelecaniformes (pelicans and cormorants)394, Falconiformes (diurnal birds of 
prey)395·396 , Strigiformes (owls)395•396 , Struthioniformes (ostriches, emus)391, 
Columbiformes (doves and pigeons)372•394 , Passeriformes (perching birds) 
372
•
392
•
394·397·398 , and Psittaciformes (parrots )395• This unprecedented spread of 
outbreaks, with a broadening of host range including mammalian species: 
leopards, tigers 176•216, domestic cats 177•178•399 , domestic dogs 212 , mustelids 400 , 
viverrids 218 , and humans (with 256 human cases and 151 deaths to date (181h 
of October 2006) 401 ), has major implications for animal and human health 
around the globe, spawning concern for a new pandemic. 
HPAI is classified by the World Organisation for Animal Health (OlE) 
as a notifiable disease, for which the European Union has a non-vaccination 
policy. Standard measures in the face of a HPAI virus outbreak are long term 
confinement or large scale pre-emptive culling of birds. However, this would 
be detrimental to the welfare and breeding programmes of valuable and 
endangered avian species in zoos. As an alternative, the Dutch Zoo Federation 
proposed vaccination in zoos in 2005, as they successfully did in 2003 during 
an outbreak of HPAI H7N7 virus, when vaccination with an inactivated H7N1 
vaccine was safe and produced high serum haemagglutination antibody 
titres 402 • European Commission decision 2005/744/EC subsequently allowed 
vaccination as an additional preventive measure to prevent spread of HPAI 
H5N1 virus from wild birds to zoo birds under rigorous surveillance and control 
requirements, while reducing confinement measures. 
Inactivated monovalent and polyvalent AIV water-in-oil emulsion 
vaccines have previously been demonstrated to be effective in reducing or 
preventing morbidity and mortality and reducing viral shedding 183•188 after 
HPAI virus challenge in chickens and turkeys 187. Such a vaccine effectively 
interrupted virus transmission in poultry in the face of an outbreak in Hong 
Kong in 2002 181 • In addition to vaccination, increased bio-security measures, 
in combination with increased monitoring by PCR and sentinel birds are 
imperative in combating HPAI virus infections. The use of the "differentiating 
infected from vaccinated animals" (DIVA) strategy, which uses a heterologous 
vaccine (in which the N subtype differs from that of the field strain) makes it 
possible to distinguish vaccinated birds from infected birds, while maintaining 
acceptable efficacy 190. 
The goals of this study were to evaluate the safety and efficacy of an 
inactivated H5N2 vaccine in a wide selection of avian species in zoos, and to 
discuss the role of vaccination in conjunction with increased bio-security and 
monitoring as an alternative to large scale pre-emptive culling and confinement 
in case of an outbreak of HPAI H5N1 virus infection. 
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MATERIALS AND METHODS 
Vaccination 
An inactivated, commercial, water in oil adjuvanted H5N2 (Nduck/ 
Pottsdam/1402/86) vaccine (Nobilis influenza® H5N2, lntervet International, 
Boxmeer, the Netherlands), inducing at least 6 log2 haemagglutination 
inhibition (HI) units according to potency test was used. The vaccine strain 
had a homology of 90% to the HA gene of the H5N1 field strain (Nturkey/ 
Turkey/1/05) on the basis of nucleotide sequence (1530 base pairs, including 
basic cleavage site), and 92.4% on the basis of amino acids. The vaccine 
was produced and assayed according to the requirements in the OlE Manual 
of Diagnostic Tests and Vaccines for Terrestrial Animals, chapter 2.7.12. 
Further details may be obtained from the manufacturer. More than 3000 birds 
were vaccinated in the 1 0 Dutch zoos participating in this study. The birds 
were vaccinated twice with 6 weeks interval via the subcutaneous route. The 
vaccine dose administered was adapted to body weight: birds with a body 
weight <1.4 kg were given 0.25 ml, 1.4- 7 kg were given 0.5 ml, >7- 12 kg 
were given 0.75 ml, >12- 44 kg were given 1.25 ml, and those> 44 were 
given 2.5 mi. Published mean body weights of the species were used, rather 
than body weights of individual birds 375·376. 
Serology 
Blood was collected from the right jugular vein or the ulnar vein (left or 
right) using manual restraint on the day of first vaccination (n=376: 76 species 
from 14 taxonomic orders) and between 30 - 60 days following the second 
vaccination [n= 334: 70 species from 14 taxonomic orders (Appendix 1)], 
approximately 10% of the total number vaccinated in 10 participating zoos. 
Blood collection on the day of second vaccination was not mandatory, and 
was only performed in 2 of 10 zoos (n= 109: 44 species from 8 taxonomic 
orders). 
To evaluate the humoral immunologic response to vaccination, 
homologous H5 specific antibody titres were determined by HI test, following 
standard procedures, using turkey erythrocytes 377•378. Known positive and 
negative sera were used as controls. Undetectable titres (<1 0) were regarded 
as 5 for calculation of geometric mean titres (GMT) with 95% confidence 
intervals (CI). Vaccine-induced HI titres of;:: 40 were considered a measure 
of efficacy 402 . To evaluate the vaccine-induced immune response against 
the recently circulating HPAI H5N1 virus strain, Nturkey/Turkey/1/05 specific 
antibody titres were determined by HI test as above. To test the breadth of the 
antibody response, post-vaccination sera with a homologous antibody titre from 
32 birds (18 species from 9 taxonomic orders: Anseriformes, Ciconiiformes, 
Galliformes, Gruiformes, Pelecaniformes, Phoenicopteriformes, Psittaciformes, 
Sphenisciformes, and Struthioniformes) were titrated against prototype virus 
strains representing antigenic variants of H5: Nmallard/Netherlands/3/99 
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(representing contemporary LPAI strains), ANietnam/1194/04 (representing 
H5N1 clade 1), A/lndonesia/5/05 (representing H5N1 clade 2, subclade 1) and 
A/turkey/Turkey/1/05 (representing H5N1 clade 2 subclade 2) 403 • Antigenic 
cartography methods as previously described 404 were then used to quantify 
the magnitude and breadth of the antibody response. 
A virus neutralisation (VN) assay was performed on post-vaccination 
serum from 41 randomly selected birds from 9 taxonomic orders (Anseriformes, 
Ciconiiformes, Galliformes, Gruiformes, Pelecaniformes, Phoenicopteriformes, 
Psittaciformes, Sphenisciformes and Struthioniformes) with different HI titres. 
VN assays were performed essentially as described previously 343• Briefly, 
serial dilutions of the respective serum samples, which had been heat-
inactivated for 30 min at 56°C, were incubated 1 h at 37°C with 1 OOTCID50 
of A/turkey/Turkey/1/05 (H5N1). The mixture was then transferred to MOCK 
mono layers in microtitre plates. After incubation for 1 h, the cells were washed 
with PBS and incubated in infection medium for 5 days. The supernatants of 
the cultures were then tested for HA activity. 
Differences of GMT-values between dose or weight groups were 
tested by One-Way AN OVA, rate differences by the Pearson X2-test. Statistical 
analyses were performed using SPSS for Windows version 1 0.0. 
RNA isolation and virus detection 
Cloacal swabs were collected from birds with pre-vaccination antibody 
titres, and selected birds in surrounding enclosures. RNA isolation and 
reverse transcription polymerase chain reaction were performed as described 
previously 195• 
RESULTS 
Safety 
Mortality due to catching or handling stress reported during the 
vaccination campaign was low: 5 out of more than 3000 birds that were 
vaccinated twice. One penguin had a subcutaneous abscess at the site of 
vaccination, and died despite antibiotic treatment. No other vaccination-related 
adverse effects were reported. Indirect losses in some zoos consisted of a 
drop in reproduction due to disturbed behavioural patterns during confinement 
in some species following the vaccination campaign. 
Prevalence of pre-vaccination anti-HS antibodies 
Of 376 birds tested, 370 were seronegative for H5 AIV (98.4%) by 
HI test using the homologous antigen. Six birds (1.6%), from three orders 
[Anseriformes (n=4), Phoenicopteriformes (n=1) and Sphenisciformes (n=1 )] 
and four different zoos were seropositive: greater flamingo, Phoenicopterus 
roseus (titre: 30), Humboldt penguin, Spheniscus humboldti (titre: 40), 
black swan, Cygnus atratus, (titre: 30), mute swan, Cygnus o/or, (titre: 40), 
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common shelduck, Tadorna tadorna (titre: 20) and European eider, Somateria 
mollissima (titre: 60). 
Response after 1• vaccmat1on Response after 2"" vaccmat1on 
Dose n GMI n ("lo) uose n GMT n(%) 
(ml) (95%CI) 2:40 (ml) (95% Cl) 2:40 
0.25 51 31 26 (51.0%) 0.25 109 206 89 (81.7%) (19-50) (141-303) 
0.50 49 39 24 (49.0%) 0.50 190 197 154 (22-71) (147-264) (81.1%) 
0.75 13 62 8 (61.5%) (17-225) 
> 0.50 9 72 5 (55.6%) 1.25 17 180 14 (82.4%) (1 0-508) (75-431) 
2.50 5 151 4 (80.0%) (8-2914) 
All 109 37 55 (50.5%) all 336 190 269 (25-53) (152-236) (80.5%) 
p 0.460 0.136 p 0.370 0.533 
Table 1. Serum antibody responses measured by haemagglutination inhibition 
test are shown as geometric mean titres (GMT) and % of animals with a titre 
equal to or greater than 40. Blood was collected at the time of second vaccination 
and 30-60 days later. There were no significant differences in responses of the 
different dose groups. 
Sero-reponse after H5 vaccination 
For 1 09 birds, titres after one vaccination (at the time of the second 
vaccination) were determined. On average, GMT was 37 (95% Cl: 25-53), and 
50.5% of birds reached a serum antibody titre ;;;:: 40 against the homologous 
antigen (Table 1 ). The majority of these birds received vaccine doses of 0.25 
ml and 0.5 mi. There were no significant differences in antibody response 
between doses (P=0.136). For 334 birds, titres 30-60 days after 2nd vaccination 
were determined. On average, the birds reached a post-vaccination GMT of 
190 (95% Cl: 152-236), and 80.5% had a titre;;;:: 40 against the homologous 
antigen. The majority of these birds received vaccine doses of 0.25 ml and 
0.5 mi. There were no significant differences in antibody response between 
doses. In accordance, serum antibody titre after the second vaccination was 
not significantly dependent on weight (P=0.633, linear regression). Three of 
four birds with a pre-vaccination antibody titre tested showed an increase in 
antibody titre after vaccination. 
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Figure 1. Humoral immune response of avian species in zoos following vaccination 
with an inactivated H5N2 vaccine with dose adjusted to mean bodyweight. 
Depicted is the percentage of birds per taxonomic orders with serum antibody 
haemagglutination inhibition (HI) titre <::40, and geometric mean titres (GMT) 
vs. mean body weight of different avian taxonomic orders. An inactivated H5N2 
vaccine with dose adjusted to average body weight was used, administered 
twice with 6 weeks interval. Titres shown were measured 30 to 60 days following 
the second vaccination. Taxonomic orders of which sample size was too low 
for statistical analysis are grouped in "other orders :5:1.4 kg" (Charadriiformes, 
Columbiformes, and Passeriformes) and "other orders >1.4 kg" (Coraciiformes, 
Gruiformes, Pelecaniformes, and Strigiformes). Red points with vertical lines: 
post-vaccination GMT with 95% confidence interval (CI). Horizontal red lines: 
95% Cl of mean body weight in kg. Blue bars: % of birds with a post-vaccination 
titre <::40. Black numbers in bars: numbers of birds per order. 
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For 325 birds, serum antibody titres after second vaccination against 
both the H5N2 vaccine component and the HPAI H5N1 strain circulating in 
Europe (A/turkey/Turkey/05) were determined. The vaccine induced antibodies 
against the HPAI strain, although titres were 3.1 times lower than homologous 
titres. On average, the birds reached a post-vaccination GMT of 61 (95% Cl: 
49-76), and 61.2% had a titre ~ 40. (Figure 2). The degree of agreement 
(within a 4-fold margin) between the post-vaccination results of HI test using 
A/turkey/Turkey/1/05 as antigen and VN test against A/turkey/Turkey/1/05 
was 73.2%. 
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Figure 2. Comparison of serum haemagglutination inhibition antibody titres 
against avian influenza H5N2 vaccine virus and avian influenza H5N1 field 
virus following vaccination. Haemagglutination inhibition titres against both the 
vaccine component (H5N2: A/duck/Pottsdam/1402/86) and the HPAI field strain 
(H5N 1: A/turkey/Turkey/05) were determined in 325 birds, 30-60 days following 2 
vaccinations with 6 weeks interval. 
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Figure 3. Post-vaccination serum haemagglutination inhibition antibody titres as 
a function of the antigenic distance between vaccine and prototype strains of 4 
H5N1 clades. Sera from 32 vaccinated zoo birds were titrated against prototype 
strains of 4 H5N1 clades 403• Antigenic distances to the prototype strains were 
determined from an antigenic maps of H5 strains made using antigenic cartography 
404
• The birds clustered in 2 groups: group 1 (green); Galliformes, Anseriformes, 
Phoenicopteriformes, Struthioniformes and Psittaciformes versus group 2 (purple); 
Ciconiiformes, Gruiformes, Pelecaniformes and Sphenisciformes), based on the 
breath of the antibody responses. Lines show linear regression through points 
of the same colour. The group 1 (green) line has slope -0.7 intercept 10.41; the 
group 2 (purple) line has slope -1.07, intercept 9.47. The slope difference is 
statistically significant (p=0.021 ). 
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We further tested the breadth of the antibody response using sera 
from 32 birds belonging to 7 orders. Inspection of the HI data revealed that 
the immune response to prototype strains from 4 antigenic "clades" 403 divided 
the 7 taxonomic orders into 2 groups (group 1; Galliformes, Anseriformes, 
Phoenicopteriformes, Struthioniformes and Psittaciformes versus group 2; 
Ciconiiformes, Gruiformes, Pelecaniformes and Sphenisciformes). We created 
antigen maps 404 with the HI data to compare the breadth of antibody response 
between the two groups. Group 1 birds were found to have a statistically 
significant broader antibody response than the group 2 birds (P=0.021, linear 
regression) (figure 3). 
Virus detection 
No AIV antigen was detected in collected cloaca swabs. 
DISCUSSION 
In the present paper, we have shown that vaccination of zoo birds with 
an adjuvanted inactivated H5N2 vaccine (Nobilis influenza® H5N2, lntervet, 
Boxmeer, the Netherlands) is safe and produces an immune response. In total, 
80.5% of the vaccinated birds produced a titre of<:: 40 after booster vaccination, 
with a post-vaccination GMT of 190. This was similar to the results obtained 
after vaccination of birds in zoos with an inactivated H7N1 vaccine produced 
by the same manufacturer (81.5%, GMT 190)402 • A booster vaccination 
was required to produce serum antibody titres in 80.5% of vaccinated birds 
(50.5% after single vaccination) again similar to H7 vaccination. In our study 
vaccination was considered to be efficacious when HI titres were <:: 40 [or 2 
log2 (HI titre/1 0)], this in contrast to published protective titres of> 16 in poultry 
181 to account for the unknown interspecies variability, and the impossibility of 
performing virus challenges in the valuable and endangered species in zoos. 
There were no significant differences in antibody titres between dose 
groups, suggesting that the chosen dose regimen adjusted to mean body 
weight per species was adequate (table 1 ). The dose regimen was based 
on the results obtained after H7 vaccination, where antibody response 
significantly decreased with an increase in weight. The heaviest taxonomic 
order (Struthioniformes) had a good immune response to H5 vaccination, with 
a larger percentage reaching an antibody titre of 40 or higher, and higher 
GMTs than after H7 vaccination when vaccine dose was up to a five-fold lower. 
However, as no alternate vaccine dose regimens were tried, this difference 
between responses to H5 and H7 vaccination cannot be attributed to the used 
doses with absolute certainty. 
Differences in responses between and within taxonomic orders 
were seen (Appendix 1), as previously reported 405 • In Figure 1 the lowest 
responses are seen in two groups composed of several taxonomic orders: 
"others ~ 1.4 kg" (including orders Charadriiformes, Columbiformes, 
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Coraciiformes, and Passeriformes) and "others > 1.4 kg" (including orders 
Gruiformes, Pelecaniformes, and Strigiformes). This was primarily the 
effect of only three orders that seemed to show a lower antibody response 
[Pelecaniformes (n=9, %;:::40: 55.6%), Passeriformes (n=2, %;:::40: 50%), and 
Columbiformes (n=5, %;:::40: 20% ), although the numbers per order were very 
low. Pigeons have previously been described as being resistant, or at least 
less sensitive, to infection with HPAI virus 391 •392 , and have failed to produce 
antibodies after infection 406 . However, higher susceptibility of pigeons to more 
recent HPAI H5N1 virus strains has been shown 213A 07• Although the order 
of Galliformes showed favourable overall antibody responses, guinea-fowl, 
Numida meleagris, (n=24) reacted with low GMT (26) and %;:::40 (37.5%), 
despite having been given a vaccine dose of 0.5ml. Guinea-fowl have been 
documented with clinical disease after infection with HPAI H5N1 virus 408 , 
showing respiratory and gastrointestinal signs. The apparent failure of these 
species to respond sufficiently to H5 vaccination therefore needs to be studied 
in further detail. 
Antibody titres against the HPAI virus strain circulating in Europe 
at the time of vaccination showed a similar trend, although generally a 3-
fold lower than to the homologous strain, with 61% developing a titre ;::: 40. 
Post-vaccination HI titres and VN titres against the HPAI field strain showed 
a degree of agreement of 73.2%. The breadth of the immune response was 
demonstrated by antibody titres against prototype strains for 4 H5N1 clades. 
These responses divided the 7 taxonomic orders tested into two groups (group 
1; Galliformes, Anseriformes, Phoenicopteriformes, Struthioniformes and 
Psittaciformes versus group 2; Ciconiiformes, Gruiformes, Pelecaniformes 
and Sphenisciformes) (Figure 3). ), Group 1 birds showed the broadest 
immune response with high antibody titers against the prototype strains of all 
4 H5 clades and a predicted (by extrapolating the regression line) protective 
response against future strains up to 12 antigenic units from the current 
vaccine. In contrast, group 2 birds had low HI antibody titers against the 
prototype strain of the most antigenically distant clade (A/Indonesia/5/2005). 
The longevity of serum antibody titres upon vaccination in these 
species is unknown. Ducks have been documented with antibodies up to 
1 0 months post-vaccination, and were protected from challenge infection at 
this time, but the longevity of antibodies in geese was much shorter 186. In 
Singapore, a small sub-sample of vaccinated zoo birds showed persistence 
of serum antibodies when tested 6 months post H5 vaccination 405·405 . Re-
vaccination 6-1 0 months post-vaccination may therefore be required to 
maintain protective titres among the large variety of avian species in zoos. We 
recommend further research into the longevity of serum antibody titres upon 
vaccination in different exotic species. 
Pre-vaccination antibody titres to H5 were found in 6 birds, all housed 
in outdoor enclosures with ponds (4 Anseriformes, 1 Phoenicopteriformes, 
1 Sphenisciformes ). Titres were low (range 20-60), no virus excretion was 
found, and the birds were from different zoos, therefore not suggesting acute 
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infection or outbreak. These titres may therefore be attributed to previous 
incidental infections with low pathogenic HS viruses obtained from free-ranging 
avian species. It appeared that pre-exposed birds also show an increase in 
titre following vaccination, although the number tested was very small. 
The advantages of vaccination are that it reduces the risk of infection 
(a higher dose is required for infection), and concurrently reduces morbidity, 
mortality and shedding of virus. Therefore outbreaks are less likely to occur, 
and easier to contain without the need for large-scale culling or confinement, 
especially in zoos where levels of bio-security, quarantine measures and 
veterinary care are high. Additionally, derogations to bio-security measures 
(such as an alleviation of confinement measures) can be made in vaccinated 
zoo birds (European Commission Decision 2005/94/EC), provided that 
such derogations do not endanger disease control. Disadvantages can be 
"masking" of infection: delaying detection of the virus, and the potential loss 
of birds during large scale catching and handling. Direct losses experienced 
during or just after vaccination were low and attributed mainly to injury and 
stress, while indirect losses (a drop in reproduction rate) were reported for 
some species. To minimise losses, future vaccination campaigns should 
ideally be conducted when animals are scheduled to be handled for other 
reasons, e.g. when moved indoors for winter, which would minimise stress, 
be at a favourable time relative to the breeding season, and provide enough 
time to build up immunity before the birds go back outside and bird migration 
in spring has started. 
In conclusion, vaccination with an inactivated H5N2 vaccine is 
expected to be a useful and necessary component of the preventive measures 
(including increased bio-security and monitoring) which can be undertaken to 
protect valuable birds in zoos against HSN 1 virus infection, and would obviate 
the need for large scale culling and confinement in case of an outbreak. The 
dose regimen used, where dose was adapted to body weight, is generally 
immunogenic throughout the range of species tested and aimed against a 
broad variety of HS AIV strains, although a booster vaccination is necessary 
to produce high GMT and % of animals with a titre 2!40. 
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Appendix 1: Humoral immune response of avian species in zoos, vaccinated 
twice (6 weeks interval) with an inactivated H5N2 vaccine with dose adjusted to 
average body weight. Geometric mean titres (GMT) and the percentage of birds 
from each species with a post-vaccination serum haemagglutination inhibition (HI) 
titre of~ 40 shown were measured 30 - 60 days after the second vaccination. 
Species HI antibody titres 
Order 
Common name Scientific name GMT %~ n 40 
Anseriformes 69 192 84.1 
Bahama pintail Anas bahamensis 3 96 66.7 
bar-headed goose Anser indicus 2240 100 
barnacle goose Branta leucopsis 4 569 100 
black swan Cygnus atratus 4 599 100 
black-necked swan Cygnus 1920 100 
melanocoryphus 
Canada goose Branta canadensis 200 100 
cinnamon teal Anas cyanoptera 2 847 100 
common shelduck Tadorna tadorna 9 324 82 
common shoveler Anas clypeata 200 100 
coscoroba swan Coscoroba 2 1693 100 
coscoroba 
emperor goose Anser canagicus 4 139 100 
Eurasian wigeon Anas penelope 2 40 50 
European eider Somateria 2 <10 0 
mo//issima 
European Mergus merganser 3 80 100 goosander 
fulvous whistling Dendrocygna 120 100 duck bicolor 
greylag goose Anseranser 4 268 100 
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Hawaiian goose Branda <10 0 
sandvicensis 
hooded merganser Mergus cucullatus 2 196 100 
mallard Anas platyrhynchos 280 100 
Mandarin duck Aix galericulata 5 33 60 
marbled teal Marmaronetta 2240 100 
angustirostris 
red-crested Netta rufina 3 183 66.7 pochard 
rosy-billed pochard Netta peposaca 4 260 100 
smew Mergus a/bel/us 2 160 100 
trumpeter swan Cygnus buccinator 2 905 100 
whistling swan Cygnus 2 14 100 
columbian us 
wood duck Aix sponsa 259 100 
2 
Charadriiformes 3 306 100 
pied avocet Recurvirostra 3 306 100 
avosetta 
Ciconiiformes 38 119 76.3 
bald ibis Geronticus eremita 2 2217 100 
black stork Ciconia nigra 70 100 
black-crowned night Nycticorax 8 277 87.5 heron nycticorax 
black-headed ibis Threskiomis 3 207 66.7 
melanocephalus 
glossy ibis Plagadis fa/cine/Ius 2 20 50 
little egret Egretta garzetta 89 71.4 
7 
marabou stork Leptopilos 3 32 66.7 
crumeniferus, 
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puna ibis Plegadis ridgwayi 10 64 70 
white stork Ciconia ciconia 2 320 100 
Columbiformes 5 14 20 
rock dove Columba Iivia 4 18 25 
crested pigeon Ocyphaps lophotes <10 0 
Coraciiformes 560 100 
blue-winged Dacelo leachii 560 100 kookaburra 
Galliformes 92 236 77.2 
chukar partridge Alectoris chukar 200 100 
Congo peacock Afropavo congensis 7 874 100 
red junglefowl Gallus gallus 50 582 92 
helmeted Numida meleagris 24 26 37.5 guineafowl 
Himalayan mona! Lophophorus 2 57 50 pheasant impeyanus 
Malay great argus Argusianus argus 480 100 
Palawan peacock Polyplectron 180 100 pheasant emphanum 
Reeve's pheasant Syrmaticus reevesi 2 28 50 
wild turkey Meleagris 4 1002 100 gallopavo 
Gruiformes 15 109 80 
black crowned Balearica pavonina 
crane 
2 283 100 
common trumpeter Psophia crepitans 40 100 
Manchurian crane Grus japonensis 2 40 50 
sandhill crane Grus canadensis 2 960 80 
South African Balearica regulorum 6 283 100 
crowned crane regulorum 
white-naped crane Grus vipio 2 14 50 
Passeriformes 2 28 50 
raven Corvus corax 2 28 50 
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Pelecaniformes 9 37 55.6 
dalmatian pelican Pelecanus crispus 2 32 50 
Eastern white Pelecanus 7 39 57.1 pelican onocrotalus 
Phoenicopteriformes 16 332 81.3 
Chilean flamingo Phoenicopterus 7 128 57.1 
chilensis 
greater flamingo Phoenicopterus 
rose us 
9 697 100 
Psittaciformes 25 1152 96 
blue-fronted macaw Amazona aestiva 7 403 86 
hyacinth macaw Anodorhynchus 2 1810 100 hyacinth in us 
Panama amazon Ara ochrocephala 2560 100 panamensis 
scarlet macaw Ara macao 15 1678 100 
Sphenisciformes 35 119 91.4 
Humboldt penguin Sphenicus 32 119 90.6 humboldti 
jackass penguin Spheniscus 3 115 100 demersus 
Strigiformes 2 89 50 
snowy owl Nyctea scandiaca 2 89 50 
Struthioniformes 22 173 81.8 
Dromaius 240 100 emu 
novaehol/andiae 
nandu/rhea Rhea Americana 16 177 81.3 
ostrich Struthio came/us 5 151 80 
all 334 190 80.5 
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Highly pathogenic avian influenza (HPAI) viruses of the H5 and H? 
subtypes are highly contagious viruses that can cause up to 1 00% mortality 
in infected poultry. Although HPAI was thought to affect only poultry species, 
since 2002 a large number of non-domestic bird species have been diagnosed 
with HPAI infection 409 . HPAI is classified by the World Organisation for Animal 
Health (OlE) as a notifiable disease, for which the European Union has a non-
vaccination policy. Standard measures in the face of a HPAI virus outbreak are 
long term confinement or large scale pre-emptive culling of birds. However, 
since this would be detrimental to the welfare and breeding programmes of 
valuable and endangered avian species in zoos, vccination of zoo birds as 
an additional preventive measure against HPAI virus infection (while reducing 
confinement measures) in Belgian, Dutch and German zoos was first allowed 
during an outbreak of HPAI H7N7 virus in poultry in 2003 (Decision 2003/291/ 
EC). In 2005, Decision 2005/744/EC allowed vaccination in European zoos 
against the encroaching HPAI H5N1 subtype. 
In the present paper we demonstrate serum HI antibody titres of 
different non-domestic avian species housed in Rotterdam Zoo detected two 
years after two vaccinations with the H7N1 vaccine and one year after two 
vaccinations with the H5N2 vaccine, as well as the antibody response to one 
vaccine dose one year after the first two H5N2 vaccinations. 
MATERIALS AND METHODS 
During the 2003 HPAI H7N7 outbreak in poultry, birds in Dutch zoos 
were vaccinated twice with six weeks interval using a whole inactivated oil-
adjuvanted vaccine (Nobilis influenza®, lntervet International, Boxmeer, the 
Netherlands) based on influenza virus A/chicken/ltaly/4 73/99 (H7N 1 ), with 
high homology to the field strain HPAI H7N7 A/chicken/Netherlands/1/03 
(97.4% nucleotide and 98.7% amino acid sequence identity). This resulted in 
the induction of antibody titres ~40 in 81.5% of the vaccinated birds, with an 
overall GMT of 190 402• Homologous H7 specific antibody titres (using H7N1 
A/chicken/ltaly/473/99 as antigen) were determined two years later in 48 birds 
when a new vaccination campaign was started in Dutch zoos against the H5 
subtype. These birds were not re-vaccinated with the H7N1 vaccine. 
In 2005, birds in Dutch zoos were vaccinated twice with six weeks 
interval using a whole inactivated adjuvanted H5N2 vaccine (Nobilis influenza® 
H5N2, lntervet International, Boxmeer, the Netherlands), with vaccine doses 
adapted to mean body weight per species, using data collected during the 
H7N1 vaccination campaign. The vaccine strain (A/duck/Pottsdam/1402/86) 
had a homology of 90% to the HA gene of the H5N1 field strain (A/turkey/ 
Turkey/1/05) on the basis of nucleotide sequence (1530 base pairs, including 
basic cleavage site), and 92.4% on the basis of amino acids. Vaccination 
was safe, and proved immunogenic throughout the range of species tested, 
with some variations between and within taxonomic orders. After booster 
vaccination the overall homologous GMT to the vaccine strain, was 190, and 
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80.5% of vaccinated birds developed a titre of:::: 40. Titres to the HPAI H5N1 
virus followed a similar trend, but were lower (GMT: 61; 61%:::: 40) 410 . In both 
studies there was high agreement between post-vaccination antibody titres 
determined by serum HI test, and virus neutralisation titres. 
One year after the initial two vaccinations, the birds were re-
vaccinated with a single dose of the same H5N2 vaccine and dose-weight 
regimen as the previous year 410 , Blood was collected from the right 
jugular vein or the ulnar vein (left or right) at the time of revaccination and 
4 weeks later, using manual restraint. Serum samples from 72 previously 
vaccinated birds from 8 taxonomic orders could be evaluated 4 weeks 
after re-vaccination (25 Anseriformes, 12 Ciconiiformes, 4 Galliformes, 6 
Gruiformes, 3 Pelecaniformes, 7 Phoenicopteriformes, 11 Sphenisciformes 
and 3 Struthioniformes). Only 44 of these (15 Anseriformes, 10 Ciconiiformes, 
3 Galliformes, 4 Gruiformes, 1 Pelecaniformes, 6 Phoenicopteriformes, 3 
Sphenisciformes and 2 Struthioniformes) could be evaluated at all three times 
of blood collection as some samples were not suitable for testing (e.g. auto-
haemolysis, not enough serum, etc) 
HI serum antibody titres were determined in laboratory 11 for the 
responses to the first two vaccinations, but one year post-vaccination and 
4 weeks after revaccination had to be determined in the national veterinary 
reference laboratory (laboratory 22), therefore serum samples were split 
to compare results from both labs. To evaluate the humoral immunologic 
response to vaccination, homologous and heterologous H5 specific antibody 
titres (A/duck/Pottsdam/1402/86 in lab 1 and A/Ost/Den/7 4420/96 in lab 2) 
were determined by HI test, following standard procedures, using turkey 
erythrocytes 377•378• Undetectable titres: <1 0 (lab 1) and < 4 (lab 2) were 
regarded as 5 and 2 respectively for calculation of GMT. Antibody titres of 16, 
32 and 40 are known to protect domestic ducks and chickens from infection 
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, therefore these are used as correlates of protection, as vaccination/ 
challenge experiments cannot be carried out in most zoo bird species. Titres 
considered protective are :::: 40 (as in previous studies in zoo birds) for the 
results of lab 1, and :::: 32 for lab 2, due to the different titration methods used 
in the 2 labs. 
RESULTS 
In all Dutch zoos, two years after H7N1 vaccination, H7 specific 
serum HI antibody titres from both 2003 and 2005 were available from the 
same 48 birds (figure 1.). Within this period, titres clearly decreased: while 
81% of birds had a positive titre (:::: 1 0) and 75% a high positive titre (:::: 40) 
in 2003, these figures were 19% and 10%, respectively, in 2005. The GMTs 
decreased from 95 in 2003 to 7 in 2005. As these birds were not revaccinated 
with an H7 vaccine, the effect of revaccination two years after the initial two 
1 Department of Virology, Erasmus MC, Rotterdam 
2 Department of Virology, Central Institute for Animal Disease Control, Lelystad. 
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vaccinations is not known. 
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Figure 1. Persistence of H7 specific HI serum antibodies, 2 years after vaccination. 
Forty-eight birds that were vaccinated with an H7N1 vaccine in 2003 were tested 
for H7-specific serum HI antibody titres in 2003 and 2005. Within this period, 
titres clearly decreased: While 81% of birds had a positive titre (~10) and 75% a 
high positive titre (~ 40) in 2003, these figures were 19% and 10%, respectively, 
in 2005. The GMT decreased from 95 in 2003 to 7 in 2005. Squares depict HI 
titres 4 weeks after two vaccinations; circles depict HI titres two years later. 
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Figure 2. Serum samples from previously vaccinated and unvaccinated birds 
(n=144) collected at time of re-vaccination (one year after the initial 2 vaccine 
doses) and 4 weeks later were tested for H5 specific serum HI antibody titres 
in 2 labs and natural logarithms of these titres were compared. The correlation 
coefficient is 0.87. 
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H5 specific serum antibody titres determined in the two labs showed 
a correlation coefficient of 0.87 (Figure 2.). As antibody titres determined at 
laboratory 2 had to be reported to the Dutch government, these titres are used 
in the results from the time of re-vaccination and 4 weeks later. 
H5 specific antibody titres had decreased substantially one year 
after vaccination (n = 62; GMT 1 0; 28 % :::: 32), compared to the total GMT 4 
weeks after the initial 2 vaccinations (n = 51; GMT: 7 4; 69%:::: 40). Four weeks 
after revaccination with one vaccine dose, H5 specific HI antibody titres had 
increased to comparable levels of the previous year (n = 72; GMT 59; 7 4% :::: 
32). 
This decline in H5 specific HI serum antibody titres one year after 
the initial two vaccinations and boost effect by one vaccine dose was reflected 
in the serum samples from 44 birds, from 8 different taxonomic orders, which 
could be tested at every time of blood collection (figure 3. ). A larger percentage 
of these 44 birds have a serum HI antibody titre :::: 32 four weeks after re-
vaccination than 4 weeks after the initial two vaccinations, and the GMT after 
revaccination is lower, but comparable to the GMT after 2 vaccine doses one 
year before (89 vs 66). The GMT one year after two vaccinations (at the time 
of revaccination) was 12. 
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Figure 3. H5 specific serum HI antibody titres 4 weeks after 2 vaccinations in 2005 
(squares), at time of re-vaccination one year later (circles), and 4 weeks after 
re-vaccination (triangles) were available for 44 birds from 8 different taxonomic 
orders in Rotterdam Zoo. The graph depicts the percentage of birds per serum HI 
antibody titre class ("2: titre). 
Longevity of H7 and H5 vaccination of zoo birds 
As previously reported for the initial 2 vaccine doses 410 , there are 
differences in responses between taxonomic orders. In all orders (except for 
Phoenicopteriformes), GMTs per taxonomic order had decreased to values 
<32 one year after vaccination. One vaccine dose boosted antibody levels 
such that 6 out of 8 taxonomic orders tested had a GMT ~ 32 four weeks 
after revaccination (figure 4.). Pelecaniformes and Gruiformes reacted to 
revaccination with lower antibody titres, as previously reported for the initial 
two vaccinations, although the number of Pelecaniformes tested was low 
(n=3). 
In conclusion, to maintain high levels of antibodies in birds in zoological 
collections, the initial vaccination against HPAI (twice, with dose adjusted to 
mean bodyweight per species) should be repeated one year later with a single 
dose. 
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at time of booster 1 year later, 
and after booster 
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Figure 4. GMTs determined in Rotterdam Zoo, 4 weeks after 2 vaccinations, at 
the time of re-vaccination one year later, and 4 weeks after re-vaccination. Large 
bars depict total GMT at times of blood collection (n= 51, 62 and 72 respectively), 
smaller bars depict GMT per taxonomic order. Vertical lines: 95% Cl; Horizontal 
line: antibody titre 40. 
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Vaccination of pigeons against HPAI virus (H5N1) 
The currently ongoing outbreaks of highly pathogenic avian 
influenza (HPAI) caused by the H5N1 virus subtype is unprecedented in 
its duration, spread and host range, which includes humans. Feral and 
domestic rock pigeons (Columba Iivia) are abundantthroughoutthe world 
and live in close proximity to humans. Consequently their susceptibility 
to infection with HPAI viruses has been subject of discussion. 
Experimental intra-tracheal and intra-oesophageal infection with 108 
TCID50 of HPAI virus of the H5N1 subtype from two different antigenic 
clades (A/Indonesia/5/05 or A/turkey/Turkey/1/05) induced systemic 
infection with low morbidity and mortality in rock pigeons. Clinical signs 
of infected animals were limited to depression, general malaise, and 
neurological signs (ataxia, tremors, opisthotonus, torticollis). At 3 days 
post-inoculation (dpi) immunohistochemistry revealed the presence of 
viral nucleoprotein in lungs, airsac and brain. Virus could be isolated 
from several organs at 3 dpi, and viral RNA was demonstrated by RT-
PCR in several organs at 3 and 27 dpi of animals infected with either of 
the two viruses. Beyond 4 dpi no virus was isolated from oropharyngeal 
swabs, and no virus was isolated from cloacal swabs throughout the 
duration of the experiment. Vaccination of pigeons with a commercial 
inactivated adjuvanted H5N6 vaccine for poultry was safe and largely 
limited extra-respiratory infection, prevented development of severe 
clinical signs and mortality, and limited oropharyngeal virus shedding 
to 1 dpi, with either of the two virus strains. Thus, vaccination effectively 
reduced the possible risk posed by pigeons infected with HPAI H5N1 
viruses 
INTRODUCTION 
Avian influenza viruses (AIV) belong to type A influenza viruses of the 
Orthomyxoviridae family, and can be classified on the basis of the antigenic 
properties of their surface glycoproteins haemagglutinin (H) and neuraminidase 
(N), and on the basis of their pathogenicity for chickens after intravenous 
inoculation. Currently, 16 H (H 1-H 16) subtypes and 9 N subtypes (N 1-N9) 
have been identified which are found in many different combinations 151 •160. 
Aquatic avian species (of the taxonomic ordersAnseriformes, Charadriiformes) 
are considered the main natural reservoir for AIV, and generally experience 
little if any morbidity and mortality after infection. Highly pathogenic avian 
influenza (HPAI) viruses are restricted to the H5 and H7 subtypes, and have 
been isolated mainly from Galliformes (chickens, turkeys, grouse, pheasants 
and quails) in which they can cause acute generalised disease, of which the 
mortality in poultry may be as high as 100%. Although outbreaks of HPAI were 
historically restricted to poultry flocks, in 2002 an outbreak of HPAI virus of 
the H5N1 subtype caused severe disease in wild migratory birds and resident 
waterfowl in Hong Kong, with high mortality 163•372• Since 2002, HPAI viruses 
of the H5N1 virus subtype have made an unprecedented spread from South-
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East Asia throughout Asia and into the middle East, Europe and Africa, with 
a broadening of host range including a large number of avian species: to 
date at least 1 05 species from 14 different taxonomic orders 164 and several 
mammalian species, including humans. 
Rock pigeons (Columba Iivia) are abundant throughout the world, 
mainly as feral pigeons in cities, kept as pets, and are selectively bred as 
racing pigeons which fly large distances. Controversy has arisen over the 
susceptibility of pigeons to AIV infection. Pigeons have previously been 
described as being resistant, or largely resistant, to infection with HPAI 
viruses of the H7 and H5 subtypes 391 ·392•411 , and failed to produce antibodies 
after experimental infection 406 • However, higher susceptibility of pigeons to 
more recent HPAI virus strains of the H5N1 subtype has been documented 
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, with neurotropism of the virus shown by antigen detection by 
means of immunohistochemistry in only the central nervous system. Bird-to-
bird transmission has not been documented and sentinel chickens housed 
with experimentally infected pigeons did not become infected 407 . Infected 
feral and domestic pigeons would pose a potential threat to poultry, certain 
mammalian species and humans if HPAI H5N1 virus shedding occurs, since 
feral pigeons are abundant in cities, and domestic pigeons are kept in large 
numbers in close contact with humans. 
Vaccination is a useful means of reducing the horizontal spread of avian 
influenza viruses in poultry 179·180 , and has proven to be effective in protecting 
poultry from HPAI under field conditions 181 . However, H5 and H7 vaccination 
of pigeons and other species of the taxonomic order Columbiformes induced 
relatively low serum antibody responses compared to other taxonomic orders 
tested in zoos, suggesting that vaccination would be less efficacious in these 
species 402.41o_ 
The aim of this study was (1) to determine safety and efficacy of a 
whole inactivated adjuvanted H5N6 vaccine against infection with one of two 
strains of HPAI from different antigenic clades, and (2) to determine the tissue 
tropism, associated disease and virus excretion in pigeons infected with either 
of these viruses. 
MATERIALS AND METHODS 
Animals and experimental design 
The experimental protocol was approved by an independent animal 
ethics committee, and all experiments were performed under bio-safetylevel3 
conditions. Forty-eight male and female rock pigeons from the same breeder 
were housed together in an indoor aviary from the age of approximately 4 
weeks onward, and given coloured leg-bands to randomly create 4 groups 
of 12 birds each. Two groups were vaccinated subcutaneously at the age 
of 4-5 weeks and 6 weeks later with 0.25 ml of an inactivated adjuvanted 
H5N6 avian influenza virus vaccine for poultry (Nobilis Influenza® H5N6, 
lntervet, Boxmeer, the Netherlands). The vaccine strain used (A/duck/ 
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Potsdam/2243/84) had a homology of 88% and 87% to Nlndonesia/5/05 and 
Nturkey/Turkey/1/05 on the basis of nucleotide sequence of the HA gene 
(1692 base pairs, excluding the basic cleavage site), and 91.5% and 91.5% on 
the basis of amino acids respectively. The vaccine was produced and assayed 
according to the requirements made in the OlE Manual of Diagnostic Tests 
and Vaccines for Terrestrial Animals (chapter 2. 7 .12) and induces at least 6 
log2 haemagglutination inhibition (HI) units according to the potency test in 
chickens (further details may be obtained from the manufacturer). The control 
groups were sham-vaccinated with 0.25 ml of phosphate buffered saline 
(PBS). Three weeks after the second vaccination each group was moved to 
separate negatively pressurised bio-security level 3 isolators. Four weeks 
after the second vaccination, two groups (one vaccinated and one sham-
vaccinated) were inoculated with Nlndonesia/5/05 (Nindonesia), and two 
groups (one vaccinated and one sham-vaccinated) with Nturkey/Turkey/1/05 
(Nturkey). Inoculation was performed with allantoic fluid containing 1 x 108 
TCID5/ml HPAI H5N1 virus divided over trachea (0.5ml) and oesophagus (0.5ml). At this time transponders for temperature registration were implanted 
subcutaneously. Records were kept for clinical signs (daily by a qualified 
veterinarian), temperature (daily) and body weight (every 3 days) until27 days 
post-inoculation (dpi). 
Blood (0.5-1ml) was collected from the right jugular vein under manual 
restraint at the times of vaccination, on the day of infection, 14 dpi, and at time 
of euthanasia (3 dpi or 27 dpi). Blood collection tubes with clot activator and 
serum separator (MiniCollect®, Greiner Bio-One) were centrifuged, and serum 
was stored at -70°C. Cloacal and oropharyngeal samples were collected with 
cotton swabs and stored at -70°C in transport medium consisting of Hanks' 
balanced salt solution, 10% vol/vol glycerol, 200 U/ml penicillin, 200 jJg/ml 
streptomycin, 100 U/ml polymyxin B sulfate, and 250 jJg/ml gentamicin (MP 
Biomedicals, Zoetermeer, the Netherlands). Swabs were taken at times of 
vaccination, and daily for two weeks post infection. Hereafter swabs were 
collected twice a week. Three dpi, 5 pigeons from each group were euthanised 
by bleeding after isoflurane anaesthesia. Remaining animals were euthanised 
when moribund, or at 27 dpi. Necropsies were performed on all animals 
for gross pathology, histopathology, immunohistochemistry and virological 
examination. 
After starting the vaccinations, intercurrent Salmonella (Salmonella 
enterica, serovar Typhimurium) and Trichomonas infections were diagnosed 
when all the pigeons were housed together. In spite of immediate start of 
anti-bacterial and trichomonacidal treatments, three animals were lost due 
to these infections. Consequently one group of 12, and three groups of 11 
pigeons were left for challenge infection. All pigeons were clinically healthy 
and tested negative to these pathogens at the time of infection. 
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To evaluate humoral immune responses to vaccination and infection, 
Nduck/Potsdam/2243/84 (vaccine strain), Nturkey and Nlndonesia specific 
antibody titres were determined in duplicate by haemagglutination inhibition 
(HI) test, following standard procedures, using turkey erythrocytes 377·378 • 
Undetectable titres (<1 0) were regarded as 5 for calculation of geometric 
mean titres (GMT) with 95% confidence intervals (CI). The percentage 
of pigeons with a titre ;;::: 40 was calculated for comparison with previously 
published vaccination of species from the taxonomic order Columbiformes in 
zoos 402,410_ 
Viruses 
Virus strains representing 2 antigenic variants 404 were used: Nturkey/ 
Turkey/1/05 from H5N1 clade 2, subclade 2; and Nlndonesia/5/05 from 
H5N1 clade 2, subclade 1 413• Stocks were produced by second passage in 
embryonated chicken eggs, and allantoic fluids were harvested after 3 days. 
Infectious virus titres were determined as 50% tissue culture infective dose 
(TCID50) in Madin-Darby Canine Kidney (MOCK) cells (ATCC: Product CCL-
34 (NBL-2)) as described previously 414 • 
Histopathologic and immuno-histochemical examination 
Necropsies and tissue sampling were performed according to a 
standard protocol. Samples were collected from lung, air sac, oesophagus, 
proventriculus, duodenum, pancreas, jejunum, ileum, caecum, colon, liver, 
spleen, kidney, adrenal glands, cerebrum, cerebellum, and brain stem. 
After fixation in 10% neutral-buffered formalin and embedding in paraffin, 
tissue sections were cut to a thickness of 4 !Jm, de-waxed, and stained with 
hematoxylin and eosin for histological evaluation. Duplicate sections were 
stained by an immunohistological method using a monoclonal antibody against 
the nucleoprotein of influenza A virus as a primary antibody for detection of 
influenza viral antigen, and an lgG2a isotype-control 415 • 
Virological examination 
Duplicate samples of the same tissues collected for histopathology 
and immunohistochemistry were stored at -7oac until virological examination. 
Tissue samples were weighed and homogenised with a homogeniser 
(Kinematica Polytron, Lucerne, Switzerland) in 3 ml of infection medium 
(Eagles Minimal Essential Medium [EMEM], bovine serum albumin [fraction V 
7.5%, 1 :25], 4 !Jg/ml trypsin, 2 mM 1-glutamin, 100 U/ml penicillin, 100 !Jg/ml 
streptomycin, 7.5% NaHC03 , 1 M Hepes). The homogenised solution (200 !JI) 
was then added to 300 !JIIysis buffer for RNA isolation, and stored at -70°C. 
RNA isolation and reverse transcription-polymerase chain reaction 
(RT-PCR) were performed as described previously 380 • RNA was isolated by 
using a MagnaPure LC system with the MagnaPure LC total nucleic acid 
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isolation kit (Roche Diagnostics, Almere, the Netherlands), and influenza A 
virus was detected by using a real-time RT-PCR assay 416 • Amplification and 
detection were performed with an ABI7700 machine with the TaqMan EZ RT-
PCR Core Reagents kit (Applied Biosystems, Nieuwerkerk aan den IJssel, the 
Netherlands) by using 20 1-fl eluate in an end volume of 50 1-fl. 
Infectious virus titres were determined for all swabs collected, and 
all influenza A virus RT-PCR-positive homogenised tissue samples. To this 
end ten-fold serial dilutions were inoculated on MOCK cells in triplicate to 
determine TCID50 per ml or gram tissue as described previously 414• 
RESULTS 
Adverse effects, clinical signs and mortality 
None of the birds exhibited general or local adverse effects that could 
be attributed to vaccination. All birds, regardless of vaccination status showed 
signs of general malaise after tracheal and oesophageal challenge infection 
with 108 TCID50 HPAI H5N1 virus (A/turkey orA/Indonesia): depression, ruffled 
plumage, minor increase in body temperature) for 1 dpi. In all groups a minor 
mean rise in body temperature (up to 0.5°C) was seen during the first 2 dpi, 
although mean temperatures remained between 42 - 43°C for 27 dpi (results 
not shown). Fluctuations in mean body weight were not substantially different 
between the groups during the experiment. 
Sham vaccinated pigeons 
One out of 6 sham-vaccinated pigeons inoculated with A/turkey 
exhibited minor neurological signs (tremors) at 4 dpi and progressive 
severe neurological signs (torticollis, hemiparalysis of the wings, ataxia, and 
eventually unable to stand) at 5 dpi, when it was euthanised. Three out of 
6 sham-vaccinated pigeons showed minor clinical signs (ruffled feathers, 
tremors) from 1 dpi until 7 dpi. Inoculation of sham-vaccinated pigeons with 
A/Indonesia caused no mortality, and low morbidity with minor clinical signs 
(ruffled feathers, tremors) in 2 out of 7 pigeons from 1 dpi until 7 dpi. At 7 
dpi in one of these A/Indonesia inoculated pigeons the clinical signs became 
severe (opisthotonus/torticollis, ataxia, tremors- worsening with excitement, 
depression, and ruffled plumage). This pigeon was able to stand and feed 
-therefore not euthanised- and slowly recovered with remaining occasional 
tremors, ataxia and opisthotonus until 27 dpi. 
Vaccinated pigeons 
Tracheal and oesophageal challenge infection of vaccinated pigeons 
with 108 TCID50 HPAI H5N1 virus (A/turkey or A/Indonesia) resulted in signs 
of general malaise (depression, ruffled plumage, minor increase in body 
temperature) for 1 dpi, and no mortality. 
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At the time of challenge infection (0 dpi), vaccinated animals had 
responded to 2 vaccinations with high serum HI antibody titres and high 
percentage seroconversion to the homologous H5N6 antigen used in the 
vaccine (GMTs: 132 and 217; 80% and 100% for A/Indonesia and A/turkey 
respectively) (Figure 1.), but with low serum HI antibody titres against the 
heterologous HPAI H5N1 virus strains (GMTs of the A/turkey and A/Indonesia 
inoculated groups using A/turkey in the HI test: 22 and 11, with 36% and 30% 
sera-conversion respectively; and GMTs of A/turkey and A/Indonesia inoculated 
groups using A/Indonesia in the HI test: 5 and 5, with 0% seroconversion). 
Three dpi, the GMTs were comparable to those in pre-infection samples in 
all groups, and all but one vaccinated bird had detectable antibody titres to 
the vaccine antigen, followed at 14 dpi by an increase in GMT, and 100% 
seroconversion in the vaccinated birds. 
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Figure 1. Geometric mean titres (GMT) of vaccinated pigeons from 1st vaccination 
to 27 days post-inoculation (dpi) with a high dose (108TCID50) of either AJ 
lndonesia/5/05 or Alturkey/Turkey/1/05 (H5N1 ). HI tests were performed with 
different antigens. Circles: Alduck/Potsdam/2243/84 (vaccine strain); triangles: AJ 
turkey/Turkey/1/05; squares: Allndonesia/5/05. Lines depict standard deviation. 
All sham-vaccinated pigeons were sero-negative at the time of 
inoculation and three dpi to all three antigens used in the HI test. Inoculation of 
sham-vaccinated pigeons with A/turkey induced higher GMTs and percentages 
of sera-conversion at 14 and 27 dpi than A/Indonesia inoculation, using AI 
turkey (14 dpi: 40% vs 14%; 27 dpi: 80% vs 28%) and the vaccine strain (14 
dpi: 40% vs 0%; 27 dpi: 40% vs 14%) as antigens in the HI test. The GMTs 
were higher against the vaccine strain after inoculation, and no A/Indonesia-
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specific antibodies were observed in sham-vaccinated pigeons inoculated 
with either strain. 
Viral RNA detection (RT-PCR) in swabs 
Oropharyngeal swabs from all sham-vaccinated, and 90% of 
vaccinated birds tested positive by RT-PCR at 1 dpi, regardless of virus strain 
used for inoculation (figure 2.). Virus load in oropharyngeal swabs declined 
after 1 dpi, and was detectable up to 5 dpi in vaccinated birds and 9 dpi in sham-
vaccinated birds, regardless of virus used for inoculation. No oropharyngeal 
swabs were positive by RT-PCR after 9 dpi. 
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Figure 2. Virus detection by means of RT-PCR in oropharyngeal swabs taken 
from sham- vaccinated and vaccinated pigeons, after intra-tracheal and intra-
oesophageal infection with 108TCID50 of either A/lndonesia/5/05 or A/turkey/ 
Turkey/1/05 (H5N1 ). Swabs were taken up to 27 days post infection, but were all 
negative after day 9. Bars represent the geometric mean virus detection (40-Ct 
value), error bars indicate standard deviation, and % represents the percentage 
of RT-PCR positive animals per group. To calculate geometric means, 0.1 was 
used as 40-Ct for the negative samples. 
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Cloacal swabs of sham-vaccinated birds were positive by RT-PCR 
for up to 11 and 9 dpi after A/Indonesia and A/turkey inoculation respectively. 
Geometric mean values of virus detection (40-Ct value) were low (:s; 1) on 
each day with positive viral RNA detection (on 2, 6, 8, 9 and 11 dpi for AI 
Indonesia, and on 8 and 9 dpi for A/turkey). Vaccinated birds had low RT-PCR 
positive cloacal swabs (geometric means :s; 1 on each day) only on 2 DPI after 
A/Indonesia, and on 2 and 9 DPI after A/turkey inoculation. 
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Figure 3. Geometric mean virus isolation from oropharyngeal swabs taken 
from sham-vaccinated and vaccinated pigeons, after intra-tracheal and intra-
oesophageal infection with 108TCID50 of either Nlndonesia/5/05 or Nturkey/ 
Turkey/1/05 (H5N1 ). Swabs were taken up to 27 days post infection, but were all 
negative after day 4. Cloacal swabs were taken during the same period, but no 
virus could be isolated and results are therefore not shown. Bars represent virus 
titre: geometric means of Log1 OTCID50/ml, error bars represent the standard 
deviation, and % represents the percentage of virus isolation positive animals 
per group. 
Virus isolation from swabs 
Virus was isolated from the oropharynx of the majority of birds from 
all groups at 1 dpi (figure 3.). Virus was isolated at low titres from a minority 
of sham-vaccinated birds up to 3 dpi or 4 dpi (A/turkey and A/Indonesia 
respectively). No virus was isolated from vaccinated birds after 1 dpi. No virus 
was isolated from any cloacal swabs at any time after inoculation, regardless 
of vaccination status. 
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Viral RNA detection by RT-PCR in organs 
At 3 dpi, viral RNA was detected by RT-PCR in all organs tested 
(brain, lung air sac, pancreas, spleen, liver and duodenum) from sham-
vaccinated animals. Vaccinated animals inoculated with A/Indonesia (figure 
4.) tested positive in all organs by RT-PCR except brain and duodenum, 
those inoculated with A/turkey (figure 5.) tested positive in all organs except 
pancreas. Geometric mean viral RNA load (represented as 40-Ct value) per 
organ, and the percentage of positive animals per group were generally lower 
for the vaccinated groups. In one sham-vaccinated A/turkey inoculated pigeon 
euthanised at 5 dpi high viral RNA loads were detected in all organs except 
pancreas and duodenum. At 27 dpi, viral RNA was detected in lungs from 
all groups, regardless of vaccination status, although geometric mean titres 
and % positive birds was lower for the vaccinated, A/turkey inoculated group. 
The only other organ in which viral RNA was detected by RT-PCR at 27 dpi 
was brain for sham-vaccinated animals, and liver for vaccinated birds after 
A/turkey inoculation. 
Virus Isolation and quantification from organs 
Virus could be isolated from several organs in sham-vaccinated birds 
at 3 dpi (figure 6.). Virus could only be isolated from the lungs of vaccinated 
birds at 3 dpi. For the lungs, the percentage of birds positive by virus isolation, 
and geometric mean TCI050 per gram lung tissue was lower in the vaccinated 
groups than in the sham-vaccinated groups (A/turkey: 20% vs 60%; geometric 
mean TCID5/g: 10°·18 vs10°·92 ; A/Indonesia: 80% vs 80%; geometric mean 
TCID5/g: 1 01·57 vs 1 01·86l. The highest virus titres (TCID5/g tissue) isolated 
from sham-vaccinated pigeons at 3 dpi was 107·0 (air sac, A/turkey infection) 
and 1 04·3 (lung, A/Indonesia infection). The highest virus titres isolated from 
vaccinated pigeons at 3 DPI was1 03·9 (lung, A/Indonesia infection) and 1 02·0 
(lung, A/turkey infection). The one sham-vaccinated pigeon infected with AI 
turkey that was euthanised due to severe neurological signs at 5 dpi was 
positive by virus isolation in the brain (1 06.46 TCID5/g) and air sac (1 03·66 TCID5/ 
g). No virus was isolated at 27 dpi from any organs of any of the pigeons, 
regardless of vaccination status. 
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Figure 4. Virus detection by means of RT-PCR in organs taken from sham-
vaccinated and vaccinated pigeons: 3 and 27 days after tracheal and intra-
oesophageal inoculation with 108TCID50 of A/lndonesia/5/05 (H5N1). Bars 
represent geometric mean of 40-Ct values, error bars represent the standard 
deviation, and % represents the percentage of RT-PCR positive animals per 
group. 
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Figure 5. Geometric mean virus detection by means of RT-PCR in organs taken 
from sham-vaccinated and vaccinated pigeons: 3, 5 and 27 days after tracheal 
and intra-oesophageal inoculation with 1 08TCID50 of A/turkey/Turkey/1/05 (H5N1). Bars represent geometric mean of 40-Ct values, error bars represent 
the standard deviation, and % represents the percentage of RT-PCR positive 
animals per group. 
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Figure 6. Virus isolation (TCID5/g tissue) from organs taken from sham-
vaccinated, and vaccinated pigeons, 3 days after intra-tracheal and intra-
oesophageal inoculation with a high dose of either Nlndonesia/5/05 or Nturkey/ 
Turkey/1/05 (H5N1). Bars represent geometric mean log10TCID5/g tissue, error 
bars represent the standard deviation, and % represents the percentage of virus 
isolation positive animals per group. 
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Figure 7. Vaccination reduces viability of highly pathogenic avian influenza virus in 
organs of infected pigeons. Graphs depict virus titre (log10TCID5/g) vs PCR virus 
detection (Ct value) in organs taken from sham-vaccinated (n=5) and vaccinated 
pigeons (n=5), 3 days after intra-tracheal and intra-oesophageal inoculation 
with 108TCID50 of either Nlndonesia/5/05 or Nturkey/Turkey/1/05 (H5N1 ). Black 
circles and solid line represent values and regression line for sham-vaccinated 
animals, white circles and dotted line represent values and regression line for 
vaccinated animals. 
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Gross Pathology 
All animals (vaccinated and sham-vaccinated) necropsied at 3 dpi 
showed consolidation of the ventrocaudal left lung, of varying extent (1 0 to 
30% of lung volume). No changes were seen in the right lung. Opaque air 
sacs were seen in sham-vaccinated (A/Indonesia: 40%, A/turkey: 20%) and 
vaccinated (A/turkey: 40%) pigeons at 3 dpi. Splenomegaly was seen in sham-
vaccinated and vaccinated pigeons after A/Indonesia infection (40% and 40% 
at 3 dpi, and 71 and 80% at 27 dpi respectively. No further gross lesions were 
seen at 27 dpi. One sham-vaccinated, A/turkey infected pigeon necropsied at 
5 dpi had subcutaneous oedema of the head and neck, consolidation of the 
left lung, and demarcated brittle grey liver (approximately 90% of the surface 
area). 
Immunohistochemistry 
Lung and air sacs were the only organs in which nucleoprotein 
was detected by means of immunohistochemistry (IHC) at 3 dpi (Table 1. ). 
Immunohistochemistry positive cells were found mainly in the parabronchi, 
and were more widely distributed throughout lungs of sham-vaccinated 
birds infected with A/Indonesia compared to vaccinated birds. No difference 
in distribution was seen between lungs of vaccinated and sham-vaccinated 
birds infected with A/turkey. At 5 dpi, nucleoprotein was detected in the 
cerebellum of one pigeon that was euthanised with severe neurological signs, 
but no nucleoprotein was detected in any other organs. No nucleoprotein was 
detected by IHC in organs from any groups at 27 dpi. 
Histopathology 
At 3 dpi a consistent histopathological finding in both the A/Indonesia 
and A/turkey infected pigeons was a bronchopneumonia with mononuclear 
infiltrates and (peri-) vasculitis. There were no remarkable differences in 
severity of bronchopneumonia between the vaccinated and sham-vaccinated 
groups infected with A/turkey, but vaccinated A/Indonesia infected pigeons 
were affected to a lesser extent than sham-vaccinated pigeons. A meningo-
encephalitis with peri-vascular cuffing, gliosis and neuronal necrosis was 
seen in brains of 3/5 sham-vaccinated, A/turkey infected pigeons, but not in 
vaccinated animals. No histopathological changes were seen in the brains of 
A/Indonesia infected pigeons, regardless of vaccination status. 
At 27 dpi histopathological findings were far less severe, and no 
differences in severity were observed between vaccinated and sham-
vaccinated groups. In the A/turkey infected group, meningo-encephalitis was 
seen in one sham-vaccinated and one vaccinated pigeon, with gliosis and 
peri-vascular cuffing respectively. In the A/Indonesia infected group, one 
sham-vaccinated pigeon showed meningo-encephalitis with peri-vascular 
cuffing and gliosis. 
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Cerebrum Cerebellum Lung Air sac 
Sham-vaccmated 
A/lndonesia/5/05 3 dpi 
Pigeon 1 
Pigeon 2 
Pigeon 3 
Pigeon 4 
Pigeon 5 
Vaccinated 
A/lndonesia/5/05 3 dpi 
Pigeon 1 
Pigeon 2 
Pigeon 3 
Pigeon 4 
Pigeon 5 
Sham-vaccinated 
A/turkey/Turkey/1/05 3 dpi 
Pigeon 1 
++ 
++ 
++ 
++ 
+++ 
++ 
+ 
+ 
+ 
+ 
+ 
Pigeon 2 ++ 
Pigeon 3 
Pigeon 4 
Pigeon 5 
Sham-vaccinated 
A/turkey/Turkey/1/05 5 dpi ** 
Pigeon 1 
Vaccinated 
A/turkey/Turkey/1/05 3 dpi 
Pigeon 1 
Pigeon 2 
Pigeon 3 
Pigeon 4 
Pigeon 5 
+ 
+ 
++ 
+ 
+ 
Table 1. Average distribution* of Influenza A nucleoprotein, as determined by 
immunohistochemistry in (non-) vaccinated pigeons, 3 or 5 days after intra-tracheal 
and intra-oesophageal infection with 106TCID50 of either A/lndonesia/5/05 or AI 
turkey/Turkey/1/05 (H5N1 ). No nucleoprotein was detected in other organs tested 
3 dpi (pancreas, spleen, liver, kidney, oesophagus, proventriculus, duodenum, 
jejunum, ileum, caecum, colon, testis, ovary, adrenal gland), or in any organ 27 
dpi.*- = none, + = infrequent; ++ = common; +++ =widespread.** This pigeon 
was euthanised because of severe clinical signs 
+ 
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DISCUSSION 
In the present paper we have shown that simultaneous intra-tracheal 
and intra-oesophageal infection with an extremely high dose of HPAI virus 
of the H5N1 subtype (A/Indonesia/5/05 or Alturkey/Turkey/1/05) induces 
systemic infection in pigeons, with low morbidity and mortality. Clinical signs 
of infected animals were depression, general malaise, and neurological signs 
(ataxia, tremors, opisthotonus, torticollis). Severe clinical signs were seen in 
one out of six pigeons after A/turkey -, and one out of seven pigeons after AI 
Indonesia inoculation, and started at 4 dpi and 7 dpi respectively. The systemic 
infection was demonstrated by the presence of nucleoprotein by IHC in the 
lungs, air sacs, and brain, and histopathological changes in the lungs and 
brains. 
Virus was detected by means of RT-PCR (brain, lung, air sac, pancreas, 
spleen, liver and duodenum), and virus could be isolated from several organs 
at 3 dpi (A/Indonesia: lung, air sac, spleen, duodenum; A/turkey: brain, 
lung, air sac, pancreas, spleen, and liver). Immunohistochemistry was less 
sensitive (brain, lung and airsac were positive) than RT-PCR or virus isolation 
to measure influenza virus infection, as IHC detects viral antigen in cells- and 
thus requires replication of virus, whereas virus isolation measures infectious 
virus, and RT-PCR detects presence of viral RNA. 
Our findings of IHC positive cells of the parabronchi in the lungs, the 
air sacs and brain, and the (transient) bronchopneumonia induced by A/turkey 
and A/Indonesia inoculation suggest that primary replication took place deep 
in the lungs and air sacs. The parabronchi, which are closely surrounded by 
blood capillaries and are involved in gaseous exchange, probably allow for 
passage of virus into the bloodstream, and subsequent haematogenic spread 
to the brain. After penetration of the blood-brain barrier, further replication can 
occur in glial cells and neurons, as described in chicks inoculated via the air 
sac route 417. Neurotropism of HPAI virus (H5N1) in pigeons has previously 
been described 407 without IHC positive cells in the respiratory tract, although 
these pigeons were euthanised later than 3 dpi, and route of inoculation and 
virus strain used were different. Whereas endothelial tropism appears to play 
an important role in the pathogenesis of HPAI in chickens, and death at 1-2 
dpi is associated with lung oedema, congestion, and the presence of viral 
antigen predominantly in vascular endothelial cells, but also parenchyma 
of multiple organs 408•418.419 , no viral antigen was detected in endothelial or 
parenchymal cells of H5N1 infected pigeons. The virus isolation described in 
several organs in the present study may thus reflect the presence of virus in 
the blood of organs other than the lungs and brains during the viraemic phase. 
The difference in cell-tropism and pathogenesis of H5N1 virus infection in 
pigeons compared to e.g. chickens may explain the lower susceptibility of this 
species. 
The presence of infectious virus in the oropharynx was observed in 
a number of sham-vaccinated pigeons (A/turkey: 64%; A/Indonesia: 58%) at 
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1 dpi, and continued for 3 and 4 dpi after A/turkey and A/Indonesia infection 
respectively. The maximum titre isolated at 1 dpi was 1x1 03·2 TCID5/ml, and 
it cannot be excluded that this was residual virus from the inoculation (1 x1 08 
TCID5/ml), and does therefore not confirm virus replication on the first day. 
Oropharyngeal swabs were positive by RT-PCR in sham-vaccinated birds 
until 11 dpi and 9 dpi after A/Indonesia and A/turkey infection respectively. 
Cloacal swabs were positive in a small number of pigeons by RT-PCR, 
with low individual levels and geometric means, and a small peak in sham-
vaccinated birds on 8 and 9 dpi. No infectious virus was isolated from cloacal 
swabs, regardless of vaccination status. Virus excretion predominantly from 
the respiratory tract after HPAI H5N1 virus infection has been previously 
described in various species of ducks 162A20 in contrast to viral shedding in ducks 
upon LPAI virus infection, which occurs mainly from the gastrointestinal tract 
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• Previous attempts to isolate virus from oropharyngeal swabs taken from 
pigeons after experimental HPAI virus (H5N1: A/chicken/HongKong/220/97) 
have not been successful 391 • 
Vaccination of pigeons with the inactivated, adjuvanted H5N6 vaccine 
(Nobilis H5N6, lntervet, Boxmeer, the Netherlands) was safe, and produced 
protection against severe clinical disease after inoculation with viruses from 2 
different antigenic clades. Furthermore it induced complete protection against 
the presence of extra-respiratory detectable infectious virus (Figure 6), with 
IHC positive cells and virus isolation at 3 DPI from only the lungs, and it largely 
reduced the systemic spread of virus as detected by RT-PCR. Although 
geometric mean virus detection by RT-PCR (40-Ct value) 3 dpi was higher 
in some organs of the vaccinated groups compared to the sham-vaccinated 
groups (A/Indonesia infection: lung: 18.4 vs 15.2; air sac: 3.1 vs 2.5; A/turkey 
infection: lung 19.7 vs 15.5), the percentage of birds from which virus could 
be isolated from the lungs and geometric mean virus titres were much lower 
in vaccinated birds than in sham-vaccinated birds. 
Protection against systemic infection appeared to be more effective 
against the A/turkey strain than against the A/Indonesia strain. Although virus 
was detected by RT-PCR in organs of some vaccinated birds inoculated with 
A/Indonesia, the level of correlation with virus isolation from these organs was 
much lower than that in birds infected with A/turkey (figure 7). At the time of 
inoculation, vaccinated birds had high GMTs and percentage seroconversion 
measured in the HI test, especially compared to serum HI antibody titres 
induced in Columbiformes after H5N2 vaccination 410 . Vaccination induced 
highest GMTs against the homologous vaccine virus strain, and high titres 
against A/turkey (figure 1.). In sham-vaccinated birds GMTs induced by 
infection were much lower than those induced by vaccination, and highest 
against A/turkey. An explanation for the low correlation between virus isolation 
and virus load by RT-PCR is that antibodies induced by vaccination effectively 
neutralised virus, while neutralised virus could still be detected by means of RT-
PCR (figure 7). However, the absence of high titres of virus specific antibodies 
does not mean that pigeons would not be protected from clinical disease. Two 
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weeks post inoculation with A/turkey, only 40% of sham-vaccinated pigeons 
had a virus specific antibody titre while morbidity was low, and all but one 
survived inoculation with a high dose of virus. None of the sham-vaccinated 
birds inoculated with A/Indonesia produced virus specific antibodies, while 
all of these birds survived, and clinical signs were seen in two out of seven 
specimens. Experimental infections of ducks with recent H5N 1 strains have 
failed to induce antibody titres detectable by HI test in some infected birds 
420 
Antibodies specific to A/Indonesia were absent in all groups throughout 
the duration of the experiment, except for 1 vaccinated bird at 14 DPI after 
A/turkey inoculation (antibody titre: 1620), and one more from the same 
group at 27 dpi (antibody titres: 560 and 30). At 14 and 27 dpi the serum 
antibody titre of these birds determined by HI test using vaccine strain or AI 
turkey were much higher (7680 or 640 and 1280 or 140 respectively). It has 
previously been reported that vaccination of certain taxonomic orders of birds 
with an inactivated adjuvanted H5N2 vaccine induces low HI antibody titres 
against the A/Indonesia virus strain 410 • Additionally, an asymmetry in antibody 
recognition pattern, with low A/Indonesia-specific antibodies detectable by HI 
test compared to other virus strains used, was observed in mice after MVA-
HA vaccination and in ferrets after infection with the original influenza viruses 
413,421 
It may be concluded that on the basis of the histopathological data, 
the H5N6 vaccine did not prove to be protective against the (transient) 
bronchopneumonia induced by A/turkey and A/Indonesia infection. However, 
some protective effect was seen in brains of vaccinated, A/turkey inoculated 
pigeons at 3 dpi. Surprisingly, at 3 dpi histopathological signs of meningo-
encephalitis were seen in sham-vaccinated, A/turkey inoculated pigeons 
that did not show severe neurological signs. At 3 dpi no histopathological 
signs of meningo-encephalitis were seen in A/Indonesia inoculated pigeons, 
regardless of vaccination status. Sham-vaccinated pigeons that exhibited 
severe clinical neurological signs had demonstrable meningo-encephalitis at 
5 dpi (A/turkey infection) and 27 dpi (A/Indonesia infection). Infection of the 
brain with A/Indonesia may occur later than with A/turkey (severe neurological 
signs after A/Indonesia inoculation became apparent at 7 dpi, compared to 
4 dpi after A/turkey inoculation) and could explain the histopathological and 
immuno-histochemical differences seen between these virus strains at 3 dpi. 
Virus was isolated from the oropharynx in a limited numberofvaccinated 
pigeons (A/Indonesia: 1 0%; A/turkey: 36%) for 1 dpi (Figure 3). Oropharyngeal 
swabs were positive by RT-PCR in vaccinated birds up to 5 dpi (A/Indonesia 
infection), compared to 11 dpi in sham-vaccinated pigeons. Virus detected 
and isolated at 1 dpi (maximum virus titre isolated: 103·2 TCID5/ml) may be 
residual virus from the inoculation one day prior to swab collection (inoculation 
dose was 108 TCID5/ml), and does not confirm replication on the first day. 
Cloacal swabs were positive in a small number of vaccinated pigeons by RT-
PCR at two dpi (A/turkey and A/Indonesia) and 9 dpi (A/Indonesia), although 
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viral loads were extremely low. No infectious virus was isolated from cloacal 
swabs, regardless of vaccination status. Vaccination thus effectively reduces 
the threat of H5N1-infected pigeons as a source of virus by excretion. 
Consolidation of only the cauda-ventral left lung in all inoculated 
pigeons at 3 dpi can be attributed to the mode of inoculation, as birds in the 
isolator at the time of inoculation were held in a left-lateral position - and 
therefore the virus inoculum was deposited in the left lung. 
Although previous studies have shown the low susceptibility of pigeons 
to HPAI H5N1 virus infection, with 21% mortality after infection with a strain 
from 2003 407 , morbidity and mortality in the present study are even lower, using 
the same virus doses for challenge. A possible immune-modulating effect of 
the Salmonella and Trichomonas infection prior to HPAI virus challenge in the 
present study cannot be excluded. Several bacteria species and cholera toxin 
can activate macrophages non-specifically and enhance cytokine production, 
causing subsequent enhancement of the adaptive immune responses against 
influenza viruses in mice 422424 . The effect of Salmonella and Trichomonas 
infection on the innate immunity of pigeons against influenza viruses has not 
been documented. 
In conclusion, although the susceptibility of pigeons to high dose 
challenge with these two HPAI H5N1 virus strains is relatively low, with low 
morbidity and mortality, virus spreads systemically to different organs - virus 
was isolated from organs up to 5 dpi, and limited shedding of virus via the 
respiratory route takes place for up to 4 days. Vaccination is safe, and prevents 
severe clinical signs and mortality, limits extra-respiratory infection of both 
virus strains, provides partial protection against lung infection and disease 
(after A/Indonesia infection), and limits virus shedding to 1 dpi, although the 
presence of infectious virus in lung and air sacs at 3 dpi could still pose a risk 
to predators and scavengers. 
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Summarising Discussion 
In part adapted from: 
Opinion of the Scientific Panel on Animal Health and 
Welfare on a request from the Commission related 
with the vaccination against avian influenza of HS and 
H7 subtypes as a preventive measure carried out in 
Member States in birds kept in zoos under Community 
approved programmes. The EFSA Journal (2007) 200 
(first draft prepared by J. Philippa, in close collaboration 
with J.Pujols Romeu, W Schaftenaar, M. Hartmann, 
R. Fouchier, E. Sos, O.Rib6, H.Fernandez and A. 
Osterhaus). 
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Infectious diseases can have great impact on free-ranging and captive 
populations of non-domestic animals. Our understanding of the prevalence 
of infectious diseases in free-ranging animals is limited. Early detection 
by laboratory and syndromic surveillance plays a major role in managing 
outbreaks of such infectious diseases. Surveillance for certain viruses, 
especially those with zoonotic potential like avian influenza viruses, is currently 
being conducted on a large scale in free-ranging species. From these studies 
we have learned that free-ranging birds play a crucial role in the persistence 
of avian influenza and that a large number of avian and mammalian species 
are susceptible to infection with these viruses. Preventive vaccination is one 
of the tools that can be used to combat infections in individual animals and 
large scale outbreaks. However, little is known about the efficacy of vaccines, 
which have been produced for domestic animals, in non-domestic species. 
This thesis focuses on the efficacy of preventive vaccination of captive non-
domestic species against two groups of viruses which have caused large 
outbreaks in free-ranging and captive animal populations: morbilliviruses and 
highly pathogenic avian influenza (HPAI) viruses. 
Serologic surveys for antibodies to selected pathogens in free-
ranging species 
Since the 1980's, emerging and re-emerging infectious diseases have 
made an enormous impact on public and animal health. Although emergence 
and re-emergence of infectious diseases can in part be attributed to improved 
interest or attention and diagnostic methods, the foremost cause should be 
sought in changes in human behaviour. These changes in human behaviour 
have resulted in, amongst others, a shrinking orfragmentedwildlife habitat which 
has changed population numbers and in some areas has caused increased 
population densities. An increased population density can result in increased 
inter- and intra-species contacts and exposure to new pathogens, dependent 
on contact rates and pathogen transmission. The ability of a pathogen to 
infect multiple hosts, including hosts in other taxonomic orders, poses a direct 
threat of the "spill-over'' of infectious agents from reservoir (domestic and non-
domestic) animal populations to other susceptible species. The translocation 
of wildlife for rehabilitation, conservation, agriculture, or hunting can bring an 
additional inherent risk of exposure of free-ranging species to new infectious 
agents by connecting populations that were previously separated. 
Early detection of outbreaks, by improved surveillance in wild and 
domestic animals for (zoonotic) pathogens is critical for the management 
of emerging infections 10•11 •16. Improved surveillance for infectious diseases 
in animals can thus aid in disease management of both human and (free-
ranging) animal populations. There are many examples of projects in which 
free-ranging animals are trapped or otherwise caught for reasons other than 
serum collection, and additional collection and storage of serum samples from 
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these animals can prove to be of use in identification of causative agents 
of outbreaks, or retrospective epidemiological studies. Serologic surveys can 
provide information on the prevalence of viral infections in species of free-
ranging non-domestic animals. Although the resulting morbidity or mortality 
caused by these infections is often not known, these surveys may help to 
guide further studies on the impact of infectious diseases on free-ranging 
populations, and provide information to (future) rehabilitation and translocation 
projects. 
Such a collection of stored sera or whole blood samples, collected 
from several species of monitored or hunted free-ranging terrestrial carnivores 
and marine mammals in Canada, were used to evaluate the prevalence of 
antibodies to selected pathogens in these species (Chapter 2.2.1.). Between 
1984 and 2000, samples were taken at several locations in Canada from 
cougars (Felis concolor), lynxes (Felis lynx), American badgers (Taxidea taxus), 
fishers (Maries pennanti), wolverines (Gulo gulo), wolves (Canis lupus), black 
bears (Ursus americanus), grizzly bears (Ursus arctos), polar bears (Ursus 
maritimus), walruses (Odobenus rosmarus), and belugas (Delphinapterus 
leucas). We documented the presence of antibodies against a number of 
viruses in species in which these infections have not been reported before: 
antibodies to CAV in walruses, to PDV in black bears, grizzly bears, polar 
bears, lynxes, and wolves, to DMV in grizzly bears, polar bears, walruses 
and wolves, to CPIV in black bears and fishers, and to DRV in belugas and 
walruses. We found regional differences in the prevalences of the different 
pathogens in some of the species tested. These may be related to differences 
in population densities of the species tested, or in the contact rate with other 
species (including domestic species) that may act as sources of infection. 
For example, the wolverines were sampled in very remote areas, where 
less exposure to sources of infection may be a possible explanation for the 
absence of antibodies to any of the pathogens tested for. In several species 
the antibody response was directed at more than one of the morbilliviruses 
tested for (CDV, PDV, and DMV). The presence of antibodies to the two 
morbilliviruses which are usually associated with marine mammals (PDV and 
DMV) in terrestrial species was surprising. All the morbilliviruses exhibit cross-
reactivity in serological assays, but titres are highest against the homologous 
virus 269 . Titres indicated infection of some of the terrestrial species with not 
only CDV, but also PDV and DMV. 
Another use of serum banks was to study the potential risk of viral 
disease on a small population of endangered European mink (Mustela lutreola), 
in an area where future re-introduction of this species may be performed 
(Chapter 2.2.2.). The European mink, a small semi-aquatic mustelid, has 
withdrawn dramatically from its former territory during the last century and 
is currently listed as endangered by the IUCN. Reasons implicated for the 
decline include excessive trapping, change or loss of habitat, interspecies 
competition by the larger American mink (Mustela vison), and mortality from 
infectious diseases. Breeding programmes have been set up in Estonia and 
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Spain with the intention of releasing European mink into its former territory, to 
aid in the conservation of this species. In order to investigate the possible role 
of selected pathogens in the decline of the endangered European mink, and 
the risk of infection of captive-bred European mink to be released in the area, 
a serologic survey was conducted. Sera were collected from 481 free-ranging 
individual animals of five mustelid species trapped between March 1996 and 
2003 in monitoring projects or pest-control programmes in eight departments 
of South-western France. Antibodies to CDV were detected in all species, 
i.e., in 8.7% of 127 European mink, 20% of 210 polecats (Mustela putorius), 
5% of 112 American mink, 33% of 21 stone marten (Martes foina) and 5% 
of 20 pine marten (Martes martes). Prevalences were significantly higher in 
stone marten and polecats, possibly in relation with their habitat which is in 
closer proximity to humans (and therefore domestic carnivores which may 
have acted as a source of the virus) than the other species tested. Antibodies 
to CAV were detected in all species but the pine marten, with seroprevalence 
ranging from 2 to 10%. Seroprevalence of CPIV was 1% in European mink, 
1% in American mink and 5% in polecats, and was not detected in Martes 
species. The detection of antibodies to RV in three animals was surprising, as 
the sampling area is considered to be rabies-free, but may rather be due to 
spill-over of closely related bat-lyssa viruses, which cannot be distinguished 
by the serological methods used. Alternatively it may be due to non-specific 
reactions in the ELISA used. Indeed normally the cut-off used in this assay 
is rather 100 than 50, which was used here. Therefore a non-specific nature 
of this borderline titre is a more likely explanation. The high prevalence and 
number of species with documented antibodies to CDV suggests that this 
pathogen could have significant effects on the highly susceptible free-ranging 
mustelid populations, and has several implications for the conservation and 
re-introduction of the endangered European mink: (1) European mink to be 
released into areas with endemic CDV, or where prevalence is high due to an 
external source, should be vaccinated before release; (2) domestic dogs and 
hunting hounds, likely sources of virus for free-ranging carnivores, should be 
vaccinated in designated release areas; (3) pest-trapping programmes (which 
sometimes accidentally trap European mink), should use proper disinfection 
of traps to exclude traps as sources of infection. 
The above mentioned sera-surveys in Canada and France have 
shown that CDV is common pathogen in many free-ranging carnivore species. 
All families of the taxonomic order Carnivora are susceptible to infection with 
CDV, a morbillivirus which is among the most significant infectious agents 
of domestic dogs and many non-domestic species in terms of morbidity and 
mortality. These vary per species, but case-fatality rate in narve susceptible 
species can be as high as 100%. Outbreaks of CDV and the closely related 
PDV have caused large scale epidemics in naive (and highly fragmented) 
populations of terrestrial carnivores and marine mammals. 
Although antibodies to morbilliviruses were found in sera from all the 
locations in Canada, and throughout the sampled area in France, suggesting 
4. 
that they are widespread among free-ranging carnivores, there have been 
no mass mortalities associated with CDV infection in free-ranging animals 
in Canada or France, although there certainly is CDV-infection associated 
mortality. This may be explained by low susceptibility to infection or the 
low population density of some of the species tested (e.g., bears), which 
decreases the likelihood of a mass mortality. Mortalities of some of the more 
susceptible species (e.g., the mustelids) may go by unnoticed due to their 
small size. Alternatively, the levels of seroprevalence suggests that CDV is 
endemic (i.e., it is able to persist in a population for a long time without the 
need for introducing new infectious animals from external populations) in 
certain species and test areas, in which case mortality would be spread more 
evenly throughout the year, and go by unnoticed. 
Clinical signs of PDV infection in harbour seals 
In contrast to the above-studies species in Canada and France, in 
which no mass mortalities due to morbillivirus infections were recorded, the 
Northern European harbour seal (Phoca vitulina) population experienced 
two mass mortality events caused by PDV infection: one in 1988, and one in 
2002. Interestingly, at the time of writing (July 2007) there are indications that 
increased mortality due to a morbillivirus infection has recently taken place at 
the same location in Denmark as where the previous two epidemics started. 
During the most recent PDV epidemic that occurred in 2002, when 22 000 
seals died, the clinical signs were recorded for 20 harbour seal pups that 
were admitted to the Seal Rehabilitation and Research Centre (SRRC) with 
clinical disease suggestive of PDV-associated disease. They were diagnosed 
by RT-PCR at necropsy to have indeed died from PDV infection (Chapter 
2.1.). Clinical signs are recorded for every animal that is admitted to the 
SRRC, and due to a higher presumed prevalence of neurological signs than 
expected from published data and experiences from the 1988 PDV epidemic, 
the clinical signs of seals with a confirmed PDV infection were evaluated to 
confirm this presumption. The most prominent clinical signs were respiratory 
signs of variable extent in 100%, conjunctivitis in about 70%, and neurological 
signs in about 50% of the infected seals. Severe neurological signs were one 
of the euthanasia criteria during the epidemic, and a large number of juvenile 
seals that were euthanised on humane grounds outside the SRRC could not 
be included in this study, because a full data set (including haematology and 
serum biochemistry) was not available. Documented clinical signs during the 
1988 epidemic suggested a much lower occurrence of neurological signs, 
confirming the suspicion of a higher prevalence of neurological signs in 2002. 
At time of admittance, a higher percentage of seals had a positive serum 
immunoglobulin (lgG) titre compared to lgM titres, suggesting that seals were 
in a relatively late stage of infection, and making the detection of lgG titres a 
useful diagnostic method. This was possible because the seroprevalence of 
PDV-specific serum antibodies in the harbour seal population had declined 
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to negligible levels after the 1988 epidemic. High levels of lgG at admittance 
were not correlated to absence of clinical signs or longer survival. Reported 
lymphoid depletion in dead seals collected during the epidemic was not 
reflected in the total mononuclear leukocyte count of seals upon admittance. 
Haematological tests further showed absolute granulocytosis, thrombocytosis, 
anaemia, and an increase in total white blood cell count in most of the animals 
evaluated. 
Vaccination against morbillivirus infections 
In zoos and rehabilitation projects, infection risks can be minimised by 
reducing contact with unvaccinated wild or domestic species through proper 
fencing, the use of strict hygiene, and implementation of quarantine protocols 
for animals before they enter into the collection. In rehabilitation centres, 
health and immunological status of animals upon admittance are likely to be 
compromised, and the high population densities cause higher intra-, and often 
inter-species contact rates than in natural situations. When quarantine and 
hygienic protocols are not strictly adhered to, the risk of infection increases. 
Preventive vaccination cannot be a substitute for proper quarantine and 
hygienic measures, but it is one of the tools that lowers infection risks, and 
can be used to prevent infections in individual animals, as well as large scale 
outbreaks. 
A problem faced with vaccination of non-domestic carnivores against 
morbilliviruses - a major cause of mortality in these species - is the variation 
between and within species in their susceptibility to modified-live virus (MLV) 
vaccines. Many species have been documented with CDV vaccine-induced 
canine distemper with often lethal consequences. Currently the commercially 
available vaccines in the EU are all MLV vaccines. Safer alternatives would be 
inactivated vaccines, which do not cause infections, but their ability to induce 
an adequate immune response is much lower than that of their attenuated 
counterparts. Currently there are no inactivated CDV vaccines commercially 
available. Other safe alternatives are experimental subunit and recombinant 
vaccines, the latter of which is commercially available and is authorised for 
use in ferrets in the USA, but not in the EU. 
A prime example of the beneficial effects of stringent hygiene and 
quarantine measures in combination with safe and effective vaccination was 
seen in the SRRC during the PDV outbreak in 2002. Harbour seals were 
vaccinated using a CDV immune-stimulating complex (ISCOM) vaccine 
(developed during the PDV outbreak in 1988) upon entry into quarantine 
units, which they left after 30 days if they show no clinical signs of disease and 
after vaccine-induced antibodies had been determined. The close antigenic 
relationship between CDV and PDV provides cross-protection against both 
of these morbilliviruses. The duration of protective immunity following this 
vaccination in seals is unknown, but it is intended to last for at least the duration 
of stay in the rehabilitation centre. Seals that had left the quarantine units, 
167 
4. 
but which were still present in the SRRC while PDV-infected animals were 
admitted (into quarantine units), remained free from PDV-related morbidity 
and mortality throughout the duration of the epidemic. 
Vaccination of European mink against CDV 
The endangered European mink is highly susceptible to infection 
with CDV, and MLV vaccine-induced CDV infections have been reported in 
this species 126•323 . Safe and effective vaccination against CDV in European 
mink would be especially useful in breeding centres aiming at re-introduction 
of the species, where the population density is high, while the vaccine-
induced immunity obtained would benefit survival of these animals upon 
release into CDV-endemic areas. However, currently there is no safe and 
effective commercially available CDV vaccine for use in highly susceptible 
non-domestic species like the European mink. We evaluated the safety and 
efficacy of the experimental CDV vaccine used in seals (CDV-ISCOM, 10 IJg/ 
ml, ErasmusMC, Rotterdam, The Netherlands) and a recombinant vaccine 
(Purevax®, Merial, Duluth, USA) which is commercially available outside the 
EU, in European mink (Chapter 2.3.1.). Both vaccines were safe and induced 
antibodies to CDV, although the ISCOM did so sooner, and geometric mean 
titres (GMT) were generally higher than those induced by the recombinant 
vaccine. One year after the third vaccination, antibodies were still present in 
both groups, although GMTs were higher in the ISCOM vaccinated group, 
and percentage of animals with a high VN titre (;::: 80) was 100%, compared to 
much lower percentages in the recombinant vaccine group. 
Serum antibody titres measured by ELISA followed a similar trend as 
those measured by VN test, but were generally higher. The VN test is regarded 
the gold standard method for determination of immunity to morbilliviruses339 
because it measures functional neutralising antibodies, directed at the 
haemagglutinin (H) and fusion (F) surface proteins ofthe virus 425 . The ELISA, 
which is based on Vera cell culture-grown detergent-treated virus antigens, 
detects antibodies directed at the H and F surface proteins of the virus, but it 
also detects antibodies against the nucleoprotein (NP) antigen and possibly 
cell components. Antibodies to NP do not contribute directly to neutralisation 
and are therefore missed in a VN test; nevertheless, antibodies against these 
structures are abundantly produced in response to infection or vaccination 
with conventional vaccines 357, although not in response to the ISCOM- or 
recombinant vaccinations. Using an ELISA with Vera cell lysate to determine 
background optical densities excludes serum antibodies directed at the Vera 
cell components from the results. The ELISA furthermore detects antibodies 
directed at a large range of epitopes on the H and F proteins, not only the 
conformational epitopes, and titres will thus be higher than those measured 
in the VN test. 
These results suggest that while both vaccines induce a humoral 
response, the CDV-ISCOM vaccine would protect European mink better 
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against CDV infection based on the induction of higher antibody titres in this 
species. However, the contribution of other protective mechanisms induced 
by vaccination with either of these vaccines, such as induction of cellular 
immunity should also be considered. Obviously, final conclusions about 
efficacy of these vaccines could come from challenge experiments, which are 
not appropriate given the endangered status of this species, 
Vaccination of African wild dogs against CDV 
The African wild dog (Lycaon pictus) is one of the most endangered 
species of the taxonomic family Canidae. They once ranged widely throughout 
39 sub-Saharan African countries, but currently their population is estimated at 
3 000- 5 500, in 15 countries. Their dramatic decline is largely due to human 
persecution (snaring, shooting, and road accidents), habitat fragmentation, 
reduced prey availability, competition with other carnivores, and diseases. 
A fragmented wildlife habitat has altered population numbers and densities, 
and resulted in increased inter-species contacts (including with unvaccinated 
domestic dogs) and exposure to new pathogens such as CDV and rabies. 
We evaluated the safety and efficacy of the same CDV-ISCOM and 
recombinant vaccine (Purevax®) in African wild dogs (Chapter 2.3.2.) as we 
have done for the European mink. For both vaccines, two vaccine doses 
were required to induce antibody titres, although the GMT and percentage of 
animals with a high antibody titre tested by VN was very low (ISCOM group: 
GMT 8 and 8%; recombinant group: GMT 28 and 25%). One year post-
vaccination the percentage of animals with high VN serum antibody titres was 
higher in the recombinant group than in the ISCOM group (39% vs 0%). The 
increase in GMT and percentage of animals with high titres one year after 
three vaccinations, compared to those after two vaccinations, suggest that 
the antibody responses of the animals were boosted by the administration 
of the third vaccine dose, although no blood was collected at the time of the 
expected peak in antibody titres. 
These results indicated that both vaccines were safe but, using 
vaccine-induced VN antibodies as a correlate of protection, neither vaccine was 
sufficiently efficacious (the recombinant vaccine was slightly more efficacious). 
Surprisingly, vaccination did induce satisfactory antibody titres detected by 
ELISA (GMT: 80; 85% ;:: 80 and GMT: 84; 69% ;:: 80 for the recombinant and 
ISCOM groups respectively), suggesting that ISCOM vaccination does induce 
CDV specific antibodies in African wild dogs, although they do not neutralise 
virus in the VN test. As previously stated in the discussion on antibody titres 
in European mink, the ELISA measures antibodies directed at a much larger 
range of epitopes than the VN test, which is regarded as the gold standard 
method for determination of immunity to morbilliviruses. However, the observed 
discrepancy between VN and ELISA titres after ISCOM vaccination of African 
wild dogs was not observed in similar vaccination evaluations in European 
mink vaccinated with the same batch of CDV-ISCOM vaccine, as discussed 
'169 
previously (Chapter 2.3.1 ). There was no interruption of the cold chain required 
for preservation of the CDV-ISCOM vaccine as was previously suggested 
as one of the possible causes of vaccine failure in African wild dogs 13 . The 
antigen concentration used in the ISCOM may have been too low, although 
this concentration has proven to be efficacious in terms of VN serum antibody 
titre induction in many other non-domestic species. It therefore appears that 
the reason for this discrepancy should be sought in the intrinsic capability/ 
inability of the African wild dog to produce neutral ising antibodies in response 
to CDV-vaccination. The population bottleneck created by the decimated and 
fragmented populations of African wild dogs may have resulted in a lack of 
genetic variability of this species, which subsequently can have had negative 
consequences for the immune system. This may have led to a sub-optimal 
response to a vaccine that may also have sub-optimal characteristics for this 
species. 
Vaccination of carnivores in Rotterdam Zoo against CDV 
In Rotterdam Zoo several CDV-susceptible species are housed, which 
are vaccinated with CDV-ISCOM using standard protocols: juvenile animals 
are vaccinated 3 times at 3 week intervals, starting at around 10 weeks of 
age, and re-vaccinated annually with one vaccine dose. Adult animals of 
unknown vaccination status are vaccinated twice with 3-4 weeks interval, and 
re-vaccinated annually. At time of vaccination a blood sample is collected and 
CDV-specific antibodies are determined by ELISA and VN test. To evaluate 
the CDV-ISCOM vaccine-induced antibody responses, only those animals 
with no prior vaccination history were used, as prior vaccination may influence 
the efficacy of the CDV-ISCOM, and influences the results. No comparisons 
could be made with the efficacy of the recombinant vaccine in these species, 
as its use is not permitted in the EU. 
Red pandas (Ai/urus fu/gens), members of the taxonomic family 
Ailuridae, are highly susceptible to CDV infection, and were reported with 
vaccine-induced distemper in 1976 120 . In Rotterdam Zoo pandas had 
previously been vaccinated with a CDV-ISCOM, and data were available for 
16 animals (Figure 1: triangles). The GMTs measured by ELISA were low, 
and a number of animals did not seroconvert at all. However, during the last 
five years the red pandas reacted to vaccination with higher antibody titres, 
and results are therefore depicted separately from those from previous years. 
The total antigen concentration of the CDV-ISCOM previously used was 5 
!Jg/ml, whereas the CDV-ISCOMS used in the last 5 years contained 10 !Jg/ml, 
and higher titres were induced, measured by both ELISA and VN (Figure 1: 
circles). Other species discussed in the following section were vaccinated with 
the vaccine with higher antigen concentration ( 1 0 !Jg/ml). 
Maned wolves (Chrysocyon brachyurus) of the taxonomic family 
Canidae, are very susceptible to CDV infection, and have been reported with 
vaccine-induced CDV infection previously. CDV-ISCOM vaccination could be 
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evaluated in two animals in Rotterdam Zoo (Figure 2). 
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Figures 1 to 5.Antibody titres induced by CDV-ISCOM vaccination, with an antigen 
concentration of 10f.Jg/ml, in several species: red pandas, Ai/urus fu/gens (Figure 
1 ), maned wolves, Chrysocyon brachyurus (Figure 2), Asiatic small-clawed 
otters, Amblonyx cinereus (Figure 3), European otters, Lutra lutra (Figure 4) and 
Malay civets, Viverra tangalunga (Figure 5). The animals were kept in Rotterdam 
Zoo, and vaccinated three times with three weeks interval, then yearly with one 
vaccine dose. Blood was collected at times of vaccination. White circles depict 
serum antibodies measured by ELISA, black circles depict serum antibody titres 
measured by virus neutralisation test, and black triangles depict serum antibody 
titres measured by ELISA in response to vaccination with a CDV-ISCOM vaccine 
with an antigen concentration of 5f.Jg/ml. 
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CDV infections have been described in different species of the 
subgroup Lutrinae (family Mustelidae): captive and free-ranging Eurasian 
otters (Lutra /utra) 426-428 , Asiatic small-clawed otters (Aonyx cinerea), (W. 
Schaftenaar pers. comm), as well as North American river otters (Lutra 
canadensis), and serologic surveys have shown the presence of antibodies 
against CDV in free-living North American river otters 273•429 . We evaluated 
three Asiatic small-clawed otters (Figure 3) and two European otters (Figure 
4) in Rotterdam Zoo. 
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The Malay civet (Viverra tangalunga) is a member of the taxonomic 
family Viverridae, which has previously been documented to be susceptible 
to CDV infection 115• In Rotterdam Zoo we evaluated 5 Malay civets for three 
years after first CDV-ISCOM vaccination, and three animals for 4 years (Figure 
5). 
Figure 5. 
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In general, most species needed two vaccinations before antibody 
titres were induced. The two otter species were the only species that had 
detectable antibodies after one vaccination. Antibody titres ~ 40 were induced 
by two vaccinations in all animals. From the limited data obtained in Rotterdam 
Zoo, three weeks after the third vaccination, the antibody titre had increased 
further. One year after the initial three vaccinations, antibody levels dropped 
substantially in most species evaluated. Re-vaccination with one yearly vaccine 
dose following the initial vaccinations boosted the GMT to higher values, and 
antibodies remained present using yearly revaccination. GMT determined 
by ELISA was generally higher than, or equal to those determined by VN. 
Big discrepancies between ELISA and VN titres, as were seen in African wild 
dogs, were not seen in the species evaluated in Rotterdam Zoo. 
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Conclusions: morbilliviruses in non-domestic carnivores 
In this thesis the presence of antibodies against a number of viral 
pathogens in populations of free-ranging non-domestic carnivores, both in 
France and Canada has been shown. The prevalence of antibodies against 
CDVwasthe mostprominentofthevirusestested, and it is knownthatthisvirus, 
and the closely related PDV and DMV have caused major epidemics in non-
domestic species. The high prevalence of antibodies against CDV suggests 
that CDV is endemic in certain areas and species. An infectious agent that does 
not persist in the individual host can only become endemic if the population 
size is large enough (the critical population size), as the pool of susceptible 
individuals in small populations is exhausted rapidly, which leads to extinction 
of the infection. Whether a disease can become endemic furthermore depends 
on e.g., the basic reproduction number, length of latency and infectious period, 
as well as seasonal effects 430 • Fragmentation of habitat as a result of human 
interaction can favour the emergence of morbillivirus epidemics in wildlife by 
creating fragmented (smaller) populations, and additionally by forcing different 
species to co-inhabit certain areas, which may expose naive populations to an 
external source of morbillivirus, causing "virgin soil" epidemics. The ability of 
CDV to infect multiple host species increases the likelihood of its transmission 
to naive populations. Domestic dogs, which have increased contact rates with 
free-ranging species due to an encroachment of human habitation on the 
natural habitat of these species, have been implicated as possible sources of 
CDV infection in a number of epidemics in naive populations of free-ranging 
carnivores and marine mammals (e.g., African wild dogs, African lions, black-
footed ferrets, and Caspian seals 15.92•95-105,344)_ 
Human actions can additionally influence the occurrence of epidemics 
in free-ranging populations through well-intentioned re-introduction and 
translocation programmes which do not take the incidence of infectious 
agents into account. For these programmes to be maximally effective, it is 
important to know the status of infectious agents in the designated area, so 
that animals can obtain suitable levels of vaccine-induced protection before 
release. Equally important is a screening of the animals before release to 
ensure that they do not introduce a new pathogen into the designated release 
area. 
Although serological studies assess immunological responses to 
exposure to infectious agents, no information is obtained concerning the 
disease agents, or their ability to cause clinical disease signs. Future studies 
should thus focus on the isolation and identification of these viruses in order 
to improve our understanding of their epidemiology, pathogenicity, and impact 
(with regards to morbidity or mortality) on free-ranging species. Clinical signs 
documented during a PDV epidemic in harbour seals were substantially 
different from those recorded during an epidemic 14 years earlier, emphasising 
the additional importance of careful documentation of clinical signs. 
Early detection of outbreaks may aid in managing outbreaks of 
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infectious diseases, and can be complemented by vaccination of domestic and 
rehabilitated animals as well as free-ranging animals under certain conditions. 
Management of CDV epidemics in free-ranging species should include 
vaccination of domestic dogs in the area, and should try to restrict contact 
rates between domestic and non-domestic species to reduce the infection risk 
from this source. The same holds true for rabies virus outbreaks. Attention 
should be payed to the possibility of (reduced) excretion of attenuated CDV 
by vaccinated dogs, which are vaccinated with a MLV vaccine, and could 
potentially still infect susceptible non-domestic species. 
We evaluated two candidate CDV vaccines for use in non-domestic 
species. The CDV-ISCOM vaccination was safe and efficacious in terms 
of inducing adequate levels of VN antibody titres in most species tested, 
although numbers per species tested was low for some, and differences in 
response to CDV vaccination were seen in these studies. Antibody titres 
remained at acceptable levels with yearly re-vaccination with one dose. Virus 
neutralising antibodies were induced by the CDV-ISCOM in all species except 
the African wild dog. Although the CDV-ISCOM vaccine performed well in all 
the other non-domestic species tested, neither this vaccine, nor a recombinant 
canarypox-based vaccine that is authorised for use in the USA, induced VN 
antibody levels indicative of protection in African wild dogs. This suggests an 
intrinsic inability of this species's immune system to react adequately to these 
vaccines. 
These studies give an increased knowledge of the effect of preventive 
vaccination against CDV in non-domestic carnivores, but currently no safe and 
efficacious vaccine is authorised in the EU for use in non-domestic species. 
The ISCOM is an experimental vaccine. The safe and efficacious canarypox-
vectored vaccine against CDV is currently not authorised in the EU, because 
it is a genetically-modified organism, even though other canarypox-vectored 
vaccines have been authorised successfully in the EU. To protect susceptible 
non-domestic species in the EU against CDV infection, this, or another safe 
and effective CDV vaccine, should be authorised as soon as possible for use 
in non-domestic species in EU member states. 
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Vaccination of non-domestic avian species against HPAI viruses 
In the European Union, routine vaccination of poultry against avian 
influenza viruses is currently not practised as this would interfere with 
international trade agreements. Instead, eradication measures during an 
outbreak in poultry include (long-term) confinement, humane killing and safe 
disposal of carcasses of all poultry on the infected farm, and, depending on 
the poultry density in the area and the epidemiological situation, pre-emptive 
culling of poultry on neighbouring farms and emergency vaccinations (Directive 
92/94/EEC). Since 2003, more than 220 million birds have been culled to 
eradicate H5N1 HPAI outbreaks. 
The standard measures used to prevent and eradicate HPAI virus 
outbreaks in poultry (long-term confinement and large scale preventive 
culling) would be detrimental to the welfare, conservation status and 
breeding programmes of zoo birds, which often are irreplaceable, valuable 
and endangered avian species (IUCN Red list, http://www.iucnredlist.org/). 
Directive 2005/94/EC foresees a derogation from killing of birds provided 
the birds can be brought inside and are subjected to virus detection tests 
(after the last death/positive finding, 2 tests at an interval of 21 days have 
to be performed according to the diagnostic manual Decision 2006/437/EC). 
However, most zoos do not have the capability to suitably confine their entire 
bird collections for extended time, and many species would not be able to 
adjust to confinement and increased stress with subsequent welfare problems 
and increased exposure to pathogens resulting in disease (e.g., aspergillosis, 
bumblefoot) 192-194• 
Instead of confinement, vaccination of zoo birds against HPAI virus 
was allowed as an additional preventive measure (while reducing confinement 
measures) in Belgian, Dutch and German zoos during an outbreak of HPAI 
H7N7 virus in poultry in 2003 (Decision 2003/291/EC). Similarly, in 2005, 
Decision 2005/7 44/EC allowed vaccination in European zoos against the 
encroaching H5N1 subtype. Since then, targeted preventive vacclnation 
campaigns as an alternative to indoor confinement have also been authorised 
in poultry. In the Netherlands, voluntary vaccination of hobby poultry and 
free-range laying hens was allowed (Decision 2006/147/EC). In France, it 
was allowed for domestic ducks and geese (Decision 2006/148/EC). These 
campaigns were subject to rigorous surveillance and control requirements. 
During the HPAI H7N7 outbreak in poultry in 2003, birds in Dutch zoos 
were vaccinated twice with six weeks interval using a whole inactivated oil-
adjuvanted vaccine, based on influenza virus Nchicken/ltaly/473/99 (H7N1), 
with high homology to the field strain HPAI H7N7 Nchicken/Netherlands/1/03 
(97.4% nucleotide and 98.7 % amino acid sequence identity of the H gene). 
This resulted in the induction of antibody titres ;:: 40 (used as a correlate of 
protection in this study) in 81.5% of the vaccinated birds, with an overall 
GMT of 190. Birds of the taxonomic orders Anseriformes, Galliformes and 
Phoenicopteriformes showed higher GMT, and larger percentages developed 
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a serum HI antibody titre ::::: 40 than those of the other orders. Furthermore, 
a decrease in antibody response with an increase in body weight > 1.5 kg 
was shown. The high agreement between post vaccination antibody titres 
determined by serum HI test (using the vaccine strain), and VN titres (using 
the field strain), was used as a further measure of immunogenicity. The broad 
efficacy demonstrated in a large variety of taxonomic orders illustrated the 
value of vaccination as an additional preventive measure against HPAI virus 
infection (Chapter 3.1.). 
In 2005, the Dutch zoos were the first to implement Decision 
2005/744/EC to provide protection against the encroaching HPAI H5N1 
subtype. Birds were vaccinated with an inactivated adjuvanted H5N2 vaccine 
with vaccine doses adapted to mean body weight per species, using data 
collected during the H7N1 vaccination campaign. The vaccine strain (A/duck/ 
Pottsdam/1402/86) had a homology of 90% to the H gene of the H5N1 field 
strain (A/turkey/Turkey/1/05) on the basis of nucleotide sequence (1530 base 
pairs, including basic cleavage site), and 92.4% on the basis of amino acids. 
Vaccination was safe, and proved immunogenic throughout the range of 
species tested, with some variations between and within taxonomic orders. 
After booster vaccination the overall homologous GMT to the vaccine strain, 
measured in 334 birds, was 190 (95% Cl: 152-236), and 80.5% of vaccinated 
birds developed a titre of:=::: 40. Titres to the HPAI H5N1 virus followed a similar 
trend, but were lower (GMT: 61 (95% Cl: 49-76); 61%::::: 40) (Chapter 3.2.). 
The breadth of the immune response was further demonstrated by 
measuring antibody titres against prototype strains of four antigenic clades of 
currently circulating H5N1 viruses. Antigenic distances to the prototype strains 
were determined using antigenic cartography 404 . Antigenic cartography uses 
the antigenic properties of influenza viruses in combination with epidemiological 
and genetic data, and is used to select virus strains for use as human pandemic 
(H5N1) vaccine candidates 431 • Influenza vaccines whose haemagglutinins are 
antigenically similar to circulating strains provide the highest level of protection 
from infection in humans 432 . The birds clustered in two groups based on 
the breadth of antibody responses. Group 1 (Anseriformes, Galliformes, 
Phoenicopteriformes, Psittaciformes and Struthioniformes) showed a very 
broad response to vaccination, with predicted protection against future strains 
up to 12 antigenic units from the current vaccine. Group 2 (Ciconiiformes, 
Gruiformes, Pelecaniformes and Sphenisciformes) had low HI antibody 
titres against the prototype strain of the most antigenically distant clade (AI 
I ndonesia/5/05). 
In 2006, a working group of animal health and welfare experts was 
established by the European Food Safety Authority (EFSA), to provide a 
scientific assessment of the preventive vaccination against avian influenza 
of H5 and H7 subtypes carried out in zoos in Member States (MS). The total 
number of birds vaccinated, as reported by 12 MS, was 44721. Individual data 
from 4718 birds (374 species from 19 taxonomic orders) were submitted. Not 
all of these could be used for every evaluation: pre-vaccination titres could be 
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evaluated for 3039 birds; titres after first vaccination were evaluated for 1429 
birds, and post-second vaccination titres for 2296 birds. 
Differences in vaccination schedules, doses and routes, differences 
in methodology and antigens used in the HI tests between laboratories (due 
to the absence of international reference standards, and the absence of inter-
laboratory standardisation of methodology), the use of different vaccines1 
in different taxonomic orders and the sometimes incomplete reporting of 
results, limited the evaluation of some of the data provided by EU MS. Cut-off 
points varied with laboratory, and titres considered a measure of adequate 
immune response were 8, 16, 32, 40, and 64. Most countries used dilution 
series starting at 4 or 8, therefore results were evaluated for titres 16 and 
32 (documented surrogate markers for protection in chickens 154.181 ·183.186), 
and undetectable titres were regarded as 4 for calculation of GMT. In the 
absence of (and unfeasibility of obtaining) vaccination/challenge data in often 
endangered zoo bird species, the evaluation had to be based on extrapolation 
of serological data from poultry and limited other bird species. 
The H5 and H7 vaccines registered for poultry in the EU showed 
differences in efficacy, measured as serum HI antibodies induced by two 
doses of vaccine (Annex 1 ). Three of the five vaccines evaluated induced 
relatively high GMT and high percentage seroconversion in the vast majority 
of vaccinated birds. The HI titres induced by vaccination showed marked 
differences between and within taxonomic orders. Both routes of vaccination 
(i.m. and s.c.) were effective in inducing HI serum antibody responses, and 
for most avian species the poultry dose was suitable. In some larger species 
higher doses, adjusted to body weight, induced higher serum antibody titres. 
(e.g., for ostriches a 1 0-fold increase of the poultry dose: 10 x 0.25 mi. However, 
extremely high doses at a single site of injection (e.g., vaccination of ostriches 
with 10 ml of vaccine) appeared to have a negative effect on the induction of 
serum antibody titres, and induced local adverse reactions. 
There were indications that one vaccination was sufficient to induce 
high serum antibody titres in at least two taxonomic orders of birds. However, 
a second vaccine administration ensured seroconversion in the majority of 
birds of most species. Limited data indicated that antibody titres persisted in 
several species for six months after vaccination. Adverse effects and mortality 
associated with vaccination were low and were mainly attributable to handling 
stress or trauma. Differences in adverse effects reported from different zoos 
highlight the importance of proper skilled handling. 
Vaccine A: H5N9 (Nturkey/Wisconsin/68). 
Vaccine B: H5N2 (Nduck/Pottsdam/1402/86). 
Vaccine C: H5N2 (Nchicken/Mexico/232/94/CPA). 
Vaccine D: H5N9 (Nchicken/ltaly/22N98). 
Vaccine E: H5N9 (Nchicken/ltaly/22NH5N9/1998). 
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longevity of serum antibodies in non-domestic avian species 
upon vaccination against HPAI viruses 
One year after vaccination with the H5N2 vaccine, birds in Dutch 
zoos were revaccinated with the same vaccine. Antibody titres one year after 
the initial two vaccinations and the effect of one booster vaccination at this 
time were evaluated. In Rotterdam Zoo, 72 previously vaccinated birds could 
be evaluated for the effect of one booster vaccination (Chapter 3.3.). For 
44 birds, serum samples were available from 4 weeks after the initial two 
vaccinations the previous year, at the time of revaccination, and 4 weeks later. 
Birds which had been vaccinated with the H7 vaccine two years prior to the 
H5N2 revaccination were additionally tested for the presence of H7 -specific 
antibodies. 
Serum collected at the time of revaccination had to be tested at the 
National veterinary reference laboratory, while previously this was done at the 
ErasmusMC. In order to compare titres, the correlation between results from 
these two laboratories was determined by sub-sampling 141 serum samples 
and conducting the tests at both laboratories. The correlation coefficient of the 
results from the two laboratories was high (CC=0.87). 
Serum antibody titres of the birds tested in Rotterdam Zoo had 
clearly decreased in one year time: while 80% of birds had a positive titre (~ 
8) and 68% a high positive titre (~ 32) after 2 vaccinations, these figures were 
61% and 30% respectively one year later. Four weeks after re-vaccination 
these figures increased to 93% and 77% respectively. Although a larger 
percentage of these 44 birds had a serum HI antibody titre ~ 32 after re-
vaccination, the GMT was lower than GMT after 2 vaccine doses one year 
before (88 vs 66). 
As previously reported for the initial 2 vaccine doses, there were 
differences in responses between taxonomic orders. Of all birds tested (8 
taxonomic orders) 4 orders did not have a GMT> 5 one year after vaccination, 
and only one order (Phoenicopteriformes) had a GMT> 40. Four weeks after 
revaccination 6/8 taxonomic orders tested had a GMT> 40. 
GMTs had decreased even further two years after vaccination, as was 
shown by the H7 specific serum HI antibody titres (Chapter 3.3.). As these 
birds were not revaccinated with an H7 vaccine, the effect of revaccination two 
years after the initial vaccinations is not known. 
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Vaccination of pigeons against HPAI H5N1 virus. 
Rock pigeons (Columba Iivia) and other orders of the taxonomic order 
Columbiformes have previously been described as being resistant, or at least 
less sensitive, to infection with HPAI virus of the H7 and H5 subtypes, and 
have failed to produce high levels of antibodies after infection or vaccination. 
However, higher susceptibility of pigeons to more recent HPAI virus strains of 
the H5N1 subtype has been documented, and transmission of virus to cats 
which fed on infected pigeons has been shown, although excretion of virus or 
bird-bird transmission has not been documented. Feral pigeons are ubiquitous 
near human settlements, and large numbers of pigeons are kept as pets or 
as racing pigeons, thus potentially posing an infection risk to humans if virus 
excretion would occur. 
We inoculated vaccinated and unvaccinated rock pigeons with high 
doses of highly pathogenic avian influenza virus of the H5N1 subtype from 
two different antigenic clades: A/lndonesia/5/05 (A/Indonesia) or A/turkey/ 
Turkey/1/05 (A/turkey) via the intra-tracheal and intra-oesophageal route 
(Chapter 3.4.). The vaccine strain used (A/duck/Potsdam/2243/84; H5N6) 
had a homology of 87% and 88% to A/turkey and A/Indonesia on the basis 
of nucleotide sequence of the H gene (1692 base pairs, excluding the basic 
cleavage site), and 91.5% and 91.5% on the basis of amino acids respectively. 
Low morbidity and mortality were observed in unvaccinated pigeons, while 
pigeons vaccinated with an inactivated adjuvanted H5N6 vaccine were 
protected from developing clinical signs. Clinical signs of infected animals 
were depression, general malaise, and neurological signs (ataxia, tremors, 
opisthotonus, torticollis). Virus could be re-isolated from several organs at 3 days 
post-inoculation (dpi) (A/Indonesia: lung, airsac, spleen, duodenum; A/turkey: 
brain, lung, airsac, pancreas, spleen, and liver), and immunohistochemistry 
showed the presence of nucleoprotein in the lung, airsac and brain. By RT-
PCR virus could be detected in several organs at 3 and 27 dpi. Infectious 
virus was isolated from oropharyngeal swabs for up to 3 (A/turkey) and 4 dpi 
(A/Indonesia); cloacal swabs remained negative throughout the duration of 
the experiment 
Vaccination was safe, and prevented severe clinical signs and mortality, 
largely limited extra-respiratory infection of both virus strains, provided partial 
protection against lung infection and disease (after A/Indonesia infection), 
and limited virus shedding to one day after experimental infection (which may 
be due to residual virus after the extremely high inoculation dose). However, 
infectious virus was re-isolated from lung and air sacs at 3 dpi, and in one bird 
that died with severe neurological signs it was re-isolated from the brain at 5 
dpi. 
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Conclusions: Vaccination of non-domestic avian species against 
HPAI viruses 
Bio-security measures remain the first line of protection of zoo birds 
against the introduction of AI viruses and should be implemented in zoos. These 
bio-security measures should include strict hygiene and quarantine measures, 
but should also exclude the possibility of introducing AI viruses through feed 
animals such as day old chicks, other poultry or their products. Clinical and 
virological monitoring of captive and wild birds in zoos should be practised 
for early detection of introduced viruses by wild birds, domestic birds, or their 
products. Strict bio-security measures will also reduce the risk of subsequent 
infection of wild birds from zoo birds. Wild birds have been documented to 
be susceptible to HPAI virus infection, and could potentially play a role in the 
spread of HPAI virus, although the majority of avian influenza viruses detected 
in free-ranging birds have been LPAI viruses. If bio-security measures cannot 
sufficiently protect zoo birds from exposure to HPAI viruses coming from wild 
birds (based on an overall risk assessment which includes welfare aspects) 
vaccination with vaccines against HPAI of HS and H7 subtypes authorised 
for use in poultry should be used to protect these zoo birds. In designing AI 
vaccination programmes and schedules for zoo birds, recent data on wild 
bird migration and prevalence of AI virus infections in wild birds should be 
taken into account. Vaccination against AI viruses of the HS and H7 subtypes 
with current inactivated oil-adjuvanted poultry vaccines is safe and, in most 
taxonomic orders of zoo birds, effective in terms of inducing HI serum antibody 
titres. AI vaccines should be administrated in a way that elicits high HI antibody 
titres in the vast majority of the zoo birds vaccinated, i.e., by adjusting dose 
to average body weight. Although there are indications that one vaccination 
might suffice for some species, a second vaccine dose ensures high titres 
in the vast majority of species. Unless it is demonstrated that one vaccine 
administration is sufficient, two administrations are recommended. The HS 
and H7 vaccines currently registered for poultry in the EU show differences in 
the performance in terms of HI response in zoo birds after two doses. There 
appears to be no difference due to route of vaccination (s.c. or i.m.), so route 
can be adjusted to the bird species to be vaccinated. In order to maintain 
high titres in the captive populations in zoological collections, annual re-
vaccination seems to be required, as antibody titres decrease significantly in 
most taxonomic orders, and high titres are seen after a single annual booster 
dose. 
Standard protocols for vaccination, sampling, testing and reporting 
should be established at EU level to optimise evaluation and future 
implementation of AI vaccination programmes for zoo birds (see example 
in Annex 2). Inter-laboratory standardisation of serological assays to detect 
AI serum antibodies in birds should be established. There is a need for 
the preparation of international standard reference sera to facilitate this 
standardisation. 
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Mortality and adverse effects were low in all zoos evaluated in EU MS, 
and mainly attributed to handling stress and trauma. Zoos can, and should 
therefore try to minimise these losses in the execution of HPAI vaccination 
programmes. To minimise indirect losses due to decreased breeding results, 
AI vaccination during breeding seasons should be avoided whenever possible. 
Mortality due to catching and handling stress can be reduced by handling the 
birds less. Once the efficacy of a vaccination protocol has been validated for 
certain species using certain vaccines, measurement of post-vaccination HI 
serum antibody titres should no longer be mandatory by the EU. These birds 
will then only have to be handled for vaccination, and not 4 weeks later. Further 
research should be carried out to establish effective vaccination schedules, 
routes, and dose regimens in different zoo bird species. This may, amongst 
others, lead to a reduction in the number of booster vaccinations needed in 
certain species. Novel generation vaccines which may be administered in the 
form of an aerosol (as is used in vaccination of poultry against Newcastle 
disease virus) may prove to be useful in non-domestic species, and would 
eliminate the need for handling the birds. 
The vaccination campaigns against HPAI virus have focused 
on protecting birds in zoological collections. However, a large number 
of mammalian species, including tigers and leopards, have also been 
documented with HPAI virus infection with recent H5N1 subtypes. There is 
currently no commercial vaccine available to protect mammals from HPAI 
H5N1 virus infection. A recombinant fowlpox-vectored vaccine expressing the 
H5 gene has been shown to produce high antibody titres against heterologous 
H5N1 virus antigen in cats after booster vaccination 433 , and may prove to be 
useful in prophylactic vaccination programs of mammals in the future. Until 
then, these animals have to be protected by bio-security measures such as 
excluding the introduction of AIV through raw poultry used as feed. 
Vaccination has proven to be an effective tool in curtailing outbreaks 
of HPAI virus in poultry, and although infection with subsequent virus excretion 
can still occur, this is drastically decreased in vaccinated animals compared 
to unvaccinated animals. We have shown by challenge infections of pigeons 
with HPAI strains from 2 different antigenic clades that although pigeons are 
not very susceptible to infection, the occurrence of morbidity and mortality is 
decreased by vaccination. Additionally, vaccination reduced spread of virus 
to the different organs, and reduced excretion of the virus. However, the 
presence of viable virus in lung and air sacs of vaccinated pigeons at 3 DPI 
means that infected pigeon carcasses of vaccinated birds could still pose an 
infection risk to predators and scavengers. 
The broad vaccine efficacy in the different avian taxonomic orders 
illustrates that vaccination against avian influenza is a useful tool for the 
protection of non-domestic avian species in zoos, which allows for an alleviation 
of confinement measures- and is therefore beneficial to the health and welfare 
of these birds. However, increased bio-security measures in combination with 
virological monitoring remain imperative in combating outbreaks of HPAI. 
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The European vaccination campaigns in zoos should be seen as an 
additional protective measure to protect the (often irreplaceable, valuable and 
endangered) species in the zoological collections from infection by wild birds 
and other sources, while reducing confinement measures, and concurrently 
reducing the possibility of the zoos becoming a source of infection for wild 
birds. However, poultry farms should be regarded as the major sources of 
HPAI virus, as their birds have documented high susceptibility, excrete large 
amounts of virus, and population densities are high. Increased bio-security 
measures on poultry farms, reduced contact with wild birds (while not 
compromising the poultry welfare), culling and vaccination of poultry will be 
the most important steps in controlling large scale HPAI outbreaks such as the 
H5N1 outbreaks we are currently experiencing. 
GENERAL CONCLUSIONS 
Laboratory and syndromic surveillance of free-ranging non-domestic 
animals plays a major role in early detection, identification and management 
of outbreaks of infectious diseases. In addition, this surveillance can be used 
in re-introduction or translocation projects, where knowledge of the infectious 
disease status of the area can lead to the necessary precautionary measures 
to make these projects maximally successful. Vaccination of non-domestic 
species can be an important additional measure to increased bio-security 
measures in preventing and managing virus infections in these animals. This 
thesis focused on two groups of viruses which have caused major outbreaks: 
morbilliviruses and highly pathogenic avian influenza viruses. In the EU there 
are currently no authorised safe and effective CDV vaccines that can be used 
in non-domestic species. An experimental CDV-ISCOM vaccine performs well 
in most species tested, based on the induction of high levels of VN serum 
antibody titres. A commercial canarypox-based recombinant vaccine that is 
authorised in the USA, is efficacious in terms of inducing VN serum antibody 
titres. However, neither of these vaccines induces adequate serum antibody 
responses in the African wild dog. 
Vaccination of non-domestic avian species against AI viruses with 
poultry vaccines currently authorised in the EU induces adequate HI serum 
antibody responses after two vaccine doses in the majority of species and 
taxonomic orders tested. A yearly booster with one vaccine dose appears to 
be sufficient to maintain adequate antibody levels in these species. 
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Annex 1. HI serum antibody titres after first and second vaccination with an 
H5 vaccine in European zoos. Results are depicted for the different taxonomic 
orders, with the vaccines, intervals, and doses used, based on data submitted by 
EU Member States to the European Food Safety Authority (EFSA) 200• 
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Summarising discussion 
2 4-6 2 5 18 60 40 
2 4-6 2.5 80 100 100 5 151 80 80 
2 4-6 ns 44 11 49 30 55 49 
2 ns 5 32 60 40 3 81 100 100 
3 4-6 ALL 24 6 21 13 29 13 42 42 
3 4-6 3 4 23 75 75 
3 4-6 5 10 10 50 30 10 64 90 90 
3 4-6 
3 4-6 10 14 4 0 14 4 0 
5 3 ALL 30 21 47 43 28 82 82 75 
5 3 22 33 59 55 20 119 85 80 
5 3 ns 6 12 12 8 32 75 63 
Annex 2. Proposed standard protocol for reporting data on AI vaccination in zoo 
birds - European Food Safety Authority (EFSA) 200 
General information 
Route Weight- Dose Interval from last vaccination (specify if regime used Vaccine to post-Country Zoo Vaccine different in (ActuaUestimated interval vaccination different /average weight blood 
species) of species) 
collection 
Individual bird information HI serum antibody titre 
English Latin Taxonomic Individual Weight Vaccine Pre- Post- Post-
name/local 
name Order identification Dose vacc 1st 
2."d 
name (ml) vacc vacc 
Adverse Individual effects Mortality 
Local general Direct Delayed fcatchinq/handlinul (specify cause of death) 
Information required from the Laboratory 
Antigens (virus Cut-eff or end-titre Virus strain of 
strains) used in HI point used as a Reference (reference to] 
vaccine test measure of vaccine serum used Methodology 
efficacy 
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Opkomende infectieziekten 
Opkomende en opnieuw opkomende infectieziekten hebben de 
afgelopen 20 jaar een grote invloed gehad op menselijke en dierlijke 
gezondheid, voedselvoorraden, economieen, biodiversiteit, en het milieu. 
Geschat wordt dat 75% van aile opkomende infectieziekten bij de mens 
zoonotisch (pathogenen van dierlijke oorsprong die ook de mens kunnen 
besmetten) en van virale oorsprong zijn. Sinds 1980 zijn er meer dan 35 
infectieziekten opgekomen bij de mens, waarvan AIDS, SARS, West Nile 
virus infectie, Ebola virus infectie, en vogelgriep wei het meest in de publieke 
belangstelling hebben gestaan. Het recent onderkennen van het opduiken van 
deze ziekten kan deels worden toegeschreven aan verbeterde diagnostische 
technieken, maar de voornaamste oorzaak moet toch worden gezocht in 
onze veranderende wereld. Belangrijke factoren van deze veranderingen in 
het menselijk gedrag zijn: (1) demografische veranderingen: exponentiele 
groei van de bevolking, wereldwijde urbanisatie, het indringen in leefgebieden 
van wilde dieren, (2) sociale veranderingen: globalisatie van de handel, 
vermeerdering van legale en illegale diertransporten en handel in wilde 
dieren (levende dieren en "bushmeat"), (3) veranderingen in ecosystemen: 
ontbossing, eutrophicatie van water en een kleinere populatie van roofdieren 
met ziektedragers als prooi; en (4) klimaatsveranderingen: het opwarmen van 
de aarde. Vee en pluimvee hebben zwaar geleden door directe mortaliteit 
en ruimen van dieren als gevolg van infectieziekten. Zo hebben H5N1 hoog 
pathogene aviaire influenza (HPAI) virus infecties geresulteerd in de dood van 
meer dan 220 miljoen vogels in 41 Ianden in de laatste paar jaar. Het effect 
van opduikende infecties is van speciaal belang voor bedreigde diersoorten, 
die door uitbraken aan de rand van uitsterven kunnen komen te staan. 
Serologische onderzoeken naar antilichamen tegen virale 
infecties 
Het vroeg opsporen van uitbraken door uitgebreide surveillance in 
dieren naar (zoonotische) ziekteverwekkers en ziektepatronen is een kritiek 
onderdeel van het beheersen of voorkomen van uitbraken van deze infecties. 
Het verbinden van uitgebreide surveillance studies naar ziekteverwekkers 
en ziektebeelden in wilde en gedomesticeerde dieren aan soortgelijke 
surveillances bij de mens kan een belangrijke bijdrage leveren aan hetopsporen 
en bestrijden van opduikende (zoonotische) infecties. Er zijn vee! aldan niet 
wetenschappelijke projecten waarin niet-gedomesticeerde dieren worden 
gevangen, en het verzamelen van bloed en opslaan van serum kunnen van 
nut blijken bij het vroeg opsporen van uitbraken, of in retrospectieve studies. 
Serologische studies naar antilichamen tegen verschillende virussen kunnen 
een beeld geven van het v66rkomen van virale infecties in wilde populaties. 
Alhoewel het effect van deze virussen in de verschillende wilde soorten vaak 
21 
Nederlandse 
niet bekend wordt door dit soort onderzoekingen, kunnen ze tach een rol 
spelen in het vroeg opsporen van uitbraken, en informatie verstrekken over de 
ziekteverwekkers bij de betreffende diersoorten in het onderzochte gebied, en 
zo eventuele rehabilitatie- of translocatieprojecten van belangrijke informatie 
voorzien. 
Wij hebben dit soort bloed- of serumbanken meerdere keren 
kunnen gebruiken. Op verschillende locaties in Canada werden serum- en 
bloedmonsters bewaard van de een groat aantal niet-gedomesticeerde 
roofdieren en zeezoogdieren - poema (Felis concolor), lynx (Felis lynx), 
Amerikaanse das (Taxidea taxus), vismarter (Martes pennanti), veelvraat 
(Gulo gulo), wolf (Canis lupus), zwarte beer (Ursus americanus), grizzly 
beer (Ursus arctos), ijsbeer (Ursus maritimus), walrus (Odobenus rosmarus), 
en beloega (Oelphinapterus leucas) - die tussen 1984 en 2000 verzameld 
waren. Deze monsters konden gebruikt worden voor de onderzoekingen 
naar de prevalentie van antilichamen tegen verschillende virussen in deze 
soorten (Hoofdstuk 2.2.1.). Wij hebben antilichamen tegen verschillende 
virussen aangetoond in soorten waarin deze of verwante virussen niet eerder 
zijn beschreven, zoals antilichamen tegen canine adenovirus type 2 (CAV-
2) in walrussen; tegen zeehondenziekte virus/phocine distemper virus (PDV) 
in zwarte beren, grizzly beren, ijsberen, lynxen en wolven, tegen dolfijnen 
morbilli virus (DMV) in grizzly beren, ijsberen, walrussen en wolven; tegen 
canine para-influenza virus in zwarte beren en vismarters, en tegen dolfijnen 
rhabdovirus (DRV) in beloegas en walrussen. Verschillen in het v66rkomen 
van de verschillende ziekteverwekkers kan gerelateerd zijn aan verschillen 
in populatiedichtheid, en de verdeling van andere diersoorten (inclusief 
gedomesticeerde diersoorten) die bronnen van infectie kunnen vormen. Als 
voorbeeld: de veelvraten in deze stu die kwamen uit een afgelegen gebied, waar 
een verminderde blootstelling de reden zou kunnen zijn voor de afwezigheid 
van antilichamen tegen aile ziekteverwekkers waarop we hebben getest. In 
verschillende soorten waren de antilichamen gericht tegen meer dan een van 
de morbillivirussen (hondeziekte virus/canine distemper virus [CDV], PDV 
en DMV) waartop werd getest. De aanwezigheid van antilichamen tegen de 
morbillivirussen welke gewoonlijk in verband worden gebracht met infecties 
in zeezoogdieren (PDV en DMV) in op het land levende roofdieren was 
verrassend. Aile morbillivirussen kruisreageren in serologische testen, maar 
de hoogste antistoftiters worden vrijwel altijd gevonden tegen het homologe 
virus, waardoor het waarschijnlijk is dat in deze dieren naast een infectie met 
CDV, infecties met PDV- of DMV-achtige virussen ook voorkomen. 
Serum opgeslagen in Frankrijk kon worden gebruikt om het potentiele 
risico van virale infecties op een kleine populatie van de Europese nerts 
(Mustela lutreo/a) in een gebied waarin in de toekomst mogelijk gefokte dieren 
worden vrijgelaten voor het behoud van deze soort. De Europese nerts is een 
klein roofdier uit de familie der marterachtigen die zowel op het land als in het 
water actief is. Het is een ernstig bedreigde diersoort die vroeger voorkwam 
in grate delen van Europa, en nu nog slechts in twee gefragmenteerde 
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populaties (een kleine in Zuid-west Frankrijk en Noord-west Spanje, en 
een grotere in Oost Europa) voorkomt. Oorzaken van de achteruitgang zijn 
onder andere stropen, habitat verlies, competitie met de grotere en sterkere 
Amerikaanse nerts (Mustela vison) die in dezelfde gebieden voorkomt 
door ontsnappingen van pelsdierboerderijen en zich nu in Europa heeft 
gevestigd, en ziekten. Fokprogramma's zijn opgezet in Estland en Spanje 
met als doe! het vrijlaten in de gebieden waar ze vroeger voorkwamen, als 
middel om deze soort te behouden in het wild. Om de mogelijke rol van 
infectieziekten op de achteruitgang van de Europese nerts te onderzoeken 
werd een serologisch onderzoek in 480 vrij levende marterachtigen van 
vijf verschillende soorten uitgevoerd die tussen 1996 en 2003 in Zuid-west 
Frankrijk waren gevangen. Antilichamen tegen CDV werden gevonden in aile 
soorten (Europese nerts 8.7%, Amerikaanse nerts 4.5%, bunzing [Muste/a 
putorius] 20.4%, steenmarter [Martes foina] 33.3%, en boommarter [Martes 
martes] 5%). Antilichamen werden vaker gevonden in steenmarters en 
bunzingen, mogelijk als gevolg van de leefomgeving van deze soorten, die 
vee! dichter bij de mens (en dus ook niet-gevaccineerde gedomesticeerde 
dieren) is dan die van de andere soorten. Antilichamen tegen CAV werden 
gevonden in aile soorten behalve de boommarter. Antilichamen tegen canine 
para-influenza virus (CPIV) kwamen voor in !age aantallen Europese nertsen, 
Amerikaanse nertsen en bunzingen, maar in geen van de Martes soorten. Het 
vinden van antilichamen tegen hondsdolheid/rabies virus (RV) in drie dieren 
was verrassend, aangezien het onderzoeksgebied vrij van RV is verklaard. 
Een mogelijke verklaring zou kunnen zijn dat dit antilichamen tegen de nauw 
verwante vleermuislyssa virussen waren, die met de gebruikte methode niet 
kunnen worden onderscheiden van antistoffen tegen RV. Een andere mogelijke 
en misschien wei meer waarschijnlijke verklaring is, dat het hier gaat om niet-
specifieke reacties, omdat de gevonden antilichaam hoeveelheden rond de 
detectiegrens lagen. De hogere prevalentie van antilichamen tegen CDV dan 
die tegen de overige virussen, en het voorkomen van antilichamen tegen CDV 
in aile soorten suggereert dat dit virus een belangrijk effect kan hebben in de 
zeer vatbare soorten van vrij-levende marterachtigen, hetgeen verstrekkende 
gevolgen kan hebben voor het behoud van de ernstig bedreigde Europese 
nerts. 
Aile families van de taxonomische orde Carnivora (roofdieren) zijn 
voor zover bekend vatbaar voor infectie met CDV. lnfectie met dit morbillivirus 
is een van de meest belangrijke ziekten die sterfte veroorzaken. Mortaliteit en 
morbiditeit verschillen per soort, maar sterfte kan tot 100% van ge"lnfecteerde 
dieren oplopen. Uitbraken van infectie met CDV en de nauw-gerelateerde PDV 
hebben grote uitbraken met hoge sterfte veroorzaakt in na"Jeve populaties op 
het land levende roofdieren en zeezoogdieren, en hebben met name plaats 
gevonden in gefragmenteerde populaties. 
Antilichamen tegen de verschillende morbillivirussen werden in sera 
van dieren door heel Canada en door het hele onderzoeksgebied in Frankrijk 
gevonden, hetgeen nogmaals bevestigt dat CDV wijdverspreid onder vrij-
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levende roofdieren voorkomt. Er zijn nooit massale sterftes als gevolg van 
een morbillivirus infectie gerapporteerd in vrij-levende roofdier populaties in 
Canada of Frankrijk. Dit zou kunnen komen door de endemiciteit van het virus, 
een verminderde gevoeligheid, of een lage populatiedichtheid van sommige 
soorten (zoals beren). Een andere mogelijkheid is dat sterfte van sommige 
van de meer vatbare soorten, zoals de marterachtigen, niet opvalt doordat 
de dieren veel kleiner zijn, en daardoor zieke en dode dieren niet gevonden 
worden. 
Klinische symptomen van PDV infectie in gewone zeehonden 
In de zomer van 2002 werd de Noord-Europese gewone zeehond 
(Phoca vitufina) populatie getroffen door een PDV epidemie - zo'n 22 000 
zeehonden stierven als gevolg van dit virus. Klinische symptomen werden 
gedocumenteerd van zeehonden die binnengebracht werden met klinische 
verschijnselen in de zeehondencn3che in Pieterburen gedurende de 
epidemie, waarvan bij sectie door middel van RT-PCR werd vastgesteld 
dat ze ge"infecteerd waren met PDV. De meest prominente klinische 
verschijnselen waren respiratoire symptomen (in 100%), conjunctivitis (in 
70% ), en neurologische symptomen ontwikkelden zich in ongeveer de helft 
van deze zeehonden. Ernstige neurologische verschijnselen waren een 
van de euthanasie-criteria gedurende de epidemie, en een groot aantal 
zeehonden die geeuthanaseerd. werden buiten de creche werden niet in deze 
studie betrokken, door afwezigheid van een complete dataset. De klinische 
symptomen die gedurende de epidemie van 1988 werden gedocumenteerd 
suggereerden een veel lagere incidentie van neurologische symptomen, dus 
was het veelvuldig voorkomen van neurologische symptomen onverwacht 
in 2002. Op het moment van binnenkomst had een groter aantal van de 
zeehonden een imuunglobuline G (lgG) antistof titer, dan een lgM titer. Dit 
suggereert dat de zeehonden binnen werden gebracht in een later stadium 
van de ziekte, en dat lgG titers bij een uitbraak in een na"ive populatie nuttiger 
zijn bij het diagnosticeren van PDV infectie van jonge zeehonden (uit een 
na"ieve populatie) bij aankomst in een opvangcentrum dan lgM titers. De 
hoogte van lgG titers bleek niet gecorreleerd te zijn met het ontbreken van 
klinische symptomen, of met een langere overlevingsduur. De gerapporteerde 
uitputting van de lympho"ide organen in dode zeehonden tijdens de epidemie 
werd niet gereflecteerd in het bloedbeeld bij de zeehonden op de dag van 
aankomst bij de zeehondencreche. De hematologische waarden lieten verder 
een absolute granulocytose, trombocytose, anemie, en een verhoging van de 
totale witte bloedcellen zien. 
Recente technologische ontwikkelingen vergemakkelijken een 
snelle reactie op uitbraken door middel van snelle identificatie van het 
betrokken agens en verbeterde diagnostische methoden, maar ook door 
de beschikbaarheid van specifieke therapieen en vaccinaties. Het gebruik 
hiervan zal zich doorgaans moeten beperken tot in gevangenschap gehouden 
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dieren. 
Vaccinatie tegen morbillivirus infecties 
Vaccinatie is een van de middelen die gebruikt kan worden voor het 
beschermen van individuele dieren tegen infectieuze ziekten, maar ook voor 
het bestrijden van grootschalige uitbraken. In dierentuinen en in opvangcentra 
voor wilde dieren kunnen infectierisico's geminimaliseerd worden door een 
verminderde mogelijkheid van contact met niet-gevaccineerde wilde of 
gedomesticeerde dieren door middel van afscheidingen, en het gebruiken 
van strenge hygienische maatregelen en quarantaineprotocollen voor dieren 
voordat zij bij aan de collectie worden toegevoegd. In rehabilitatiecentra is de 
gezondheids- en immunologische status van dieren veelal gecompromiteerd, 
en is de populatiedichtheid en daardoor intra- (of inter-) soort contact doorgaans 
hager dan die in het wild. Wanneer biologische veiligheidsprotocollen niet 
goed worden nageleefd, ontstaat dus een hager infectierisico. 
Hoewel gedomesticeerde honden veilig kunnen worden gevaccineerd 
met een vaccin dat gemodificeerd (ofwel verzwakt) levend (MLV) CDV bevat, is 
er een grate variatie in reactie op deze vaccins in niet-gedomesticeerde dieren. 
Het virus in deze vaccins is gemodificeerd zodat het nog steeds een infectie 
in honden veroorzaakt, maar zonder ziekteverschijnselen te veroorzaken. 
Deze modificatie blijkt voor een aantal niet-gedomesticeerde dieren niet 
voldoende te zijn, waardoor de dieren toch een klinische infectie doormaken, 
soms met dodelijke afloop. Op dit moment zijn vrijwel aile commercieel 
beschikbare morbillivirus vaccins gebaseerd op MLV's. Veiligere alternatieven 
zijn ge"inactiveerde virus vaccins, die geen infectie kunnen veroorzaken, maar 
hun vermogen om een adequate immunologische response te stimuleren is 
doorgaans even redig verminderd. Op dit moment zijn er geen ge"inactiveerde 
CDV vaccins commercieel verkrijgbaar, omdat de werking minder is in 
vergelijking met de MLV vaccins, en de markt voor niet-gedomesticeerde 
dieren te klein is. Andere veilige alternatieven zijn experimentele sub-unit 
vaccins, en recombinant vaccins die kanariepokkenvirus als een drager 
hebben. Recombinant CDV vaccins zijn momenteel geregistreerd in de 
Verenigde Staten, maar mogen in de EU niet gebruikt worden aangezien het 
niet-geregistreerde genetisch gemodificeerde organismen zijn. 
Vaccins worden in het algemeen niet geproduceerd voor niet-
gedomesticeerde dieren, en er is bij het gebruik van deze vaccins in deze 
soorten dus altijd een extra risicofactor als gevolg van het niet-geregistreerde 
gebruik. Omdat bedreigde niet-gedomesticeerde diersoorten doorgaans niet 
in challenge experimenten kunnen worden gebruikt vanuit een natuurbehoud 
perspectief, worden vaccin-ge·induceerde antistoftiters gebruikt als een 
surrogaat om vaccin-effectiviteit te meten. In gedomesticeerde dieren is 
vastgesteld dat er een correlatie is tussen de hoogte van de ge"induceerde 
virus neutraliserende antistof titer en de mate van bescherming tegen infectie 
en ziekte. 
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Een goed voorbeeld van de voordelen van strenge hygiene- en 
quarantainemaatregelen in combinatie metveilige en effectieve vaccinatie werd 
duidelijk in de zeehondencreche tijdens de PDV epidemie van 2002. Zeehonden 
worden bij binnenkomst gevaccineerd met een CDV-immuunstimulerend 
complex (CDV-ISCOM) vaccin (oorspronkelijk ontwikkeld tijdens de PDV 
epidemie van 1988), en daarna gedurende 30 dagen in quarantaine geplaatst 
van waaruit ze bij de overige dieren worden geplaatst als vaccin-ge"induceerde 
CDV-specifieke antistoftiters voldoende hoog zijn bevonden. De nauwe 
verwantschap van CDV en PDV zorgt voor kruisbescherming tussen beide 
morbillivirussen. Zeehonden die de quarantaine ruimtes verlieten, maar nog 
wei aanwezig waren in de creche op het moment dat PDV-ge"infecteerde 
dieren werden binnengebracht, vertoonden geen PDV-gerelateerde klinische 
verschijnselen gedurende hun verblijf in de creche. 
Vaccinatie van Europese nertsen tegen CDV 
De ernstig bedreigde Europese nerts is zeer vatbaar voor infectie 
met CDV, en klinische vaccin-geinduceerde infecties zijn beschreven in deze 
soort. In een fokprogramma in Estland werden de veiligheid en effectiviteit 
van een experimenteel CDV-ISCOM vaccin en een in de VS geregistreerd 
recombinantvaccin (Purevax™, Merial, Duluth, USA) geevalueerd in Europese 
nertsen (Hoofdstuk 2.3.1.). Seide vaccins waren veilig, en induceerden virus 
neutraliserende antilichamen tegen CDV, al deed het ISCOM vaccine dit 
sneller, en waren de geometrisch gemiddelde titers (GMT) hager dan die na 
vaccinatie met het recombinant vaccin. Een jaar na de oorspronkelijke drie 
vaccinaties waren de antistoftiters gedaald, maar nog steeds aantoonbaar, 
alhoewel de GMT hager was in de ISCOM groep, en was het percentage 
dieren met hoge antistof titers (~ 80) 100%, vergeleken met veel lag ere 
percentages in de recombinant vaccin groep. 
Serum antistof titers bepaald door middel van een enzyme-linked 
immunosorbent assay (ELISA) volgden een vergelijkbaar patroon als die 
bepaald door middel van een virus neutralisatie (VN) test, maar waren hager. 
De VN test wordt beschouwd als de gouden standaard voor het bepalen van 
immuniteit tegen morbillivirussen, omdat deze de functionele neutraliserende 
antilichamen gericht tegen de haemagglutinine (H) en fusion (F) eiwitten op het 
virus oppervlak meet. De ELISA, gebaseerd op in celkweek geproduceerde 
virus eiwitten, meet niet aileen antilichamen gericht tegen de H en F eiwitten, 
maar vooral ook antilichamen gericht tegen het nucleoprote"ine (NP), en 
cellulaire componenten. Antilichamenichamen gericht tegen het NP leveren 
geen bijdrage aan virus neutralisatie, en worden dus niet aangetoond in een 
VN test. Desalnietemin worden deze antilichamen wei in grate hoeveelheid 
geproduceerd na infectie of vaccinatie met de klassieke vaccins, maar niet na 
vaccinatie met de gebruikte ISCOM en recombinant vaccins . 
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Deze resultaten Iaten zien dat beide vaccins veilig zijn en een 
immunologische reactie induceren in Europese nertsen, alhoewel op basis 
van de antistoftiters het CDV-ISCOM vaccin verwacht mag worden dat dit een 
betere bescherming biedt tegen CDV infectie gedurende minimaal een jaar. 
Andere beschermende mechanismen die mogelijk worden ge"induceerd door 
vaccinatie met deze vaccins, zeals inductie van cellulaire immuniteit moeten 
ook worden overwogen. Uitsluitsel over de effectiviteit van vaccins kan worden 
verkregen door middel van challenge infecties - wat in deze bedreigde soort 
onwenselijk is. 
Vaccinatie van Afrikaanse wilde honden tegen CDV 
De Afrikaanse wilde hond (Lycaon pictus) is een van de meest 
bedreigde soorten van de taxonomische familie Canidae. Vroeger had deze 
soort een uitgebreid leefgebied door 39 Afrikaanse Ianden ten zuiden van 
de Sahara, maar op dit moment wordt hun aantal geschat op 3000-5500, 
verdeeld over 15 Ianden. De dramatische vermindering van deze soort is 
voornamelijk veroorzaakt door menselijk toedoen, zeals stropen, jacht, en 
verkeersongevallen, fragmentatie van leefgebieden, competitie met andere 
roofdieren, en ziekten. Het gefragmenteerde habitat heeft de populatiedichtheid 
veranderd, en gezorgd voor een grotere kans op inter-species contacten 
(inclusief niet-gevaccineerde gedomesticeerde honden) en blootstelling aan 
nieuwe ziekteverwekkers zeals CDV en rabiesvirus. 
In een fokgroep Afrikaanse wilde honden in Mkomazi, Tanzania 
en in Artis Amsterdam Zoo werd de veiligheid en effectiviteit van het CDV-
ISCOM vaccin en het recombinante vaccin (Purevax™, Merial, Duluth, USA) 
geevalueerd, zeals eerder werd gedaan in de Europese nerts. Met beide 
vaccins waren twee vaccinaties noodzakelijk voor het induceren van lage 
antistof titers. Na 2 vaccinaties waren de GMT en het percentage dieren met 
een hoge antistoftiter in de VN test laag voor beide vaccins (ISCOM groep: 
GMT=8 en 8% ;:: 80; recombinant groep: GMT=28 en 25% ;:: 80). De GMT 
getest met een ELISA na twee vaccinaties met het recombinante vaccin was 
vergelijkbaar met die in de Europese nerts, terwijl 2 doses van het ISCOM 
vaccin lagere GMT induceerden dan in de Europese nerts. Een jaar na 
vaccinatie was het percentage dieren met een hoge antistoftiter groter in de 
recombinant groep, in zowel ELISA als VN testen. De GMT in de recombinant 
groep was vergelijkbaar met die van de ISCOM groep in de ELISA (84 vs 
80), maar hoger in de VN test (38 vs 6). De hogere antistoftiters in de dieren 
1 jaar na vaccinatie vergeleken met die na 2 vaccinaties toont aan dat een 
"booster effect" optreedt na de derde vaccinatie, alhoewel dit niet geverifieerd 
kon worden omdat geen bleed was afgenomen na de derde vaccinatie. 
De resultaten geven aan dat CDV-ISCOM vaccinatie CDV-specifieke 
antilichamen in Afrikaanse wilde honden induceert, maar dat deze niet 
effectief virus neutraliseren, en de vaccins dus waarschijnlijk weinig effectief 
zijn. Alhoewel beide vaccins veilig en weinig effectief zijn in het induceren 
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van VN antilichamen, kan aan de hand van de ge"induceerde antistof titers 
worden verwacht dat het recombinant vaccin een betere bescherming biedt 
gedurende minimaal een jaar na vaccinatie. Echter, beide vaccins induceren 
lage gemiddelde antistoftiters, en slechts een klein percentage van de dieren 
behaalt een voldoende hoge antistoftiter. Aan de hand van ge"induceerde 
serum antistoftiters in andere niet-gedomesticeerde soorten met dezelfde 
batch van dit CDV-ISCOM vaccin, lijkt de reden voor inductie van lage VN 
antistoftiters gezocht te moeten worden in het intrinsieke onvermogen van de 
wilde hand om adequaat te reageren op deze vaccins. De fragmentatie van 
het leefgebied en van de populaties van de Afrikaanse wilde hand kan hebben 
geresulteerd in een kleine genetische basis, wat negatieve gevolgen voor het 
immuunsysteem kan hebben gehad. 
Vaccinatie van carnivoren in Diergaarde Blijdorp tegen CDV 
In Blijdorp worden een aantal roofdieren gehouden die vatbaar zijn 
voor infectie met CDV. Ze worden gevaccineerd met CDV-ISCOM volgens 
een standaard protocol: jonge dieren krijgen drie vaccinaties met drie weken 
tussentijd vanaf de leeftijd van ongeveer 10 we ken, waarna jaarlijks wordt 
gevaccineerd met een dosis. Bleed wordt afgenomen v66r vaccinatie, en 
antistoftiters worden bepaald door mid del van ELISA en VN test. In de evaluatie 
van de door het CDV-ISCOM ge"induceerde immuniteit werden aileen dieren 
gebruikt die niet eerder waren gevaccineerd, omdat dit de resultaten zou 
be"invloeden. Er kon geen vergelijking worden gemaakt met het recombinant 
vaccin, omdat gebruik hiervan niet is toegestaan in Nederland. 
De kleine panda (Ailurus fu/gens) behoort tot de taxonomische familie 
Ailuridae, en is zeer vatbaar voor infectie met CDV. Reeds in 1976 werd bij 
deze dieren vaccin-ge"induceerde CDV infectie beschreven. In Blijdorp werden 
panda's al gedurende langere tijd gevaccineerd met CDV-ISCOM, en data 
van 16 dieren waren beschikbaar. De GMT gemeten met ELISA was laag, en 
een aantal dieren had helemaal geen antilichamen. Echter, de laatste jaren 
reageerden de pandas met hogere antistoftiters, zowel in ELISA als VN test. 
Deze resultaten komen overeen met een verhoging van het totale antigeen 
gehalte in het toegediende vaccin van 5 1-'Q/ml naar 10 1-'Q/ml in de laatste 5 
jaar. Overige soorten die in het hieropvolgende deel worden besproken werden 
allemaal gevaccineerd met het vaccin met het hogere antigeengehalte. 
Manenwolven ( Chrysocyon brachyurus) behoren tot de taxonomische 
familie Canidae, zijn zeer vatbaar voor CDV infectie, en zijn beschreven met 
vaccin-ge"induceerde CDV infectie. De CDV-ISCOM vaccinatie kon worden 
geevalueerd in 2 dieren. Meerdere soorten van de Lutrinae subgroep van de 
Mustelidae zijn beschreven met CDV infectie: Europese otters (Lutra /utra), 
Aziatische kleinklauw otters (Aonyx cinerea), en Noord-Amerikaanse otters 
(Lutra canadensis). In Blijdorp konden we de CDV vaccinatie van 3 Aziatische 
klein-klauw otters, en 2 Europese otters evalueren. De Maleise civetkat 
(Viverra tangalunga), behoort tot de familie Viverridae, waarin CDV infectie is 
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beschreven. In Blijdorp konden wij 5 civetkatten 3 jaar volgen, en 3 dieren 4 
jaar. 
De meeste soorten hadden minimaal twee doses CDV-ISCOM nodig 
voordat VN antilichamen worden ge"induceerd. De twee ottersoorten zijn 
de enige waarin antistof titers aantoonbaar zijn na een vaccinatie. Antistof 
titers 2::: 40 zijn aantoonbaar in aile dieren na twee vaccinaties. Alhoewel 
maar bij weinig dieren bloed is afgenomen na de derde vaccinatie, zijn er 
aanwijzingen dat antistoftiters verder omhoog gaan na de toediening van de 
derde dosis. Een jaar na vaccinatie daalt de GMT in aile soorten, maar deze 
wordt weer omhoog gebracht door (een) boostervaccinatie (s), en blijft op 
vergelijkbare hoogte met jaarlijkse hervaccinatie met een vaccindosis. GMTs 
getest met ELISA zijn doorgaans hager of gelijk aan de GMT getest met VN. 
Grote verschillen tussen de gemeten ELISA en VN titers, zoals gezien bij de 
Afrikaanse wilde hand, werden niet gezien in de soorten die in Blijdorp werden 
gevaccineerd. 
Conclusies: vaccinatie van niet-gedomesticeerde roofdieren 
tegen morbillivirussen 
De aanwezigheid van antilichamen tegen een aantal virale 
ziekteverwekkers werd aangetoond in populaties van vrij-levende roofdieren in 
Canada en Frankrijk. Antistof titers tegen CDV hadden de hoogste prevalentie 
van aile virussen die werden getest, en het is bekend dat dit virus, en het 
nauwverwante PDV grate epidemieen met hoge mortaliteit hebben veroorzaakt 
in vrij-levende niet-gedomesticeerde roofdieren en zeezoogdieren. De klinische 
symptomen gedocumenteerd in jonge gewone zeehonden tijdens een PDV-
epidemie lieten een ander beeld zien dan gerapporteerd in ge"infecteerde 
dieren tijdens een soortgelijke PDV-epidemie 14 jaar eerder, hetgeen het 
belang van goed gedocumenteerde klinische symptomen benadrukt voor het 
stellen van een vroege waarschijnlijkheidsdiagnose. Een vroege identificatie 
van de verantwoordelijke ziekteverwekker is essentieel in het bestrijden van 
uitbraken. Vaccinaties kunnen deel uitmaken van de bestrijdingsstrategieen 
tijdens een uitbraak. CDV-ISCOM vaccinatie is veilig en effectief in het 
induceren van specifieke antistof titers in vrijwel aile soorten waarin het is 
getest. Verschillen in vatbaarheid voor CDV infectie zijn beschreven voor 
verschillende soorten van niet-gedomesticeerde dieren, en verschillen in de 
antistofproductie in respons op vaccinatie is eveneens gezien in deze studies. 
Antistoftiters worden op peil gehouden door jaarlijkse hervaccinatie met een 
dosis. Het gebruik van het recombinant vaccin was veilig en effectief in de 
Europese nerts, terwijl geen van beide vaccins effectief waren in Afrikaanse 
wilde honden. De mate van bescherming, gebaseerd op antistof titers, was 
hoger dan dat ge"induceerd door het CDV-ISCOM vaccin in de Afrikaanse 
wilde hand, maar lager in de Europese nerts. Deze studies geven een beter 
inzicht in het effect van veilige vaccinaties in niet-gedomesticeerde roofdieren, 
maar op dit moment is er nag steeds geen veilig en effectief commercieel 
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verkrijgbaar CDV vaccin dat gebruikt kan worden in niet-gedomesticeerde 
dieren in de EU. 
Vaccinatie van niet-gedomesticeerde vogelsoorten tegen 
hoogpathogene aviaire influenza virussen 
Aviaire Influenza virussen zijn type A influenza virussen, negatief-
strengs RNA virussen die behoren tot de familie van Orthomyxoviridae. Ze 
worden onderverdeeld op basis van de oppervlakte eiwitten: haemagglutinine 
(H, dat zorg draagt voor de binding van het virus aan en het binnendringen van 
de gastheercel), en neuraminidase (N, een eiwit dat zorgt voor een efficiente 
eel tot eel verspreiding na vermenigvuldiging van het virus). Er zijn totaal 16 
verschillende H subtypen, en 9 verschillende N subtypen, die theoretisch 
in allerlei combinaties kunnen voorkomen. Aviaire influenza virussen zijn 
verder onder te verdelen op grand van hun biologische eigenschappen 
in laag-pathogene aviaire influenza (LPAI) virussen die geen tot milde 
ziekteverschijnselen veroorzaken, en haag-pathogene aviaire influenza 
(HPAI) virussen die massale sterfte onder pluimvee veroorzaken (ook 
bekend als klassieke vogelpest). HPAI virussen zijn altijd van de H5 en H7 
subtypen, al zijn niet aile H5 en H7 subtypen hoogpathogeen. Tot 2002 werd 
aangenomen dat HPAI een pluimveeziekte was, en dat wilde (water-) vogel 
soorten de natuurlijke gastheren waren van LPAI virussen, en dat deze geen 
ziekteverschijnselen vertoonden na aviaire influenza infectie. In 2002 was er 
een uitbraak van HPAI virus van het H5N1 subtype in wilde trekvogelsoorten 
en in gevangenschap gehouden watervogels. Sindsdien heeft dit subtype 
ten minste 1 05 verschillende vogelsoorten uit 14 verschillende taxonomische 
ordes ge"infecteerd, en heeft het zich op een niet eerder vertoonde wijze 
verspreid door Azie, Europa en Afrika. 
In de EU is er momenteel een non-vaccinatiebeleid met betrekking 
tot routine vaccinatie van pluimvee tegen aviaire influenza. In plaats van 
vaccinatie worden uitroeirngsmaatregelen gebruikt tijdens een uitbraak in 
pluimvee, waaronder vallen: (langdurig) ophokken, ruimen van dieren op het 
ge·infecteerde bedrijf, en afhankelijk van de pluimveedichtheid in het gebied en 
de epidemiologische situatie preventief ruimen op dichtbijzijnde bedrijven, en 
eventueel noodvaccinaties. Sinds 2003 zijn wereldwijd meer dan 220 miljoen 
vogels geruimd om H5N1 influenza-uitbraken de kop in te drukken. 
De standaardmaatregelen zoals die voor pluimvee worden gehanteerd 
(ophokken en ruimen) kunnen zeer nadelig zijn voor het welzijn van dieren 
in dierentuinen en voor fokprogramma's van bedreigde vogelsoorten. Op 
grate schaal ruimen van dierentuin-collecties met bedreigde en zeldzame 
vogelsoorten zou niet wenselijk zijn vanuit een natuurbeschermings oogpunt. 
Op Europees niveau kan worden afgeweken van grootschalig preventief ruimen 
als dieren langdurig kunnen worden opgehokt, en uitvoerig getest worden. 
Echter, de meeste dierentuinen zullen niet de mogelijkheden hebben om hun 
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gehele vogelpopulatie voor langere tijd op te hokken, en veel soorten zullen 
zich niet kunnen aanpassen aan het ophokken met toegenomen stress en 
welzijnsproblemen en verhoogde blootstelling aan andere ziekteverwekkers 
zoals de verwekkers van aspergillose en "bumblefoot". Om de waardevolle 
collecties van dierentuinen, onder meer bestaande uit bedreigde en 
zeldzame vogelsoorten, te kunnen beschermen tegen infectie met HPAI 
virus, preventieve ruiming en langdurig ophokken, mogen deze onder strenge 
toezichtsmaatregelen worden gevaccineerd. 
Vaccinatie van vogels in dierentuinen als extra toevoeging aan de 
preventieve beschermende maatregelen tegen HPAI virus infectie (terwijl 
ophokregels kunnen worden versoepeld) werd voor het eerst in 2003 toegepast 
toen zich in Nederlands pluimvee een uitbraak van HPAI virus van het H7N7 
subtype voldeed. Vogels in dierentuinen werden gevaccineerd met een 
ge"inactiveerd geadjuveerd (H7N 1) vaccin, waarvan de gebruikte virusstam 
een grote homo Iogie bezat ten opzichte van het veldvirus (Hoofdstuk 3.1. ). Na 
vaccinatie had 81.5% een HI antistof titer:::: 40, een beschreven antistof titer 
die in pluimvee correleert met bescherming, en die ook bij de gevaccineerde 
vogels in de dierentuinen als beschermend wordt beschouwd, aangezien 
infectie experimenten niet in al deze (bedreigde) vogelsoorten zijn gedaan. 
De totale GMT bij deze vogels was 190. Verschillen tussen de taxonomische 
ordes werden gezien: vertegenwoordigers van deAnseriformes (watervogels ), 
Galliformes (hoenderachtigen) and Phoenicopteriformes (flamingo's) hadden 
hogere GMT's en percentages met een titer :::: 40 dan de andere ordes. 
Een afname van de ge"induceerde antistoftiter met een toename van het 
lichaamsgewicht werd ook gezien. Serum antistoftiters werden gemeten door 
middel van een haemagglutinatie inhibitie (HI) test, en deze kwamen goed 
overeen met VN titers tegen het veld virus. Dit werd als additionele maat 
van immunogeniteit gebruikt. De relatief hoge antistoftiters in de verschillende 
taxonomische ordes onderstreepten de waarde van vaccinatie als een 
additionele preventieve maatregel tegen HPAI infectie in dierentuinen. 
In 2005 besloten de Nederlandse dierentuinen als eerste om, volgens 
Europees beleid (Decision 2005/7 44/EC) vogels te vaccineren tegen het steeds 
dichterbij komende HPAI virus van het H5N1 subtype (Hoofdstuk 3.2.). Vogels 
werden gevaccineerd met een ge"inactiveerd geadjuveerd H5N2 vaccin. De 
dosis werd aangepast aan het gemiddeld gewicht per soort, op geleide van 
de twee jaar eerder verkregen data van H7 vaccinatie. De vaccinstam had 
een grate gelijkenis met de veldstam in Europa op dat moment. Vaccinatie 
bleek veilig, en induceerde antistof titers in aile verschillende soorten, al 
werden wei verschillen tussen taxonomische ordes en soorten gezien. Na 
twee vaccinaties hadden 80% van aile vogels een HI titer tegen de vaccin 
stam :::: 40, en was de totale GMT 190. Serum HI titers tegen de veldstam 
hadden een zelfde verloop, maar waren in het algemeen lager. De breedte 
van de antistofrespons werd daarna aangetoond door het meten van serum 
HI titers tegen vier prototype stammen uit verschillende antigene "clades" 
van H5N1 virussen. De antigene en genetische eigenschappen van virussen 
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kunnen worden gebruikt om ze in "clades" in te delen op een antigene kaart, 
waarop de verwantschap tussen de verschillende stammen duidelijk kan 
worden weergegeven. In combinatie met epidemiologische data wordt deze 
informatie gebruikt om o.a. virusstammen te selecteren die gebruikt kunnen 
worden als kandidaten voor humane pandemische vaccins - stammen 
waarvan het haemagglutinine een hoge antigene verwantschap heeft met 
veldstammen geven de meeste bescherming. Op basis van de breedte van 
hun antistofrespons werden de dierentuinvogels in twee groepen verdeeld. 
Groep 1 (Anseriformes, Galliformes, Phoenicopteriformes, Psittacciformes 
[papagaaiachtigen] en Struthioniformes [struisvogelachtigen]) lieten een zeer 
brede respons zien met een voorspelde bescherming tegen toekomstige 
virus stammen die zich tot op 12 antigene eenheden van het gebruikte vaccin 
bevinden. Vogels in groep 2 (Ciconiiformes [ooievaarachtigen], Gruiformes 
[kraanvogelachtigen], Pelecaniformes [pelikaanachtigen] en Sphenisciformes 
[pinguins]) hadden lagere HI titers tegen de prototype stam van de verst 
afgelegen antigene clade (A/Indonesia/5/05). 
In navolging van de Nederlandse dierentuinen werden vogels in 
dierentuinen in 13 Europese Ianden tegen HPAI H5N1 virus gevaccineerd, 
en werd in 2006 een werkgroep opgezet van de european Food Safety 
Authority (EFSA) om een wetenschappelijke beoordeling van de effectiviteit 
van vaccinaties in dierentuinen te maken. In totaal werden 44721 vogels 
gevaccineerd, en individuele data van 4718 vogels (374 soorten van 19 
taxonomische ordes) werden door de lidstaten (MS) beschikbaar gesteld. 
Verschillen in vaccinatie schema's, doseringen, route van vaccinatie, 
verschillen in methodologie (er bestaan geen internationale referentie 
standaarden of standaardisatie), het gebruik van verschillende vaccins 1 in 
verschillende taxonomische ordes, en het soms incompleet rapporteren van 
resultaten bemoeilijkten de evaluatie. Alhoewel de meeste Ianden serum 
antistoftiters rapporteerden die bij 4 of 8 begonnen, werden de resultaten 
geevalueerd voor titers~ 16 en 32, wat beschreven beschermende titers zijn 
in kippen. 
Na toediening van twee doses van de H5 en H7 vaccins die 
geregistreerd zijn voor gebruik in kippen werden verschillen in effectiviteit 
gezien, op basis van verschillen in serum HI antistof titers. Drie van de vijf 
vaccins induceerden relatief hoge GMT's en percentage seroconversie in de 
meerderheid van de vogelsoorten. Duidelijke verschillen werden waargenomen 
tussen soorten en taxonomische ordes. De route van vaccinatie leek geen 
invloed te hebben op de resultaten, en voor de meeste soorten was de dosis 
die is aanbevolen voor pluimvee voldoende. In sommige zwaardere soorten 
1 
Vaccin A: H5N9 (A/turkey/Wisconsin/68). 
Vaccin B: H5N2 (A/duck!Pottsdam/1402/86). 
Vaccin C: H5N2 (A/chicken/Mexico/232/94/CPA). 
Vaccin 0: H5N9 (Aichicken/ltaly/22A/98). 
Vaccin E: H5N9 (Aichicken/ltaly/22AIH5N9/1998). 
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bleek een hogere dosis noodzakelijk om voldoende hoge antistoftiters te 
induceren (b.v. in struisvogels 1 0-voudige dosis voor pluimvee: 10 x 0.25 ml). 
Echter, een te hoge dosis toegediend op een plek (struisvogels met 10 ml) 
bleek een negatief effect te hebben op de antistof titer, terwijl oak vaker locale 
reacties werden waargenomen. 
Er waren indicaties dat een vaccinatie voldoende zou kunnen zijn om 
hoge antistoftiters te induceren in ten minste twee taxonomische ordes. Echter, 
twee vaccinaties gaven consistent hoge titers te zien in de meeste soorten. Er 
waren oak aanwijzingen dat antistoftiters zes maanden na vaccinatie aanwezig 
bleven in verschillende soorten, al waren slechts data van een beperkt aantal 
dieren beschikbaar. Schadelijke bijwerkingen en mortaliteit in verband met 
vaccinatie werden zelden gezien, en waren voornamelijk veroorzaakt door 
stress en trauma tijdens het vangen en hanteren. Er bleken aanmerkelijke 
verschillen in mortaliteit per dierentuin, hetgeen het belang van zorgvuldig 
vangen en hanteren van de vogels illustreert. 
Een jaar na vaccinatie met het H5N2 vaccin werden vogels in 
Nederlandse dierentuinen voor de derde maal gevaccineerd met hetzelfde 
vaccin, en konden antistof titers worden bepaald (Hoofdstuk 3.3.). 
Een van de problemen tijdens de evaluatie van aile Europese data 
was gerelateerd aan het vergelijken van data tussen verschillende laboratoria. 
Sera verzameld tijdens het hervaccineren en een maand later moest worden 
getest in het nationaal veterinaire referentie laboratorium (CIDC Lelystad), 
terwijl voorgaande bepalingen in het Eramus MC weren uitgevoerd. Om te 
bepalen of vergelijkbare titers werden verkregen, werden 141 bloedmonsters 
in beide laboratoria getest. De correlatie coefficient tussen de uitkomsten van 
de twee laboratoria bleek 0.87 te zijn. 
Van 44 vogels in Blijdorp konden titers van aile drie de bloedafname 
dagen worden beoordeeld. Antistoftiters liepen duidelijk terug in het jaar na 
vaccinatie: terwijl 80% een positieve titer (2::8), en 68 % een haag positieve 
titer (2:: 32) hadden na twee vaccinaties, waren deze getallen een jaar 
later respectievelijk 61% en 30%. Vier weken na thervaccinatie waren de 
percentages hager dan na twee vaccinaties (93% en 77%), al was de GMT 
lager dan een jaar eerder (88 vs 66). 
Zoals oak werd opgemerkt na twee vaccinaties, was er weer een 
verschil in respons tussen de verschillende taxonomische ordes. Gebruik 
makend van data van aile vogels getest in Blijdorp (8 ordes) waren er vier 
die een jaar na vaccinatie geen aantoonbare antistoftiters hadden, en was er 
maar een orde (Phoenicopteriformes) waarvan de GMT hager dan 40 was. 
Vier we ken na hervaccinatie hadden totaal 7 4% van de vogels, en zes van de 
acht ordes een titer> 40. 
Twee jaar na twee vaccinaties met een H7 vaccin, zonder hervaccinatie 
een jaar later, bleek de antistoftiter nag verder gedaald, zoals werd aangetoond 
door tevens H7 specifieke antilichamen te meten in sera van dieren die 2 jaar 
eerder waren gevaccineerd met een H7N1 vaccin. 
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Vaccinatie van duiven tegen HPAI H5N1 virus 
Van rotsduiven (Columba Iivia) en andere soorten van de taxonomische 
orde Columbiformes werd beschreven dat zij resistent zijn tegen, of in ieder 
geval minder gevoelig zijn voor infectie met HPAI virussen. Oak zouden zij 
lage serum antistoftiters na infectie en vaccinatie vertonen. Een verhoogde 
gevoeligheid van duiven voor meer recente stammen van het H5N1 virus 
subtype, en katten die ge"infecteerd werden door het eten van een met H5N1 
virus ge"infecteerde duif zijn recent aangetoond, alhoewel er geen vogel-vogel 
overdracht van het virus lijkt plaats te vinden. 
Om te onderzoeken hoe gevoelig duiven zijn voor infectie met 
HPAI H5N1 virus, en of eventuele uitscheiding van virus verminderd kan 
worden door vaccinatie werden gevaccineerde en niet gevaccineerde 
duiven met hoge doses van een van twee stammen HPAI virus van het 
H5N1 subtype (respectievelijk A/lndonesia/5/05 en A/turkey/Turkey/1/05) 
uit twee recente antigene clades ge"infecteerd via inoculatie in de luchtpijp 
en slokdarm (Hoofdstuk 3.4.). De vaccinstam (H5N6) gebruikt in het vaccin 
had een grate mate van gelijkenis met de twee stammen. Alhoewel duiven 
inderdaad weinig gevoelig bleken te zijn voor infectie met deze zeer hoge 
doses HPAI H5N1 virus, trad tach enige morbiditeit en mortaliteit op in de 
ongevaccineerde groepen, terwijl gevaccineerde groepen beschermd waren 
tegen het ontwikkelen van klinische verschijnselen. Klinische verschijnselen 
waren voornamelijk van neurologische aard: ataxie, tremoren, opisthotonus 
en torticollis. Virus kon worden aangetoond in verschillende organen 
(hersenen, long, luchtzak, alvleesklier, milt, lever en dunne darm) door 
middel van RT-PCR op 3 en 27 dagen post-inoculatie (dpi), en kon worden 
ge"isoleerd op 3 dpi (A/Indonesia/5/05: long, luchtzak, milt, dunne darm; AI 
turkey/Turkey/1/05: hersenen, long, luchtzak, alvleesklier, milt en lever). Door 
middel van immuunhistochemie kon de aanwezigheid van nucleoprote"ine 
in de long, luchtzak en hersenen worden aangetoond. lnfectieus virus werd 
ge"isoleerd uit keel swabs tot 3 (A/turkey/Turkey/1/05) en 4 (A/Indonesia/5/05) 
dpi. Cloacaswabs bleven negatief tot 27 dpi. Uit gevaccineerde dieren kon 
aileen op 3 dpi uit de long virus worden gere"isoleerd, was er minder virus 
aantoonbaar door middel van RT-PCR in de verschillende organen, terwijl 
het virus slechts tot de eerste dag na inoculatie uit de keelswabs kon worden 
ge"isoleerd. Aangezien de toegediende toegediende dosis een dag eerder 
zeer hoog was, zou de aangetoonde (lag ere) virustiters in de pharyngeale 
swabs een restant van het inoculum kunnen zijn, en bewijst dit niet dat er 
uitscheiding is opgetreden 
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Conclusies: vaccinatie van niet-gedomesticeerde vogels tegen 
HPAI virussen 
De implementatie van biologische veiligheidsmaatregelen is 
vooralsnog de voornaamste maatregel die dierentuinen tegen de introductie 
van aviaire influenza virussen kunnen gebruiken. Dit zal ook bijdragen aan 
het verminderen van het risico van eventuele verdere verspreiding, mocht 
het virus wei geYntroduceerd worden. Klinische en virologische controles 
dienen te worden uitgevoerd in het geval van een dreigende dichtbijzijnde 
uitbraak om te komen tot een vroege opsporing van het virus. Als biologische 
veiligheidsmaatregelen niet voldoende bescherming kunnen bieden aan 
vogels in dierentuinen tegen infectie met HPAI virussen afkomstig van wilde 
vogels - dit mede gebaseerd op een risico-analyse waarin ook welzijn van 
de vogels wordt betrokken- kunnen H5 of H7 vaccins geautoriseerd voor 
gebruik in pluimvee worden gebruikt. Recente data van wilde vogelmigratie 
en prevalentie van HPAI in deze vogels moeten worden meegenomen in de 
beslissing om al dan niet te gaan vaccineren. 
Vaccinatie van dierentuinvogels met de thans in de EU geautoriseerde 
H5 en H7 vaccins is veilig en effectief gebleken in de meeste taxonomische 
ordes. lnductie van antistof titers is hierbij als effectiviteitscriterium gebruikt. 
Vaccins moeten worden toegediend op een manier die hoge antistoftiters 
induceert in de meerderheid van de gevaccineerde vogels. Alhoewel er 
aanwijzingen zijn dat een vaccin dosis voldoende is in sommige soorten, 
geven twee doses zekerheid van hoge titers in de meeste soorten. Behalve 
als duidelijk is aangetoond dat een vaccinatie voldoet, blijven twee vaccin 
doses aanbevolen. 
Er zijn verschillen waargenomen in de effectiviteit van vaccinatie met 
de thans in de EU geautoriseerde vaccins tussen soorten en taxonomische 
ordes. Er is geen verschil tussen de gebruikte route van vaccinatie gebleken. 
Daarom kan men de keuze van de route van vaccinatie bij verschillende soorten 
Iaten afhangen van het gemak van toediening (bijvoorbeeld intramusculair 
met een blaaspijp bij struisvogels) of de aanwezigheid van grate subcutane 
luchtzakken hetgeen bij toediening van het vaccin hierin het effect van 
vaccinatie negatief zou kunnen be"invloeden. Dit laatste zou bijvoorbeeld bij 
pelikanen een belangrijke overweging kunnen zijn. Om hoge antistoftiters in 
vogels op peil te houden lijkt een jaarlijkse hervaccinatie met 1 dosis voor de 
meeste soorten noodzakelijk te zijn. 
Standaard-protocollen voor vaccinatie, bemonstering, uitvoering 
van laboratoriumtests en rapportage aan de EU moeten worden opgezet om 
de evaluatie van AI vaccinatie campagnes in vogels te vergemakkelijken. 
lnter-laboratorium standaardisatie van technieken, en de productie van 
internationale referentie standaarden zouden moeten worden gerealiseerd, 
om vergelijkingen tussen verschillende laboratoria en gebruikte vaccins 
mogelijk te maken. 
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Mortaliteit en schadelijke bijwerkingen ten gevolge van vaccinatie 
met de gebruikte vaccins waren laag in de dierentuinen van de EU lidstaten, 
en voornamelijk het gevolg van stress en trauma tijdens het vangen en 
hanteren van de vogels. Dierentuinen kunnen deze negatieve effecten dus 
verminderen door kundig en voorzichtig met de vogels om te gaan tijdens de 
AI vaccinatiecampagnes. Om indirecte verliezen als gevolg van verminderde 
broedresultaten tegen te gaan moeten waar mogelijk broedseizoenen worden 
vermeden. Evaluatie van serologische data kan uiteindelijk zorgen dat 
dieren minder vaak hoeven te worden gevangen. Als vaccinatieprotocollen 
gevalideerd zijn voor bepaalde vogelsoorten met bepaalde vaccins, zal een 
post-vaccinatie antistofbepaling niet meer noodzakelijk zijn. Verder onderzoek 
moet worden verricht naar de meest effectieve vaccinatie schema's en dosis 
per soort. Dit zou kunnen leiden tot een vermindering van het aantal vaccinaties 
in bepaalde vogelsoorten. Daarnaast zou het ontwikkelen van een vaccin dat 
verneveld kan worden (zoals gebruikt wordt bij het vaccineren van pluimvee 
tegen Newcastle disease virus) het hanteren van de vogels overbodig kunnen 
maken in de toekomst. 
De vaccinatiecampagnes in de dierentuinen hebben zich toegespitst 
op het beschermen van vogels. Naast vogels zijn ook meerdere zoogdieren, 
waaronder katachtigen en honden, gedocumenteerd met HPAI H5N1 virus 
infectie. Alhoewel er op dit moment geen commercieel verkrijgbaar vaccin is 
dat zoogdieren beschermt, heeft een experimenteel recombinant vaccin hoge 
antistoftiters ge"induceerd in katten. Dit vaccin zou in de toekomst misschien 
ook in dierentuindieren gebruikt kunnen worden, al zijn de richtlijnen van de 
EU voor het gebruik van genetisch gemodificeerde organismen streng (zie 
ook CDV vaccinatie ). Tot dan moeten deze dieren worden beschermd door 
het uitsluiten van infectie door middel van rauw pluimveevlees (gekookt vlees 
vormt geen gevaar voor infectie ). 
lnfectiestudies hebben Iaten zien dat alhoewel duiven niet erg 
gevoelig zijn voor infectie met een van twee recente HPAI H5N1 stammen, 
zij na vaccinatie toch beschermd zijn tegen het ontwikkelen van klinische 
ziekteverschijnselen, verminderde virus verspreiding in de verschillende 
organen Iaten zien, en in mindere mate of geen virus uitscheiden. 
De brede vaccin-effectiviteit in de vele verschillende soorten in 
dierentuinen illustreert het belang van vaccinatie als een van de maatregelen 
die gebruikt kunnen worden om niet-gedomesticeerde dieren te beschermen 
tegen de gevolgen van HPAI virus infectie, zoals preventief ruimen, en 
langdurig ophokken. Echter, verhoogde biologische veiligheids maatregelen 
in combinatie met virologisch onderzoek blijven onmisbaar in het bestrijden 
van uitbraken van HPAI. 
Vaccinatie van vogels in dierentuinen moet worden gezien als een 
extra maatregel om ze te beschermen tegen HPAI virus infecties, terwijl 
het welzijn van deze vogels niet wordt benadeeld. Daarnaast voorkomt 
het dat dierentuinen een bron van virus kunnen worden. Desalniettemin 
blijven pluimvee bedrijven de grootste bron van HPAI virus, aangezien deze 
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vogels een aangetoonde hoge vatbaarheid hebben, grate hoeveelheden 
virus uitscheiden, en de populatiedichtheid groat is. Verhoogde biologische 
veiligheidsmaatregelen op pluimveebedrijven, verminderd contact tussen 
pluimvee en wilde vogels (zonder hierdoor het welzijn te benadelen), ruimen, 
en vaccinatie van pluimvee zullen belangrijkere stappen zijn in het beheersen 
van grootschalige uitbraken zoals de huidige uitbraak van het H5N1 virus. 
ALGEMENE CONCLUSIES 
Het vroeg opsporen en de identificatie van uitbraken door uitgebreide 
surveillance in dieren naar (zoonotische) ziekteverwekkers en ziektepatronen 
is een kritiek onderdeel van het beheersen of voorkomen van uitbraken van 
deze infecties, en kan gebruikt worden voor her-introductie of translocatie 
programma's van bedreigde diersoorten. Vaccinatie kan een toegevoegde 
waarde hebben voor de biologische veiligheidsmaatregelen die gebruikt 
worden bij het voorkomen en bestrijden van virusinfecties van niet-
gedomesticeerde dieren in gevangenschap. Twee groepen van virussen die 
verantwoordelijk zijn geweest voor grate uitbraken in niet-gedomesticeerde 
diersoorten, morbillivirussen en HPAI virussen, kunnen ook bestreden worden 
door middel van vaccinatie. Op dit moment is er echter geen geautoriseerd 
veilig en effectief CDV vaccin verkrijgbaar in de EU voor gebruik in deze 
dieren. Een commercieel recombinant vaccin dat geautoriseerd is in de USA 
lijkt redelijk te werken in niet-gedomesticeerde diersoorten. Een experimenteel 
CDV-ISCOM vaccin werkt goed in meerdere niet-gedomesticeerde soorten. 
Een uitzondering is de Afrikaanse wilde hand, waarin het ISCOM vaccin 
geen VN antistoftiters induceert, en waarin het recombinant vaccin lage VN 
antistoftiters induceert. 
Vaccinatie van dierentuinvogels tegen HPAI virus van de H5 en H? 
subtypes met de in de EU geautoriseerde pluimvee vaccins induceertvoldoende 
hoge antistoftiters in de meeste soorten en taxonomische ordes, die op peil 
gehouden kunnen worden met een jaarlijkse eenmalige hervaccinatie. 
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